

Children's Hospital Medical Center and Affiliates

Title 2 U.S. Code of Federal Regulations Part 200
(Uniform Guidance) Reports for the
Year Ended June 30, 2022

CHILDREN'S HOSPITAL MEDICAL CENTER AND AFFILIATES

TABLE OF CONTENTS

	Page
INDEPENDENT AUDITOR'S REPORT	1-2
CONSOLIDATED FINANCIAL STATEMENTS FOR THE YEARS ENDED JUNE 30, 2022 AND 2021:	
Consolidated Balance Sheets	3
Consolidated Statements of Operations and Changes in Net Assets	4-5
Consolidated Statements of Cash Flows	6
Notes to Consolidated Financial Statements	7-31
SUPPLEMENTARY SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS FOR THE YEAR ENDED JUNE 30, 2022	32-43
NOTES TO SUPPLEMENTARY SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS FOR THE YEAR ENDED JUNE 30, 2022	44
REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING AND ON COMPLIANCE AND OTHER MATTERS BASED ON AN AUDIT OF FINANCIAL STATEMENTS PERFORMED IN ACCORDANCE WITH <i>GOVERNMENT AUDITING STANDARDS</i>	45-46
REPORT ON COMPLIANCE FOR EACH MAJOR FEDERAL PROGRAM; REPORT ON INTERNAL CONTROL OVER COMPLIANCE; AND REPORT ON THE SCHEDULE OF EXPENDITURES OF FEDERAL REQUIRED BY THE UNIFORM GUIDANCE	47-49
SCHEDULE OF FINDINGS AND QUESTIONED COSTS	50-51



Deloitte & Touche LLP
50 W 5th Street
Suite 200
Cincinnati, OH 45202-3789
USA

Tel: +513 784 7100
Fax: +513 784 7204
www.deloitte.com

INDEPENDENT AUDITOR'S REPORT

To the Board of Trustees
Children's Hospital Medical Center and Affiliates:
Cincinnati, Ohio

Report on the Audit of the Financial Statements

Opinion

We have audited the consolidated financial statements of Children's Hospital Medical Center and Affiliates (the "Company"), which comprise the consolidated balance sheets as of June 30, 2022 and 2021, and the related consolidated statements of operations and changes in net assets, and cash flows for the years then ended, and the related notes to the consolidated financial statements (collectively referred to as the "financial statements").

In our opinion, the accompanying financial statements present fairly, in all material respects, the financial position of the Company as of June 30, 2022 and 2021, and the results of its operations and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audits in accordance with auditing standards generally accepted in the United States of America (GAAS) and the standards applicable to financial audits contained in *Government Auditing Standards (Government Auditing Standards)*, issued by the Comptroller General of the United States. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Company and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern for one year after the date that the financial statements are issued.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS and *Government Auditing Standards* will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions,

misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with GAAS and *Government Auditing Standards*, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Other Reporting Required by *Government Auditing Standards*

In accordance with *Government Auditing Standards*, we have also issued our report dated September 30, 2022 on our consideration of the Company's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Company's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Company's internal control over financial reporting and compliance.

Deloitte & Touche LLP

September 30, 2022

Children's Hospital Medical Center and Affiliates

Consolidated Balance Sheets June 30, 2022 and 2021 (dollars in thousands)

	2022	2021
CURRENT ASSETS:		
Cash and cash equivalents	\$ 293,360	\$ 274,863
Marketable securities	1,259,210	1,352,918
Cash, cash equivalents and marketable securities	1,552,570	1,627,781
Patient receivables, net	511,704	506,944
Other receivables	141,986	140,916
Inventories and prepaid expenses	80,350	74,042
Total current assets	2,286,610	2,349,683
ASSETS LIMITED AS TO USE - Funds in trust	32,275	31,250
PROPERTY AND EQUIPMENT, net of accumulated depreciation	1,432,608	1,403,713
GOODWILL	7,296	8,154
OPERATING LEASE RIGHT-OF-USE ASSETS	17,345	16,485
PENSION BENEFIT ASSET	281,043	171,709
OTHER LONG-TERM ASSETS	72,387	48,651
INTEREST IN NET ASSETS OF SUPPORTING ORGANIZATIONS	4,462,791	4,545,670
Total assets	<u>\$8,592,355</u>	<u>\$8,575,315</u>
CURRENT LIABILITIES:		
Accounts payable and accrued expenses	\$ 466,433	\$ 410,481
Current portion of long-term debt and lease obligations	17,986	28,815
Commercial paper	100,000	100,000
Bonds payable subject to remarketing, net	86,302	91,640
Total current liabilities	670,721	630,936
SELF-INSURANCE RESERVES	25,274	22,184
LONG-TERM DEBT:		
Tax-exempt bonds payable	327,916	340,776
Taxable bonds payable	596,176	595,946
Finance lease obligations	48,544	51,647
Operating lease obligations	14,949	14,242
OTHER LONG-TERM LIABILITIES	19,487	54,976
Total liabilities	1,703,067	1,710,707
COMMITMENTS AND CONTINGENCIES (Note 11)	-	-
NET ASSETS:		
Without donor restrictions	2,212,893	2,100,516
With donor restrictions	4,676,395	4,764,092
Total net assets	6,889,288	6,864,608
Total liabilities and net assets	<u>\$8,592,355</u>	<u>\$8,575,315</u>

See accompanying notes to consolidated financial statements.

Children's Hospital Medical Center and Affiliates

Consolidated Statements of Operations and Changes in Net Assets For the Years Ended June 30, 2022 and 2021 (dollars in thousands)

	2022	2021
OPERATING REVENUES, GAINS AND OTHER SUPPORT:		
Net patient service revenue	\$2,369,523	\$2,226,690
Net assets released from restriction used for operations-		
Grant revenue	218,688	202,492
Other restricted net assets used to support operations	129,721	109,627
Other revenue	193,115	207,082
Total operating revenues, gains and other support	<u>2,911,047</u>	<u>2,745,891</u>
OPERATING EXPENSES:		
Salaries	1,374,087	1,258,656
Employee benefits	372,037	347,711
Supplies, drugs and other	525,548	469,344
Purchased services	287,721	252,208
Depreciation	151,729	138,638
Utilities	20,079	18,401
Interest	30,926	23,249
Total operating expenses	<u>2,762,127</u>	<u>2,508,207</u>
Operating income	148,920	237,684
NONOPERATING (LOSSES) GAINS:		
Net investment (loss) return	(84,045)	85,743
Net benefit gain other than service cost	26,485	1,682
Net nonoperating (losses) gains	<u>(57,560)</u>	<u>87,425</u>
Revenue and gains in excess of expenses and losses	91,360	325,109
OTHER CHANGES IN NET ASSETS WITHOUT DONOR RESTRICTIONS:		
Receipts from supporting organizations	4,229	3,757
Net assets released from restrictions used for purchase of property and equipment	16,626	4,031
Transfers to supporting organizations	(82,346)	(37,181)
Pension and post-retirement health liability adjustment	<u>82,508</u>	<u>149,032</u>
Increase in net assets without donor restrictions	\$ 112,377	\$ 444,748

(Continued on next page)

Children's Hospital Medical Center and Affiliates

Consolidated Statements of Operations and Changes in Net Assets
For the Years Ended June 30, 2022 and 2021 (dollars in thousands)

	<u>2022</u>	<u>2021</u>
NET ASSETS WITH DONOR RESTRICTIONS:		
Contributions and investment income-		
Grant receipts	\$ 220,629	\$ 202,702
Gifts and contributions of financial assets and other income	139,588	140,273
	<u>360,217</u>	<u>342,975</u>
Net assets released from restriction-		
Grant expenditures	(218,688)	(202,492)
Net assets with donor restrictions used to support operations	(129,721)	(109,627)
Net assets with donor restrictions used for purchase of property and equipment	(16,626)	(4,031)
	<u>(365,035)</u>	<u>(316,150)</u>
(Loss) gain in interest in net assets of supporting organizations	<u>(82,879)</u>	<u>1,120,619</u>
(Decrease) increase in net assets with donor restrictions	<u>(87,697)</u>	<u>1,147,444</u>
INCREASE IN NET ASSETS	24,680	1,592,192
NET ASSETS, beginning of year	<u>6,864,608</u>	<u>5,272,416</u>
NET ASSETS, end of year	<u>\$6,889,288</u>	<u>\$6,864,608</u>

See accompanying notes to consolidated financial statements.

Children's Hospital Medical Center and Affiliates

Consolidated Statements of Cash Flows

For the Years Ended June 30, 2022 and 2021 (dollars in thousands)

	<u>2022</u>	<u>2021</u>
CASH FLOWS FROM OPERATING ACTIVITIES:		
Increase in net assets	\$ 24,680	\$ 1,592,192
Adjustments to reconcile increase in net assets to net cash provided by operating activities-		
Depreciation and amortization	151,095	135,955
Loss on disposal of property and equipment	2,077	1,563
Proceeds from sale of donated securities	773	2,176
Receipts from supporting organizations	(4,229)	(3,757)
Contributions of financial assets to supporting organizations	82,346	37,181
Contributions of financial assets restricted for purchase of property and equipment	(16,626)	(4,031)
Loss (gain) in interest in net assets of supporting organizations	82,879	(1,120,619)
Unrealized and realized losses (gains) on marketable securities, net	129,121	(50,232)
Gain on interest rate swap	(7,377)	(3,066)
Increase in receivables	(5,830)	(95,869)
Increase in inventories and prepaid expenses and other assets	(25,623)	(23,161)
Increase in pension benefit asset	(109,334)	(250,640)
Increase in accounts payable and accrued expenses, net	65,286	71,877
Decrease in operating lease obligations	(2,736)	(2,097)
(Decrease) increase in self-insurance reserves and other long-term liabilities	(29,443)	8,443
Net cash provided by operating activities	<u>337,059</u>	<u>295,915</u>
CASH FLOWS FROM INVESTING ACTIVITIES:		
Expenditures for property and equipment	(187,563)	(220,455)
Acquisition of pediatric primary care practices	(277)	(8,583)
Purchases of marketable securities	(1,263,928)	(1,484,503)
Sales and maturities of marketable securities	1,227,728	1,208,023
Cash withdrawn from funds in trust	5,750	1,391
Cash invested in funds in trust	(5,828)	(8,526)
Net cash used in investing activities	<u>(224,118)</u>	<u>(512,653)</u>
CASH FLOWS FROM FINANCING ACTIVITIES:		
Issuance of bonds and notes payable	-	200,000
Repayment of bonds, notes payable, and finance lease obligations	(32,006)	(30,214)
Contributions restricted for purchase of property and equipment	16,626	4,031
Receipts from supporting organizations	4,229	3,757
Contributions to supporting organizations	(82,346)	(37,181)
Net cash (used in) provided by financing activities	<u>(93,497)</u>	<u>140,393</u>
Net increase (decrease) in cash, cash equivalents, and restricted cash	19,444	(76,345)
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH, beginning of year	<u>282,902</u>	<u>359,247</u>
CASH, CASH EQUIVALENTS, AND RESTRICTED CASH, end of year	<u>\$ 302,346</u>	<u>\$ 282,902</u>
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING ACTIVITIES:		
Capital expenditures in accounts payable and accrued expenses	\$ 20,548	\$ 29,882
Acquisition of property through finance leases	\$ 3,337	\$ 5,793
Acquisition of property through operating leases	\$ 3,673	\$ 3,906

See accompanying notes to consolidated financial statements.

Children's Hospital Medical Center and Affiliates

Consolidated Financial Statements

For the Years Ended June 30, 2022 and 2021, respectively (dollars in thousands)

(1) Accounting Policies –

- (a) Basis of Consolidation – Children's Hospital Medical Center (Cincinnati Children's), River City Insurance Limited (River City), CHMC Community Health Services Network (CHSN), HealthVine LLC (HealthVine) and other entities with the purpose to hold land for future use, which are under common management, are included in the accompanying consolidated financial statements and are collectively referred to as Cincinnati Children's. Intercompany transactions and balances have been eliminated.

Cincinnati Children's is an Ohio not-for-profit corporation providing pediatric healthcare services, education, and research. River City is a captive insurance company and a wholly owned subsidiary of Cincinnati Children's. CHSN is a wholly owned subsidiary of Cincinnati Children's whose purpose is to manage primary care practices in a community setting. Other land holding entities are wholly owned subsidiaries of Cincinnati Children's whose purpose is to hold land for future use.

- (b) Supporting Organizations – The Children's Hospital (TCH) and Convalescent Hospital Fund for Children (CHFC) are both Ohio not-for-profit corporations that provide financial support to Cincinnati Children's. The TCH and CHFC purpose clauses both specify the support of Cincinnati Children's as the organization's sole purpose. Additionally, certain endowment funds of these supporting organizations are restricted by the donors for specific operating purposes of Cincinnati Children's. As such, the assets of TCH and CHFC are recorded in Cincinnati Children's consolidated financial statements as Interest in Net Assets of Supporting Organizations and as Net Assets with Donor Restrictions. Changes in the fair value of Interest in Net Assets of Supporting Organizations are recorded as a Gain (Loss) in Interest in Net Assets of Supporting Organizations in the accompanying Consolidated Statements of Operations and Changes in Net Assets.

The majority of receipts are from TCH and CHFC donor-restricted endowment funds or are other receipts that are designated by the supporting organizations' Boards of Trustees for specific operating purposes. The receipts are reflected in Gifts and contributions of financial assets and other income with donor restrictions in the accompanying Consolidated Statements of Operations and Changes in Net Assets. Upon spending, such funds are reflected in Other restricted net assets used to support operations in the Consolidated Statements of Operations and Changes in Net Assets.

Other receipts from TCH are designated by the supporting organization's Board of Trustees to provide general support. The receipts are reflected in Receipts from supporting organizations without donor restrictions in the accompanying Consolidated Statements of Operations and Changes in Net Assets.

- (c) Support Received from Supporting Organizations – TCH and CHFC provide annual support to Cincinnati Children's through transfers of dividend and interest earnings on investments, net of investment management fees, administrative expenses, and donor-required income reinvestments.

The supporting organizations' respective Boards of Trustees may also make certain pledges of principal without donor restriction in support of key projects or initiatives at Cincinnati Children's. In January 2020, CHFC's Board of Trustees made a gift in the amount of \$36,000 to support the construction of a new facility at the College Hill Campus and programmatic support of Cincinnati Children's *Pursuing our Potential in Mental Health* initiative. The agreement has certain criteria that represent donor-imposed conditions that must be overcome before Cincinnati Children's is entitled to the assets promised. Contributions of \$6,651 and \$1,855 were made for the years ended June 30, 2022 and June 30, 2021, respectively. The receipts are reflected in Gifts and contributions of financial assets and other income with donor restrictions and in Net assets used for purchase of property and equipment in the Consolidated Statements of Operations and Changes in Net Assets.

Children’s Hospital Medical Center and Affiliates

Consolidated Financial Statements

For the Years Ended June 30, 2022 and 2021, respectively (dollars in thousands)

The following table details transfers between Cincinnati Children’s and Supporting Organizations in the Consolidated Statements of Operations and Changes in Net Assets:

	<u>2022</u>	<u>2021</u>
Transfers of net assets with donor restrictions included in		
Gifts and contributions of financial assets and other		
income:		
Cincinnati Children's from TCH	\$102,823	\$103,074
Cincinnati Children's from CHFC	11,887	6,280
Total	<u>\$114,710</u>	<u>\$109,354</u>
Transfers of net assets without donor restrictions included in		
Receipts from (Transfers to) supporting organizations:		
Cincinnati Children's from TCH	\$ 4,229	\$ 3,757
Cincinnati Children's to TCH (1)	(82,346)	(37,181)
Total	<u>\$(78,117)</u>	<u>\$(33,424)</u>

(1) The purpose of this transfer is to establish funds designated to support divisional activities and strategic priorities.

- (d) **Revenue Recognition** – The following revenue streams are subject to the revenue recognition guidance in Accounting Standards Codification No. 606 (ASC 606) “Revenue from Contracts with Customers”:

	<u>2022</u>	<u>2021</u>
Net patient service revenue	\$2,369,523	\$2,226,690
Other revenue	193,115	207,082
	<u>\$2,562,638</u>	<u>\$2,433,772</u>

Net Patient Service Revenue

Cincinnati Children’s net patient service revenue generally relates to contracts with patients in which the performance obligations are to provide health care services to patients. As patients simultaneously receive and consume the benefits of health care provided by Cincinnati Children’s, the performance obligations meet the criteria to be satisfied over time. Net patient service revenue is recorded as services are provided. Payment for such services is due between thirty to forty-five days from payer receipt of claim. Consideration for patient service revenue is variable. Agreements with payers typically provide for payments at amounts less than established charges.

Effective January 1, 2021, Cincinnati Children’s signed an agreement with an Ohio Medicaid managed care company in which performance obligations are to stand-ready to provide care for approximately 130,000 children. The performance obligation to stand-ready is satisfied over time. Cincinnati Children’s is reimbursed under a variable capitation methodology for hospital services. All physician and home care services are reimbursed based on provider fee schedules. The hospital services are reimbursed through a variable capitation payment which represents the amount remaining after payment has been made for (a) Cincinnati Children’s physician services, (b) Cincinnati Children’s home care services, (c) services provided to members by facilities outside the Cincinnati Children’s network, and (d) an actuarially determined accrual for incurred but not reported claims (see Note 1h). Under delegation agreements, Cincinnati Children’s receives fixed payments to perform the required medical management, care management and care coordination functions. Medicaid managed care organizations retain risk for payments to providers. The amount of net patient service revenue recorded under this arrangement in fiscal year 2022 and 2021 was \$174,467 and \$103,836, respectively.

Laws and regulations concerning government programs, including Medicaid and Medicare, are complex and subject to varying interpretation. As a result of investigations by governmental agencies, various health care organizations have received requests for information and notices regarding alleged noncompliance with those laws and regulations, which, in some instances, have resulted in organizations entering into significant settlement agreements. Compliance with such laws and regulations may also be subject to future government review and interpretation as well as significant regulatory action, including fines, penalties, and potential exclusion from related programs. There can be no assurance that regulatory authorities will not challenge Cincinnati Children's compliance with these laws and regulations, and it is not possible to determine the impact (if any) such claims or penalties would have upon Cincinnati Children's. In addition, the contracts Cincinnati Children's has with third party payers also provide for retroactive audit and review of claims. At June 30, 2022, Cincinnati Children's has settled all Medicaid cost reports through 2016 and all Medicare cost reports through 2020.

Settlements with third party payers for retroactive adjustments due to audits, reviews or investigations are considered variable consideration and are included in the determination of estimated transaction price for providing patient care. These settlements are based on the terms of the payment agreement with the payer, correspondence from the payer, and Cincinnati Children's historical settlement activity, including an assessment to ensure that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. Estimated settlements are adjusted in future periods as adjustments become known based on new information or as years are settled and no longer subject to such audits, reviews, and investigations. Adjustments arising from a change in transaction price were not material in fiscal years 2022 and 2021.

Generally, patients who are covered by third party payers are responsible for related deductibles and coinsurance, which vary in amount. Cincinnati Children's also provides services to uninsured patients and offers those uninsured patients a discount, either by policy or law, from standard charges. Cincinnati Children's estimates the transaction price for patients with deductibles and coinsurance and from those who are uninsured based on historical experience and current market conditions. The initial estimate of the transaction price is determined by reducing the standard charge by established contractual adjustments, discounts, and implicit price concessions. Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to patient service revenue in the period of change.

Consistent with Cincinnati Children's mission, care is provided to patients regardless of their ability to pay. Therefore, Cincinnati Children's has determined it has provided implicit price concessions to uninsured patients and patients with other uninsured balances. The implicit price concessions included in estimating the transaction price represent the difference between the amounts billed to patients and the amounts Cincinnati Children's expects to collect based on its collection history with those patients.

Patients who meet Cincinnati Children's criteria for charity care are provided care without charge or at amounts less than established rates. Amounts determined to qualify as charity care are not reported as net patient service revenue.

Because the majority of its performance obligations relate to contracts with a duration of less than one year, Cincinnati Children's has elected to apply the optional exemption provided in FASB ASC 606-10-50-14(a) and, therefore, is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the fiscal year. The unsatisfied or partially unsatisfied performance obligations referred to above are primarily related to inpatient acute care services at the end of the fiscal year. The performance obligations for these contracts are generally completed when patients are discharged, which generally occurs shortly after the end of the fiscal year.

Children’s Hospital Medical Center and Affiliates

Consolidated Financial Statements

For the Years Ended June 30, 2022 and 2021, respectively (dollars in thousands)

In both fiscal years 2022 and 2021, substantially all of net patient service revenue is derived from third-party payment programs (Medicaid, insurance companies and various managed care agreements). Cincinnati Children’s classifies its patients by payer. The following table disaggregates Cincinnati Children’s net patient service revenue by payer categories for the fiscal year ended June 30, 2022 and 2021:

	2022		2021	
Commercial insurers	1%	\$ 23,695	1%	\$ 22,266
Managed care	62%	1,469,104	63%	1,402,815
Government (HMO and third party)	31%	734,552	28%	623,473
International	3%	71,086	4%	89,068
Specialty contracts ¹	2%	47,390	3%	66,801
Self-pay	1%	23,696	1%	22,267
		\$2,369,523		\$2,226,690

The following details the percentage of accounts receivable by payer category as of June 30, 2022 and 2021:

	2022	2021
Commercial insurers	1%	2%
Managed care	56%	63%
Government (HMO and third party)	23%	20%
International	11%	7%
Specialty contracts ¹	6%	7%
Self-pay	3%	1%

Other Revenue

Cincinnati Children’s other revenue generally relates to contracts with external organizations in which the performance obligations are to provide research services or other various fee-for-service arrangements outside the scope of healthcare services. Relief funds received as a result of the Coronavirus Aid, Relief, and Economic Security (CARES) Act are also included in other revenue. See Note 1(s) for further discussion on the COVID-19 Pandemic.

Revenue from industry contracts and certain government contracts is earned based on performance obligations to provide research services to the external organizations. License and royalty revenue relates to contracts with other organizations in which our performance obligations are to provide intellectual property to the organization. Revenue is also earned for various other contracted fee-for-service arrangements where services are performed for external organizations outside the scope of healthcare services for Cincinnati Children’s patients. Performance obligations for industry and government contracts, license and royalty contracts, and various other fee-for-service arrangements are satisfied over time. Consideration is fixed based on contracted price, and there is no significant variable consideration related to these agreements.

- (e) Graduate Medical Education – Cincinnati Children’s receives Federal graduate medical education funding. Other revenue of \$11,762 and \$11,188 was recognized for the years ended June 30, 2022 and 2021, respectively.

¹ Specialty contracts are single case agreements or contracts for specialty services, such as transplants.

Children’s Hospital Medical Center and Affiliates

Consolidated Financial Statements

For the Years Ended June 30, 2022 and 2021, respectively (dollars in thousands)

- (f) Tax Exempt Status – Cincinnati Children’s, CHSN and HealthVine are recognized by the Internal Revenue Service as exempt from federal income taxes under Section 501(a) of the Internal Revenue Code as charitable organizations qualifying under Section 501(c)(3). River City is a captive insurance company and has no income tax obligations. Other land holding entities with the purpose to hold land for future use are limited liability corporations whose income is taxable to Cincinnati Children’s. The income tax provisions recorded in the accompanying consolidated financial statements are immaterial for the years ended June 30, 2022 and 2021.

Cincinnati Children’s accounts for income taxes in accordance with Accounting Standards Codification Topic (ASC) 740 “Income Taxes”. It is Cincinnati Children’s policy to classify the expense related to interest and penalties, if any, to be paid on underpayments of income taxes within other expenses. There were no material penalties or interest recognized in fiscal years 2022 and 2021. Cincinnati Children’s paid \$5,227 in income taxes for unrelated business income during the year ended June 30, 2022.

Fiscal years 2019 through 2022 are subject to examination by both the Federal and State tax jurisdictions.

- (g) Cash Equivalents – Cash equivalents consist primarily of money market investments (including money market mutual funds) and demand deposits. Money market investments have maturities of 90 days or less at the time of purchase. Cash is held primarily in two financial institutions.
- (h) Inventories and Prepaid Expenses – Inventories consist primarily of medical supplies and pharmaceuticals and are valued on an average cost method.

As part of Cincinnati Children’s variable capitation agreement, reimbursement is reduced by an actuarially determined estimate for incurred but not reported claims. Cincinnati Children’s recorded incurred but not reported claims of approximately \$23,507 and \$21,107 for the years ended June 30, 2022 and 2021, respectively. The estimate is recorded as an increase in prepaid expenses and an increase in accounts payable and accrued expenses.

- (i) Marketable Securities – Cincinnati Children’s accounts for its investments under ASC 958-320 “Not-for-Profit Entities – Investments – Debt Securities” and ASC 958-321 “Not-for-Profit Entities – Investments – Equity Securities.” Cincinnati Children’s carries its marketable securities at fair value with unrealized gains and losses included in net investment return (loss) in the accompanying Consolidated Statements of Operations and Changes in Net Assets.

At both June 30, 2022 and 2021, 19% of Cincinnati Children’s marketable securities were invested in U.S. Treasury securities.

- (j) Property and Equipment – Property and equipment are stated at cost. Depreciation is computed on a straight-line basis over the estimated useful lives of the assets, ranging from three to forty years, as follows:

Land Improvements	3-25 years
Buildings and Building Improvements	5-40 years
Equipment	3-25 years

Cincinnati Children’s evaluates long-lived assets under the provisions of ASC 360 “Property Plant and Equipment.” During fiscal years 2022 and 2021, Cincinnati Children’s did not incur any losses related to impairment of property and equipment.

- (k) Goodwill – Goodwill is the excess of the purchase price over the fair value of the net assets of an entity acquired. Cincinnati Children’s acquired the assets of a pediatric primary care practice, resulting in

Children's Hospital Medical Center and Affiliates

Consolidated Financial Statements

For the Years Ended June 30, 2022 and 2021, respectively (dollars in thousands)

goodwill of \$8,583 in fiscal year 2021, and elected to apply the accounting alternatives available for not-for-profit entities. During the year ended June 30, 2022, no amounts were recorded to goodwill. Goodwill is amortized over a 10-year period and tested for impairment when a triggering event occurs. During fiscal year 2022 and 2021, \$858 and \$429 of amortization expense and no impairment losses were recognized, respectively.

- (l) Leases – Cincinnati Children's leases property and equipment under finance and operating leases. Cincinnati Children's determines if an arrangement is a lease at inception. Right-of-use assets and lease obligations are recognized for leases with terms greater than 12 months based on the net present value of the future minimum lease payments over the lease term at commencement date. When readily determinable, Cincinnati Children's uses the interest rate implicit in the lease to determine the present value of future minimum lease payments. However, most of Cincinnati Children's leases do not have a readily determinable implicit interest rate. For these leases, Cincinnati Children's uses a collateralized incremental borrowing rate based on the period and cash payment stream comparable with that of each lease. The right-of-use asset and lease obligations include a value for options to extend a lease if it is reasonably certain that the option will be exercised.

The current portion of operating lease obligations is included in the current portion of long-term debt and lease obligations and the non-current portion is separately stated as operating lease obligations on the consolidated balance sheets. The related right-of-use assets are included in operating lease right-of-use assets on the consolidated balance sheets. Operating lease expense is recognized on a straight-line basis over the lease term and is included in purchased services in the consolidated statements of operations and changes in net assets.

The current portion of finance lease obligations is included in current portion of long-term debt and lease obligations and the non-current portion is separately broken out as finance lease obligations on the consolidated balance sheets. The related finance lease right-of-use assets are included in property and equipment, net on the consolidated balance sheets. Finance lease right-of-use assets are amortized using the straight-line method over the shorter period of the lease term or the estimated useful life of the property or equipment. Such amortization expense is included in depreciation in the consolidated statements of operations and changes in net assets.

- (m) Costs of Borrowing – Interest incurred on borrowed funds, net of interest earned on restricted bond funds, during the period of construction of capital assets is capitalized as a component of the cost of acquiring those assets. In fiscal years 2022 and 2021, Cincinnati Children's capitalized \$4,329 and \$11,013 of interest related to construction in progress, respectively. Total cash paid for interest was approximately \$35,339 and \$33,655 in fiscal years 2022 and 2021, respectively.

Deferred bond issuance costs and issuance premiums are amortized using the effective interest method over the period the related obligation is outstanding.

- (n) Interest Rate Swap Agreement – Cincinnati Children's has an interest rate swap agreement to manage interest rate risk associated with the variable rate 2018Z and 2018AA bonds. The swap agreement is measured at fair value and recognized in the Consolidated Balance Sheets within other long-term liabilities. Cincinnati Children's recognizes gains and losses from the changes in fair value of the interest rate swap agreement as non-operating gains and losses within net investment return on the Consolidated Statements of Operations and Changes in Net Assets.

- (o) Net Asset Classifications – Cincinnati Children's reports its financial position and activities according to the following net asset classifications:

Children's Hospital Medical Center and Affiliates

Consolidated Financial Statements

For the Years Ended June 30, 2022 and 2021, respectively (dollars in thousands)

Net assets without donor restrictions – Net assets that are not subject to donor-imposed restrictions and may be expended for any purpose in performing the primary objective of the organization are classified as net assets without donor restrictions. These net assets may be used at the discretion of management of Cincinnati Children's.

Net assets with donor restrictions – Net assets subject to stipulations imposed by donors or supporting organizations are classified as net assets with donor restrictions. Some restrictions are temporary in nature; those restrictions will be met by fulfilling a certain purpose or by the passage of time. Other donor restrictions are perpetual in nature, whereby the donor has stipulated the principal be maintained in perpetuity.

Net assets with donor restrictions are comprised of the following:

	<u>2022</u>	<u>2021</u>
Subject to expenditure for specified purpose:		
Clinical	\$ 40,735	\$ 40,342
Research	96,634	93,558
Education	16,736	16,493
General Administration and Other	<u>35,921</u>	<u>44,831</u>
	190,026	195,224
Subject to expenditure for specified purpose, held at supporting organizations:		
Research	14,525	15,507
Education	1,075	1,144
General Administration and Other	<u>4,326</u>	<u>4,604</u>
	19,926	21,255
Subject to expenditure based on Board discretion of the supporting organization, held at supporting organizations	<u>2,179,232</u>	<u>2,202,814</u>
	2,179,232	2,202,814
Investment in perpetuity, the income from which is expendable for specified purpose, held at Cincinnati Children's:		
Clinical	1,161	917
Research	18,120	17,929
Education	1,307	1,352
General Administration and Other	<u>2,990</u>	<u>3,000</u>
	23,578	23,198

(Continued on next page)

Children’s Hospital Medical Center and Affiliates

Consolidated Financial Statements

For the Years Ended June 30, 2022 and 2021, respectively (dollars in thousands)

Investment in perpetuity, the income from which is expendable for specified purpose, held at supporting organizations:

Clinical	53,484	46,872
Research	2,044,408	2,099,458
Education	88,275	91,815
General Administration and Other	75,176	81,498
	<u>2,261,343</u>	<u>2,319,643</u>
Subject to appropriation and expenditure when a specified event occurs:		
Upon death of insured party	2,290	1,958
	<u>2,290</u>	<u>1,958</u>
Total net assets with donor restrictions	<u>\$4,676,395</u>	<u>\$4,764,092</u>

- (p) Revenue and Gains in Excess of Expenses and Losses – The Consolidated Statements of Operations and Changes in Net Assets subtotals operating revenues, gains and other support, operating expenses and nonoperating gains as Revenue and gains in excess of expenses and losses. Other changes in net assets without donor restrictions are receipts from and transfers to supporting organizations, pension and post-retirement health liability adjustments, and net assets released from restrictions used for purchase of property and equipment, which are excluded from Revenue and gains in excess of expenses and losses.
- (q) Use of Estimates – The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
- (r) New Accounting Pronouncements – In August 2018, the FASB issued ASU 2018-15, *Intangibles—Goodwill and Other (Topic 350): Internal-Use Software*. This standard aligns the requirements for capitalizing implementation costs incurred in a cloud computing arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The standard is effective for fiscal years beginning after December 15, 2020. Cincinnati Children’s adopted ASU 2018-15 effective July 1, 2021. Adopting this standard had no material impact on the consolidated financial statements.

In September 2020, the FASB issued ASU 2020-07, *Not-for-Profit Entities (Topic 958): Presentation and Disclosures by Not-for-Profit Entities for Contributed Nonfinancial Assets*. This ASU changes the presentation and disclosure requirements for not-for-profit entities to increase transparency about contributed nonfinancial assets. The ASU is effective for annual periods beginning after June 15, 2021, and interim periods within annual periods beginning after June 15, 2022, with early adoption permitted. Cincinnati Children’s adopted this standard effective July 1, 2021 and has determined that the impact on the consolidated financial statements is not material.

Children’s Hospital Medical Center and Affiliates

Consolidated Financial Statements

For the Years Ended June 30, 2022 and 2021, respectively (dollars in thousands)

- (s) The Coronavirus Aid, Relief, and Economic Security (“CARES”) Act – The CARES Act was passed by Congress on March 27, 2020 to aid organization and individuals with the economic impacts of COVID-19. Cincinnati Children’s received \$22,191 and \$50,000 in relief funds from the Department of Health and Human Services in fiscal years 2022 and 2021, respectively. Relief funds are recorded as other revenue in the Operating revenues, gains and other support section of the Consolidated Statements of Operations and Changes in Net Assets for the years ended June 30, 2022 and 2021.

In addition to the distribution of relief funds, the CARES Act also included electable payroll tax credits and deferrals. Cincinnati Children’s elected to delay payment of the employer portion of the Social Security payroll taxes on wages paid from March 27, 2020 through December 31, 2020 in the amount of \$45,656. Half of the total deferred amount was paid in December 2021 and the remaining portion is due by December 31, 2022. At June 30, 2022, deferred payroll taxes of \$22,828 are included in Accounts payable and accrued expenses on the Consolidated Balance Sheets. At June 30, 2021, deferred payroll taxes of \$22,828 were included in Other Long-Term Liabilities, and \$22,828 were included in Accounts payable and accrued expenses on the Consolidated Balance Sheets.

(2) Liquidity and Availability –

Financial assets available for general expenditure within one year of the balance sheet date consist of the following:

	<u>2022</u>	<u>2021</u>
Amounts available for general expenditure		
Cash and cash equivalents	\$ 293,360	\$ 274,863
Marketable securities	1,259,210	1,352,918
Patient receivables, net	511,704	506,944
Other receivables	141,986	140,916
	<u>2,206,260</u>	<u>2,275,641</u>
Less: Board-designated assets	100,000	100,000
Financial assets available for general expenditure	<u>\$2,106,260</u>	<u>\$2,175,641</u>

Cincinnati Children’s has cash and cash equivalents, marketable securities (more fully described in Note 4), patient receivables and certain other receivables which are liquid and available for general expenditure within one year in the normal course of operations. Accordingly, these assets have been included in the quantitative information above. During fiscal 2021, the Board of Trustees designated \$100,000 from net assets without donor restrictions to be used to support Cincinnati Children’s community pillar of the *Pursuing Our Potential Together* strategic plan. Cincinnati Children’s has other assets limited to use for professional liability, self-insurance health care and debt service, as well as perpetual endowments with donor restrictions. These assets limited to use, which are more fully described in Notes 4 and 6, are not available for general expenditure within the next year and are not reflected in the amounts above.

Cincinnati Children’s has \$186,302 in outstanding obligations for which liquid funds must be available for payment in the event of a failed remarketing. Cincinnati Children’s maintains certain balances in cash and investments and has access to a \$100,000 line of credit, as discussed in more detail in Note 9.

Additionally, Cincinnati Children’s is required to maintain certain liquidity ratios as outlined in bond covenants. As of June 30, 2022 and 2021, Cincinnati Children’s was in compliance with all such covenants.

Cincinnati Children’s forecasts its future cash flows and monitors liquidity on an ongoing basis.

Children’s Hospital Medical Center and Affiliates

Consolidated Financial Statements

For the Years Ended June 30, 2022 and 2021, respectively (dollars in thousands)

(3) Reconciliation of Cash, Cash Equivalents, and Restricted Cash –

The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the Consolidated Balance Sheets that sum to the total of the same such amounts shown in the Consolidated Statement of Cash Flows for the fiscal years ending June 30, 2022 and 2021:

	<u>2022</u>	<u>2021</u>
Cash and cash equivalents	\$293,360	\$274,863
Restricted cash included in other long-term assets	8,986	8,039
Total cash, cash equivalents, and restricted cash shown in the statement of cash flows	<u>\$302,346</u>	<u>\$282,902</u>

(4) Fair Value Measurements –

Cincinnati Children’s accounts for its assets and liabilities under ASC 820 “Fair Value Measurements.” As defined in ASC 820, fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements and related disclosures, ASC 820 establishes a fair value hierarchy that prioritizes inputs to valuation techniques used to measure fair value into three broad levels, which are described below:

Level 1: Quoted Prices (unadjusted) in active markets for identical assets or liabilities that are accessible at the measurement date for assets and liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs.

Level 2: Inputs other than quoted prices included within Level 1 that are observable for the assets or liabilities, either directly or indirectly. These include quoted prices for identical or similar assets or liabilities in markets that are not active, that is, markets in which there are a few transactions for the asset or liability, the prices are not current, or price quotations vary substantially either over time or among market makers, or in which little information is released publicly and inputs that are derived principally from or corroborated by observable market data by correlation or other means.

Level 3: Unobservable inputs, developed using Cincinnati Children’s estimates and assumptions, which reflect those that the market participants would use. Such inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs.

Determining where an asset or liability falls within the hierarchy depends on the lowest level input that is significant to the fair value measurement as a whole. In determining fair value, Cincinnati Children’s utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in the assessment of fair value.

Children's Hospital Medical Center and Affiliates

Consolidated Financial Statements

For the Years Ended June 30, 2022 and 2021, respectively (dollars in thousands)

The table below includes the major categorization for financial instruments on the basis of the nature and risk of the investments at June 30, 2022.

	Level 1	Level 2	Level 3	Total
Marketable Securities:				
U.S. Government and agency securities	\$ -	\$328,313	\$ -	\$ 328,313
Foreign bonds	-	53,936	-	53,936
Municipal bonds	-	16,595	-	16,595
Common stock	227,167	-	-	227,167
Corporate obligations	-	438,485	-	438,485
Bond mutual funds	24,782	-	-	24,782
Total marketable securities measured in the fair value hierarchy	251,949	837,329	-	1,089,278
Full discretion fixed income ²	-	-	-	169,932
	251,949	837,329	-	1,259,210
Assets Limited As To Use:				
Money market mutual funds	9,144	-	-	9,144
Common stock	23,131	-	-	23,131
	32,275	-	-	32,275
Deferred Compensation Plans (included in Other Receivables and Other Long-term Assets):				
Common stock	7,779	-	-	7,779
Mutual funds:				
Money market	1,122	-	-	1,122
Equity	663	-	-	663
International equity	325	-	-	325
Bond	732	-	-	732
Lifecycle	3,773	-	-	3,773
Variable annuities	-	73	-	73
Guaranteed insurance contract	-	-	763	763
	14,394	73	763	15,230
Derivative Investments (included in Other-Long-term Assets):				
Interest rate swap agreement	-	4,421	-	4,421
Total investments at fair value	\$298,618	\$841,823	\$763	\$1,311,136

² Certain investments that are measured at fair value using the net asset value per share (or its equivalent) practical expedient have not been categorized in the fair value hierarchy. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the Consolidated Balance Sheet.

Children's Hospital Medical Center and Affiliates

Consolidated Financial Statements

For the Years Ended June 30, 2022 and 2021, respectively (dollars in thousands)

The table below includes the major categorization for financial instruments on the basis of the nature and risk of the investments at June 30, 2021.

	Level 1	Level 2	Level 3	Total
Marketable Securities:				
U.S. Government and agency securities	\$ -	\$370,368	\$ -	\$ 370,368
Foreign bonds	-	46,067	-	46,067
Municipal bonds	-	9,347	-	9,347
Common stock	239,044	-	-	239,044
Corporate obligations	-	471,451	-	471,451
Bond mutual funds	25,086	-	-	25,086
Total marketable securities measured in the fair value hierarchy	264,130	897,233	-	1,161,363
Full discretion fixed income ³	-	-	-	191,555
	264,130	897,233	-	1,352,918
Assets Limited As To Use:				
Money market mutual funds	9,088	-	-	9,088
Common stock	22,162	-	-	22,162
	31,250	-	-	31,250
Deferred Compensation Plans (included in Other Receivables and Other Long-term Assets):				
Common stock	8,116	-	-	8,116
Mutual funds:				
Money market	1,203	-	-	1,203
Equity	950	-	-	950
International equity	587	-	-	587
Bond	972	-	-	972
Lifecycle	3,384	-	-	3,384
Variable annuities	-	208	-	208
Guaranteed insurance contract	-	-	469	469
	15,212	208	469	15,889
Derivative Investments (included in Other-Long-term Liabilities):				
Interest rate swap agreement	-	(2,956)	-	(2,956)
Total investments at fair value	\$310,592	\$894,485	\$469	\$1,397,101

The valuation methods described below may produce a fair value calculation that may not be indicative of net realizable value or reflective of future fair values. Furthermore, although management believes its valuation methods are appropriate and consistent with other market participants, the use of different methodologies or assumptions to determine the fair value of certain financial instruments could result in different fair value measurement at the reporting date.

The carrying amount and fair value of cash and cash equivalents, accounts receivable, and accounts payable approximate fair value.

Cincinnati Children's uses quoted market prices in active markets to determine the fair value of common stock and mutual funds; such items are classified as Level 1 in the fair value hierarchy.

³ Certain investments that are measured at fair value using the net asset value per share (or its equivalent) practical expedient have not been categorized in the fair value hierarchy. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the Consolidated Balance Sheet.

Children’s Hospital Medical Center and Affiliates

Consolidated Financial Statements

For the Years Ended June 30, 2022 and 2021, respectively (dollars in thousands)

Cincinnati Children’s primarily bases fair value for investments in fixed income securities, including U.S. government securities, municipal bonds and corporate obligations on a calculation using interest rate curves and credit spreads applied to the terms of the debt instrument (maturity and coupon interest rate). Consideration is also given to the counterparty credit rating. Such items are classified as Level 2 in the fair value hierarchy.

Cincinnati Children’s interest rate swap agreement (Note 14) is a derivative instrument valued using the income approach, which uses market inputs to discount future cash flows to a single present amount based on market expectations.

Cincinnati Children’s investment in Full Discretion Fixed Income is an investment in a limited liability company whose investment objective is to invest in marketable and non-marketable securities with issue and industry diversification. As set forth in the LLC agreement, the LLC will dissolve on May 22, 2047, but may dissolve earlier under certain conditions. Any Investing Member may elect to withdraw, in whole or in part from the LLC if the Member notifies of intent to withdraw sixty calendar days in advance. The Full Discretion Fixed Income is measured at fair value using the net asset value per share practical expedient.

The guaranteed insurance contract is recorded based on discounted cash flows, which is an approximation of fair value, and is classified as Level 3 based on time restrictions for redemption.

Activity and transfers into and out of Level 3 and the reasons for those transfers are as follows:

<u>2022</u>	<u>Guaranteed Insurance Contracts</u>
Purchases	\$335
Issues	-
<u>2021</u>	<u>Guaranteed Insurance Contracts</u>
Purchases	\$132
Issues	-

Cincinnati Children’s policy is to recognize transfers in and out as of the actual date of the event or change in circumstances that caused the transfer. For the years ended June 30, 2022 and 2021, there were no material transfers in or out of Levels 1, 2 or 3.

(5) Losses on the Provision of Uncompensated Care –

In accordance with its mission and purpose, Cincinnati Children’s maintains a policy of providing medically necessary services to pediatric patients within its primary service area regardless of ability to pay. This primary service area has been defined to include the four counties in Ohio, three counties in Kentucky and one county in Indiana that geographically surround Cincinnati. Under certain circumstances, Cincinnati Children’s accepts patients from outside the primary service area regardless of their ability to pay. Cincinnati Children’s defines uncompensated care as services rendered to patients whose families’ annual income or net worth falls below certain minimum standards. As such, losses absorbed by Cincinnati Children’s in rendering services to patients who are covered under governmental programs which are designed to aid low-income families (primarily the Medicaid program) are considered uncompensated care.

Children's Hospital Medical Center and Affiliates

Consolidated Financial Statements

For the Years Ended June 30, 2022 and 2021, respectively (dollars in thousands)

The following information summarizes uncompensated care provided during the years ended June 30, 2022 and 2021:

CHARGES	2022	2021
Charges under Medicaid and other entitlement programs	\$2,320,168	\$1,982,947
Charity care not eligible for Medicaid assistance, at established charges	23,405	24,580
Other uncollectible self-pay, at established charges	20,295	19,442
Total Medicaid, charity care and other uncollectible self-pay charges	<u>\$2,363,868</u>	<u>\$2,026,969</u>
COSTS/LOSSES		
Estimated costs to provide uncompensated care	\$(1,015,752)	\$(851,532)
Reimbursement from Medicaid programs	714,615	611,230
Losses on the provision of uncompensated care	(301,137)	(240,302)
Funds received from HCAP and tax levy	34,068	31,463
Losses on provision of uncompensated care net of HCAP and tax levy	<u>\$ (267,069)</u>	<u>\$ (208,839)</u>

The 2022 and 2021 cost amounts reflected in the tables above are calculated using cost to charge ratios calculated from preliminary cost reports because the current year cost report is not yet available. Management does not believe the use of preliminary data would have a material impact on the amounts calculated above.

(6) Funds in Trust –

Cincinnati Children's has certain funds, which are invested and held in trust for various specified purposes. Funds are carried at fair value with unrealized gains and losses included in net investment return in the accompanying Consolidated Statements of Operations and Changes in Net Assets. The amounts of such funds, at carrying value, and the specified purposes for which such funds may be used, are set forth below:

	June 30,	
	2022	2021
Self-insurance Funds-		
Professional liability	\$ 159	\$ 159
Employee health and workers' compensation	140	140
Bond interest and principal escrow funds	8,687	7,740
Endowment funds held in perpetual trust	23,289	23,211
	<u>\$32,275</u>	<u>\$31,250</u>

Children's Hospital Medical Center and Affiliates

Consolidated Financial Statements

For the Years Ended June 30, 2022 and 2021, respectively (dollars in thousands)

(7) Property and Equipment –

Property and equipment consists of the following:

	June 30,	
	2022	2021
Land	\$ 42,208	\$ 42,158
Land improvements	38,135	31,645
Buildings and building improvements	2,009,554	1,610,173
Equipment	765,716	693,081
Construction in progress	87,544	416,644
	<u>2,943,157</u>	<u>2,793,701</u>
Accumulated depreciation	(1,510,549)	(1,389,988)
Property and equipment, net	<u>\$1,432,608</u>	<u>\$1,403,713</u>

(8) Professional Liability –

Cincinnati Children's insurance program includes a self-insured retention for losses arising out of healthcare professional liability claims. The current self-insured retention for asserted claims is \$10,000 (\$25,000 in aggregate). Cincinnati Children's regularly purchases excess healthcare professional liability insurance on a claims made basis at varying levels.

The actuarial present value of expected costs (including incurred, but not reported claims) for the healthcare professional liability program of \$25,274 and \$22,184 for 2022 and 2021, respectively, has been accrued in the accompanying Consolidated Balance Sheets. Accrued healthcare professional liability losses have been discounted at a rate of 4% at June 30, 2022 and 2021. The costs of Cincinnati Children's healthcare professional liability program, including premiums paid for excess re-insurance, legal fees, settlements, judgments, and other administrative costs are included in Supplies, Drugs and Other in the accompanying Consolidated Statements of Operations and Changes in Net Assets. Accrued losses funding levels are actuarially determined based on management's estimation of potential outstanding loss liabilities, payout patterns, and various other assumptions, and then adjusted to reflect its best estimate of the present value of expected costs for the healthcare professional liability claims. Healthcare professional liability expense was \$12,278 and \$5,359 for fiscal years 2022 and 2021, respectively.

Children's Hospital Medical Center and Affiliates

Consolidated Financial Statements

For the Years Ended June 30, 2022 and 2021, respectively (dollars in thousands)

(9) Debt –

Debt at June 30, 2022 and 2021 is summarized as follows:

	<u>2022</u>	<u>2021</u>
Series 2018BB commercial paper, variable interest (1.50% to 1.56% at June 30, 2022), taxable	\$100,000	\$100,000
Bonds payable:		
Series 2011, 2.18% due through 2022	-	8,480
Series 2014S, 3.0% to 5.0% due through 2034, net of unamortized premium of \$1,987 in 2022 and \$2,662 in 2021	85,546	92,029
Series 2014T, 4.268% due 2044, taxable	297,899	297,804
Series 2016X, 5.00%, due through 2032, net of unamortized premium of \$7,923 in 2022 and \$8,744 in 2021	59,164	59,937
Series 2016Y, 2.853% due 2026, taxable	99,644	99,558
Series 2018Z*, variable interest (0.89% at June 30, 2022), due through 2037	33,914	36,012
Series 2018AA*, variable interest (0.88% at June 30, 2022), due through 2037	52,387	55,627
Series 2019CC, 5.0% due through 2049, net of unamortized premium of \$57,927 in 2022 and \$60,360 in 2021	192,332	194,715
Series 2020DD, 2.82% due 2051, taxable	198,633	198,585
Notes Payable:		
Term Note Payable, 2.20% due 2022	-	6,000
Total	<u>1,119,519</u>	<u>1,148,747</u>
Less:		
Current portion of bonds and notes payable	(9,125)	(20,385)
Commercial paper notes	(100,000)	(100,000)
Bonds payable subject to remarketing, net	(86,302)	(91,640)
Bonds payable and notes payable - long-term	<u>\$924,092</u>	<u>\$936,722</u>

*Denotes variable rate bonds subject to remarketing agreements

- (a) **Bonds Payable** – Cincinnati Children's has pledged gross revenues to secure the payment of 2014S, 2014T, 2016X, 2016Y, 2018Z, 2018AA, 2019CC, and 2020DD bonds. Cincinnati Children's is bound by certain financial covenants included in the bond indentures, direct placement agreements, and related agreements, including a requirement to maintain a minimum Debt Service Coverage Ratio.

The 2018Z and 2018AA tax-exempt bonds are subject to mandatory tender purchase seven days after notice from bondholders and may be remarketed. If the bonds are not remarketed, Cincinnati Children's must repay the bonds. The 2018Z and 2018AA bonds are classified as current liabilities in bonds payable subject to remarketing, net in the accompanying Consolidated Balance Sheets. The interest rates on the 2018Z and 2018AA variable rate bonds are reset weekly by a rate-setting agent.

- (b) **Commercial Paper** – The Series 2018BB taxable commercial paper was issued in the original aggregate principal amount of \$100,000 and outstanding at any one time in a principal amount not to exceed \$100,000. The Notes shall mature no later than May 15, 2048. The commercial paper notes have a maximum maturity period of 270 days and are resold at maturity. In the event the notes have not been resold, Cincinnati Children's must repay the notes. The 2018BB commercial paper is classified as current liabilities in the accompanying Consolidated Balance Sheets. The interest rates on the 2018BB commercial paper are reset with each remarketing by a rate-setting agent.

Children’s Hospital Medical Center and Affiliates

Consolidated Financial Statements

For the Years Ended June 30, 2022 and 2021, respectively (dollars in thousands)

- (c) Future Debt Maturities – The following is a schedule of future debt maturities, excluding discounts/premiums and deferred issuance costs:

2023	\$ 195,895
2024	9,060
2025	9,510
2026	9,750
2027	109,800
Thereafter	724,035
	<u>\$1,058,050</u>

- (d) Line of Credit – In June 2020, Cincinnati Children’s entered into a 1-year agreement for a line of credit of \$100,000. The line of credit agreement was amended in June 2021 to extend the maturity date to June 2024. The line of credit bears interest at the greater of the Daily Reset LIBOR Rate or 0.50%, plus 50 basis points. In the event LIBOR is no longer available, the line of credit bears interest at the daily SOFR rate, plus an adjustment spread. There were no draws on the line of credit during fiscal year 2022 or 2021.

(10) Employee Benefit Plans –

Cincinnati Children’s maintains non-contributory retirement plans covering substantially all employees. Among these plans is a defined benefit plan where benefits are based on a formula which reflects years of service and salary levels. Cincinnati Children’s funding policy for its defined benefit plan meets the funding standards established by the Employee Retirement Income Security Act of 1974 (ERISA).

Cincinnati Children’s investment strategy with respect to pension assets is designed to achieve a moderate level of overall portfolio risk in keeping with desired risk objective, which is established through careful consideration of plan liabilities, plan funded status and corporate financial condition. Cincinnati Children’s adopted an Investment Policy that adjusts allocations between return-seeking assets and liability-hedging assets based on the funded status of the Plan and prevailing yields. As the funded ratio improves, allocations to liability-hedging assets increase accordingly.

Cincinnati Children’s seeks to maintain diversified portfolios and has adopted allocation targets within the return-seeking and liability hedging portfolios as follows:

Return-Seeking Allocation:	Min - Target -Max
Global Equity	60% - 70% - 80%
Private Equity	5% - 10% - 15%
Private Real Estate	5% - 10% - 15%
Multi-Asset Credit	5% - 10% - 15%
Opportunity Allocation	0% - 0% - 10%
Liability-Hedging Allocation:	
Long Credit	50% - 75% - 100%
STRIPS (Long Duration Treasury Instruments)	0% - 25% - 50%

In order to maintain the portfolio’s actual asset allocation in line with the target allocations specified above, rebalancing will occur periodically. As of June 30, 2022, Cincinnati Children’s has made \$126,400 in funding commitments in eleven investment partnerships of which \$106,700 has been funded. Additionally, Cincinnati Children’s has made \$82,500 in funding commitments in ten real estate investment partnerships of which \$78,000 has been funded. It is anticipated that these commitments will be funded from liquid investments of the plan.

Children's Hospital Medical Center and Affiliates

Consolidated Financial Statements

For the Years Ended June 30, 2022 and 2021, respectively (dollars in thousands)

Cincinnati Children's defined benefit plan investment allocation at the actuarial measurement date of June 30, 2022 and 2021 by asset category is as follows:

	<u>2022</u>	<u>2021</u>
Cash and cash equivalents	1.3%	1.7%
Corporate bonds	12.9%	13.6%
Government bonds	1.9%	1.8%
Investment Partnerships:		
Equity	5.3%	4.0%
Bond	-	0.8%
Real estate	2.7%	2.4%
Commingled Investment Funds		
Equity	12.9%	18.7%
Bond	43.3%	40.0%
Government	19.0%	17.0%
Real estate	0.7%	0.0%
	<u>100.0%</u>	<u>100.0%</u>

At June 30, 2022, the fair value and its placement in the fair value hierarchy of the underlying assets of the Plan that are required to be measured at fair value are as follows (see Note 4 for further discussion on the fair value hierarchy and fair value principles):

	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
Cash and cash equivalents	\$18,057	\$ -	\$ -	\$ 18,057
Corporate bonds	-	184,093	-	184,093
Government bonds	-	27,241	-	27,241
Total assets in the fair value hierarchy	<u>18,057</u>	<u>211,334</u>	<u>-</u>	<u>229,391</u>
Investments measured at net asset value ⁴ :				
Investment Partnerships:				
Equity	-	-	-	76,191
Real estate	-	-	-	38,100
Commingled Investment Funds:				
Equity	-	-	-	183,853
Bond	-	-	-	617,843
Government	-	-	-	270,194
Real estate	-	-	-	10,000
Total assets at fair value	<u>\$18,057</u>	<u>\$211,334</u>	<u>\$ -</u>	<u>\$1,425,572</u>

⁴ Certain investments that are measured at fair value using the net asset value per share (or its equivalent) practical expedient have not been categorized in the fair value hierarchy. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the Change in Plan Assets disclosure.

Children’s Hospital Medical Center and Affiliates

Consolidated Financial Statements

For the Years Ended June 30, 2022 and 2021, respectively (dollars in thousands)

At June 30, 2021, the fair value and its placement in the fair value hierarchy of the underlying assets of the Plan that are required to be measured at fair value are as follows (see Note 4 for further discussion on the fair value hierarchy and fair value principles):

	Level 1	Level 2	Level 3	Total
Cash and cash equivalents	\$29,579	\$ -	\$ -	\$ 29,579
Corporate bonds	-	239,259	-	239,259
Government bonds	-	31,870	-	31,870
Total assets in the fair value hierarchy	<u>29,579</u>	<u>271,129</u>	<u>-</u>	<u>300,708</u>
Investments measured at net asset value ⁵ :				
Investment Partnerships:				
Equity	-	-	-	70,552
Bond	-	-	-	14,348
Real Estate	-	-	-	42,696
Commingled Investment Funds:				
Equity	-	-	-	327,271
Bond	-	-	-	702,807
Government	-	-	-	297,274
Total assets at fair value	<u>\$29,579</u>	<u>\$271,129</u>	<u>\$ -</u>	<u>\$1,755,656</u>

The fair values of Level 1 investments are based on quoted prices in active markets. The fair value for investments in fixed income securities, including U.S. government securities and corporate obligations, is based on a calculation using interest rate curves and credit spreads applied to the terms of the debt instrument (maturity and coupon interest rate) and considers the counterparty credit rating. Such items are classified as Level 2 in the fair value hierarchy. Investments in partnerships – U.S. equities, real estate, and bonds – are valued using the net asset value reported by the managers of the funds and as supported by the unit prices of actual purchase and sale transactions. The investments in investment partnerships generally are associated with liquidation restrictions that may range from 91 days to the life of the fund (up to fifteen years) and may require redemption penalties. Commingled investment funds are private funds for institutional investors valued at net asset value. The commingled funds primarily invest in actively traded equity mutual funds, bond mutual funds, and US Treasury STRIPS with daily liquidity and no lockup period.

There were no transfers between levels in fiscal year 2022 or fiscal year 2021.

The following table reflects the weighted average assumptions utilized to determine benefit obligations:

	<u>2022</u>	<u>2021</u>
Discount rate used to determine actuarial present value of the projected benefit obligation	5.06%	3.27%
Assumed rate of increase in compensation levels	3.50%	3.50%
Long-term rate of return	5.50%	5.50%

⁵ Certain investments that are measured at fair value using the net asset value per share (or its equivalent) practical expedient have not been categorized in the fair value hierarchy. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented in the Change in Plan Assets disclosure.

Children's Hospital Medical Center and Affiliates

Consolidated Financial Statements

For the Years Ended June 30, 2022 and 2021, respectively (dollars in thousands)

The following table sets forth the funded status of the plan and amounts recognized in the accompanying Consolidated Balance Sheets as of June 30, 2022 and 2021, utilizing actuarial measurement dates as of June 30, 2022 and 2021.

	<u>2022</u>	<u>2021</u>
Change in projected benefit obligation:		
Projected benefit obligation at beginning of year	\$1,583,947	\$1,533,155
Service cost	74,571	71,800
Interest cost	50,560	49,725
Other actuarial (gain) loss	(450,685)	33,202
Benefits paid	(113,864)	(103,935)
Projected benefit obligation at end of year	<u>\$1,144,529</u>	<u>\$1,583,947</u>
Change in plan assets:		
Fair value of plan assets at beginning of year	\$1,755,656	\$1,454,224
Actual (loss) return on plan assets	(291,220)	233,567
Employer contributions	75,000	171,800
Benefits paid	(113,864)	(103,935)
Fair value of plan assets at end of year	<u>1,425,572</u>	<u>1,755,656</u>
Funded status	281,043	171,709
Net accrued pension benefit asset in Consolidated Balance Sheets	<u>\$ 281,043</u>	<u>\$ 171,709</u>

For the Retirement Plan, the overall actuarial gain in plan obligation of approximately \$451 million is primarily attributable to an increase in the discount rate between June 30, 2021 and June 30, 2022. The discount rate increase of 179 basis points resulted in a decrease in benefit obligation of approximately \$481 million.

In 2022 and 2021, the mortality tables utilized by actuaries to value the pension liability were updated based on current experience. The impact of the change in mortality assumptions is included in other actuarial (gain) loss in fiscal years 2022 and 2021.

Amounts included in Unrestricted Net Assets but not yet recognized in pension cost consist of:

	<u>2022</u>	<u>2021</u>
Net actuarial loss	\$223,244	\$317,248
Net prior service credit	(65,290)	(77,041)
	<u>\$157,954</u>	<u>\$240,207</u>

The table below reflects the following weighted average assumptions utilized to determine benefit costs were:

	<u>2022</u>	<u>2021</u>
Discount rate used to determine benefit costs	3.27%	3.33%
Assumed rate of increase in compensation levels	3.50%	3.50%
Expected long-term rate of return on plan assets	5.50%	5.50%

The Cincinnati Children's expected long-term rate of return on plan assets is based on the expected average returns based on the portfolio mix of plan assets and is reassessed on an annual basis.

Children's Hospital Medical Center and Affiliates

Consolidated Financial Statements

For the Years Ended June 30, 2022 and 2021, respectively (dollars in thousands)

Net periodic pension cost for 2022 and 2021 related to the defined benefit plan consisted of the following components:

	<u>2022</u>	<u>2021</u>
Service cost	\$74,571	\$71,800
Interest cost	50,560	49,725
Expected return on plan assets	(91,509)	(76,121)
Amortization of prior service credit	(11,751)	(11,751)
Recognized net actuarial loss	26,048	36,339
Net periodic pension cost	<u>\$47,919</u>	<u>\$69,992</u>

Based on preliminary estimates, we do not expect any required fiscal year 2022 contributions for the qualified defined benefit plan under the current funding regulations.

The accumulated benefit obligation for the pension plan was \$1,099,257 and \$1,504,250 at June 30, 2022 and 2021, respectively.

Cincinnati Children's estimated benefit payments in each of the next five fiscal years and in aggregate for the five fiscal years thereafter are as follows:

2023	\$64,063
2024	64,539
2025	66,792
2026	68,368
2027	70,145
2028-2032	382,220

All other retirement plans maintained by Cincinnati Children's are defined contribution plans. Cincinnati Children's contributions to these plans are generally based on ten percent of salaries up to established ERISA limits. Total expense, net of forfeitures, related to these other plans was approximately \$29,650 and \$27,581 in fiscal years 2022 and 2021, respectively.

Cincinnati Children's provides individual nonqualified deferred compensation benefits to key employees with varying terms. Accounts are participant-directed, and the amounts are at a substantial risk of forfeiture and revert back to the Cincinnati Children's if the employee does not meet certain criteria as established by the plan. The amount of deferred compensation income and expense resulting from changes in market value of underlying investments are recognized in fiscal years 2022 and 2021 was \$(1,087) and \$1,358, respectively. The current portion of plan accounts are included in Other receivables with a corresponding liability in Accounts payable and accrued expenses on the Consolidated Balance Sheets. The long-term portion of plan accounts are included in Other long-term assets with a corresponding liability in Other long-term liabilities on the Consolidated Balance Sheets.

The following table displays the nonqualified deferred compensation plans assets and liabilities as of June 30, 2022 and 2021:

	<u>2022</u>	<u>2021</u>
Current portion	\$ 919	\$ 307
Long-term portion	14,311	15,582
Total assets and liabilities	<u>\$15,230</u>	<u>\$15,889</u>

Children's Hospital Medical Center and Affiliates

Consolidated Financial Statements

For the Years Ended June 30, 2022 and 2021, respectively (dollars in thousands)

(11) Commitments and Contingencies –

- (a) Litigation – Cincinnati Children's is engaged from time to time in a variety of litigation and regulatory compliance matters in addition to professional and general liability matters. Management assesses the probable outcome of unresolved litigation and records estimated reserves consistent with ASC No. 450, "Contingencies." After consultation with legal counsel, management believes that all such currently existing matters will be resolved without material adverse impact to the consolidated financial position or results of operations of Cincinnati Children's.
- (b) Laws and Regulations – The healthcare industry is subject to numerous laws and regulations of federal, state and local governments. These laws and regulations guide the healthcare industry in many domains such as licensure, accreditation, government healthcare program participation requirements, reimbursement for patient service, and Medicare and Medicaid fraud and abuse to name a few. Compliance with these laws and regulations, specifically those relating to the Medicare and Medicaid programs, is complex and can be subject to future government review and interpretation, as well as regulatory actions unknown or unasserted at this time. Management believes that Cincinnati Children's is in compliance, in all material respects, with fraud and abuse as well as other applicable government laws and regulations. Cincinnati Children's has recorded reserves for routine regulatory compliance issues and believes these reserves are adequate to cover any potential repayment of previously billed and collected revenue from patient service.
- (c) Capital Commitments – Cincinnati Children's has entered into agreements with general contractors for several new construction projects, renovations, equipment, and information system technology projects. Approximately \$592,388 has been spent through June 30, 2022 and approximately \$425,960 is expected to be spent in connection with current active projects. The commitments have expected completion dates ranging from fiscal year 2023 through fiscal year 2026.
- (d) Funding Commitments – The Board of Trustees of Cincinnati Children's approved revocable commitments for up to \$20,000 in non-recourse loans to Uptown Consortium Inc. Cincinnati Children's has provided \$17,867 of funding in relation to these commitments through June 30, 2022. Management does not anticipate any additional funding. These funds are used to invest in commercial and residential projects in the uptown area. During fiscal year 2022, none of the loans were repaid. Cincinnati Children's expects to receive an additional \$4,328 related to the loans.
- (e) Investment Commitments – Cincinnati Children's has made commitments to invest \$30,000 in six limited partnerships that focus on investing in venture capital funds or provide venture capital for companies in the high-growth sectors of the economy, including life sciences, information technology, advanced manufacturing, and healthcare. Cincinnati Children's has made commitments to invest \$12,294 in nine limited liability companies that focus on investing in early-stage venture capital funds regionally and nationally with the goals of making the Cincinnati region the place for entrepreneurs and investors to launch new ideas and driving capital into scalable technology companies in southwest Ohio. Investment values are included in Other Assets in the Consolidated Balance Sheets. Cincinnati Children's occasionally receives distributions from these investments which reduce investment values.

Children's Hospital Medical Center and Affiliates

Consolidated Financial Statements

For the Years Ended June 30, 2022 and 2021, respectively (dollars in thousands)

The following displays the amounts funded and investment values at June 30, 2022 and 2021:

	2022	Funded	Value
Investment in Limited Partnerships		\$21,099	\$ 10,041
Investments in Limited Liability Corporations		10,558	19,664
Total		<u>\$31,657</u>	<u>\$29,705</u>
	2021	Funded	Value
Investment in Limited Partnerships		\$20,349	\$ 8,075
Investments in Limited Liability Corporations		9,324	13,263
Total		<u>\$29,673</u>	<u>\$21,338</u>

(12) Leases –

Cincinnati Children's leases certain property and equipment. Cincinnati Children's determines if an arrangement is a lease at inception of a contract.

The following table presents expenses recorded related to lease arrangements for the years ended June 30, 2022 and 2021:

	2022	2021
Operating lease expense	\$ 3,588	\$ 2,765
Finance leases:		
Amortization of right-of-use assets	7,116	6,698
Interest on finance lease obligations	1,856	1,955
Short-term and variable lease expense	5,061	4,994
Total lease expense	<u>\$17,621</u>	<u>\$16,412</u>

Other information related to leases for the years ended June 30, 2022 and 2021 is as follows:

Supplemental cash flow information

Cash paid for amounts included in the measurement of lease liabilities:

	2022	2021
Operating cash flows from operating leases	\$ 2,736	\$ 2,097
Financing cash flows from finance leases	6,228	5,319

Weighted average remaining lease term (in years)

	2022	2021
Operating leases	7.6	7.4
Finance leases	9.7	10.5

Weighted average discount rate

	2022	2021
Operating leases	3.25%	3.27%
Finance leases	3.27%	3.34%

Children's Hospital Medical Center and Affiliates

Consolidated Financial Statements

For the Years Ended June 30, 2022 and 2021, respectively (dollars in thousands)

The aggregate future lease payments for operating and finance leases as of June 30, 2022 are as follows:

	<u>Operating</u>	<u>Finance</u>
2023	\$ 3,295	\$ 7,784
2024	3,221	7,032
2025	2,856	7,032
2026	1,903	6,530
2027	1,348	5,442
Thereafter	6,498	30,374
Total lease payments	<u>19,121</u>	<u>64,194</u>
<u>Present values:</u>		
Current lease liabilities	2,767	6,094
Long-term lease liabilities	14,949	48,544
Total lease liabilities	<u>\$17,716</u>	<u>\$54,638</u>
Difference between undiscounted cash flows and discounted cash flows	\$ 1,405	\$ 9,556

- (13) Functional Expenses – The cost of providing Cincinnati Children's services are summarized on a functional basis in the following tables. Accordingly, certain costs have been allocated among functions. Such allocations are determined by management on an equitable basis. The expenses that are allocated include the following:

<u>Expense</u>	<u>Method of Allocation</u>
Employee benefits	Full Time Equivalent
Depreciation	Square footage
Utilities	Square footage

The following presents expenses by both their nature and function for the year ended June 30, 2022:

	<u>Clinical</u>	<u>Research</u>	<u>Education</u>	<u>Fundraising</u>	<u>Management and General</u>	<u>TOTAL</u>
Salaries	\$ 898,559	\$196,539	\$62,454	\$4,215	\$212,320	\$1,374,087
Employee benefits	214,293	48,365	17,114	1,116	91,149	372,037
Supplies, drugs and other	402,177	39,650	3,269	491	79,961	525,548
Purchased services	90,525	49,585	2,441	917	144,253	287,721
Depreciation	92,100	29,284	152	303	29,890	151,729
Utilities	12,188	3,875	20	40	3,956	20,079
Interest	-	-	-	-	30,926	30,926
	<u>\$1,709,842</u>	<u>\$367,298</u>	<u>\$85,450</u>	<u>\$7,082</u>	<u>\$592,455</u>	<u>\$2,762,127</u>

Children's Hospital Medical Center and Affiliates

Consolidated Financial Statements

For the Years Ended June 30, 2022 and 2021, respectively (dollars in thousands)

The following presents expenses by both their nature and function for the year ended June 30, 2021:

	<u>Clinical</u>	<u>Research</u>	<u>Education</u>	<u>Fundraising</u>	<u>Management and General</u>	<u>TOTAL</u>
Salaries	\$ 814,088	\$186,686	\$57,395	\$4,159	\$196,328	\$1,258,656
Employee benefits	204,106	51,114	11,822	1,043	79,626	347,711
Supplies, drugs and other	367,962	38,150	1,936	427	60,869	469,344
Purchased services	86,164	42,605	2,258	720	120,461	252,208
Depreciation	82,628	28,282	139	416	27,173	138,638
Utilities	10,967	3,754	18	55	3,607	18,401
Interest	-	-	-	-	23,249	23,249
	<u>\$1,565,915</u>	<u>\$350,591</u>	<u>\$73,568</u>	<u>\$6,820</u>	<u>\$511,313</u>	<u>\$2,508,207</u>

(14) Interest Rate Swap Agreement –

In August 2019, Cincinnati Children's entered into a 10-year interest rate swap agreement in which Cincinnati Children's and the counterparty agree to exchange the difference between fixed rate and variable rate interest amounts calculated by reference to specified notational principal amounts during the agreement period. The objective is to manage interest rate risk associated with the variable rate 2018Z and 2018AA bonds. Parties to interest rate swap agreements are subject to market risk for changes in interest rates and risk of credit loss in the event of nonperformance by the counterparty.

The following table summarizes the general terms of Cincinnati Children's fixed payment swap agreement as of June 30, 2022:

<u>Effective</u>	<u>Expiration</u>	<u>Counterparty</u>	<u>Interest Rate Paid</u>	<u>Interest Rate Received</u>	<u>Notational Amount</u>
August 2019	August 2029	Fifth Third Bank	1.38%	USD-SIFMA Municipal Swap Index, 0.91% at June 30 th	\$86,770,000

As of June 30, 2022, the swap fair value of \$4,421 was recorded in other long-term assets in the accompanying consolidated balance sheet. As of June 30, 2021, the swap market value of \$(2,956) was recorded in other long-term liabilities in the accompanying consolidated balance sheet.

(15) Subsequent Events –

During August 2022, Cincinnati Children's entered into a private placement bond forward refunding agreement with a bank whereby Cincinnati Children's will refund and retire the outstanding principal of its Series 2014S bonds of \$66,155 through the issuance of hospital facilities bonds through Hamilton County, Ohio at a fixed rate of 2.934%. The closing of the refunding is expected to occur on May 15, 2024.

Management reviewed subsequent events through September 30, 2022, the date the consolidated financial statements were issued, noting no changes are required to the consolidated financial statements or footnotes.

Children's Hospital Medical Center and Affiliate Supplementary Schedule of Expenditures of Federal Awards
For the Year Ended June 30, 2022

Gov Agency	Division	Gov Branch	Award Title	Pass-Through Grantor	Subrecipient Name	Identifying Number	Federal Grant Number	ALN	Sub Exp	Fed Exp	Total Exp	
Department of Defense	DOD	Military Medical Research and Development	Surviving and Thriving in the				W81XWH1810677	12,420	-	117,632	117,632	
	DOD	Military Medical Research and Development	Multicenter Randomized Trial of Everolimus	Children's Hospital Boston		W81XWH1710532	W81XWH1710532	12,420	-	12,538	12,538	
	DOD	Military Medical Research and Development	Therapeutic Benefit of Hsp90 Inhibition in				W81XWH1710666	12,420	-	12,064	12,064	
	DOD	Military Medical Research and Development	Mechanisms of acute pain gener	Henry M. Jackson Foundation		5161	W81XWH1720024	12,420	-	3,872	3,872	
	DOD	Military Medical Research and Development	The Neurofibromatosis Clinical	University of Alabama-Birmingham		000516840-SC004	W81XWH1720037	12,420	-	114,651	114,651	
	DOD	Military Medical Research and Development	A Novel and Rapid System to CI				W81XWH1810269	12,420	-	33,185	33,185	
	DOD	Military Medical Research and Development	Novel Neuroimaging Assessments				W81XWH1810615	12,420	-	13,029	13,029	
	DOD	Military Medical Research and Development	Development of Virtual Surgery				W81XWH1910043	12,420	-	19,801	19,801	
	DOD	Military Medical Research and Development	A Novel FANCD2-Chromatin Bound				W81XWH1910262	12,420	-	132,506	132,506	
	DOD	Military Medical Research and Development	Single cell analyses of NF1 pI				W81XWH1910816	12,420	-	270,666	270,666	
	DOD	Military Medical Research and Development	Immune-Schwann cell signaling				W81XWH2010116	12,420	-	157,023	157,023	
	DOD	Military Medical Research and Development	Antioxidant Therapy with N-Ace				W81XWH2010139	12,420	-	260,229	260,229	
	DOD	Military Medical Research and Development	Resting State Functional MRI F	Phoenix Children's Hospital		W81XWH2010339	W81XWH2010339	12,420	-	5,444	5,444	
	DOD	Military Medical Research and Development	Merlin-ASPP2 Tumor Suppressor				W81XWH2010377	12,420	-	194,318	194,318	
	DOD	Military Medical Research and Development	Inflammatory vigor in heteroge				W81XWH2010392	12,420	-	349,449	349,449	
	DOD	Military Medical Research and Development	Inflammatory vigor in heteroge				W81XWH2010393	12,420	-	188,257	188,257	
	DOD	Military Medical Research and Development	Identification of cellular het				W81XWH2010443	12,420	-	90,587	90,587	
	DOD	Military Medical Research and Development	The Influence of Social, Educa	Vanderbilt University Medical Center		VUMC84410	W81XWH2010475	12,420	-	52,332	52,332	
	DOD	Military Medical Research and Development	Mitochondrial ALR protein def	University of Cincinnati			W81XWH2010477	12,420	106,800	459,484	566,284	
	DOD	Military Medical Research and Development	Rational Targeting Oncogenic K	University of Wisconsin-Madison		0000000812	W81XWH2010616	12,420	-	194,967	194,967	
	DOD	Military Medical Research and Development	The role of mitochondria in bo		Albert Einstein College of Medicine		W81XWH2010689	12,420	16,734	132,164	150,851	
	DOD	Military Medical Research and Development	The role of mitochondria in bo		Baylor College of Medicine.				1,953	-	-	
	DOD	Military Medical Research and Development	Evaluating the therapeutic pot				W81XWH2010870	12,420	-	78,578	78,578	
	DOD	Military Medical Research and Development	Mechanisms of acute pain gener	Henry M. Jackson Foundation		1023994	W81XWH2000031	12,420	-	14,270	14,270	
	DOD	Military Medical Research and Development	Role of endoplasmic reticulum				W81XWH2110907	12,420	-	134,738	134,738	
	DOD	Military Medical Research and Development	Regulation of Translation by N				W81XWH2210196	12,420	-	2,884	2,884	
	Department of Defense Total									125,487	3,044,668	3,170,155
	Department of Education	DOE	Research in Special Education	Sluggish Cognitive Tempo: Examining			R305A160064	84,324	-	6,580	6,580	
		DOE	Education Research, Development and Dissemination	Longitudinal Evaluation of: Su			R305A20002E	84,305	-	309,612	309,612	
		DOE	Research in Special Education	Teaching Academic Success Skill			R324A18005C	84,324	-	263,986	263,986	
	Department of Education Total									-	580,178	580,178
	Department of Justice	DOJ	Crime Victim Assistance	VOCA Mayerson 2021			2021-V/OCA-133916106	16,575	-	73,204	73,204	
		DOJ	Crime Victim Assistance	VOCA Mayerson 2022			2022-V/OCA-134716904	16,575	-	155,229	155,229	
DOJ		Edward Byrne Memorial Justice Assistance Grant Program	BJA Police Response Training I	The Arc of The United States INC		BJA Police Response	BJA Police Response	16,738	-	44,358	44,358	
DOJ		Improv Investigation & Prosec of Child Abuse & Reg & Local Children's Advoc	Mayerson NCA MH PCT				CINCI-OH-PCT-PI21	16,758	-	24,000	24,000	
Department of Justice Total									-	296,791	296,791	
National Science Foundation	NSF	Biological Sciences	NSF/MCB-BSF: Quantitative analysis			1715822	47,074	-	9,954	9,954		
	NSF	Engineering Grants	Plasma treatment for Inactivat	University of Cincinnati		013263-002	2022068	47,041	-	98,231	98,231	
	NSF	Biological Sciences	NSF/MCB-BSF: Modeling the mec		University of Cincinnati	2114650	47,074	11,697	156,277	167,974		
	NSF	Engineering Grants	Collaborative Research: Unders			2140441	47,041	-	9,827	9,827		
National Science Foundation Total									11,697	274,289	285,986	
Department of Energy Total	DOE		Joint Faculty Agreement No. JF	University of Cincinnati		4000173601	81.RD	-	92,605	92,605		
Department of Energy Total									-	92,605	92,605	
Dept of Health and Human Serv	ACF	Personal Responsibility Education Program	Evaluation of Using the Qorenc	Texas A & M		M2200564	90AP2702	93,092	-	149,320	149,320	
	ACL	Developmental Disabilities Basic Support and Advocacy Grants	Empowering Families	Ohio Coalition for the Education of Chil		Riddle_OCECD		93,630	-	14,344	14,344	
	ACL	Developmental Disabilities Basic Support and Advocacy Grants	Accommodations and Adaptions	Florida Develop Disabl Council, Inc		FDDC_#5045EM21		93,630	-	132,340	132,340	
	ACL	Developmental Disabilities Basic Support and Advocacy Grants	Healthy Lifestyles for People with Disabilit	Ohio Developmental Disabilities Council	University of Illinois at Chicago	17C403FA21	21010HSCDD	93,630	20,000	59,339	79,339	
	ACL	Strengthening Public Health Systems & Services through National Partnerships	Selling Families on a Positie				90FR9055-01-00	93,433	-	70,072	70,072	
	ACL	University Centers for Excellence in Developmental Disabilities Edu, Res & Sc	Expanding Disabilities' Network	University of Cincinnati		013610-0002	90DDCS0047	93,632	-	48,420	48,420	
	ACL	University Centers for Excellence in Developmental Disabilities Edu, Res & Sc	AUCD SCOPE (renewal) 2019_U of W	University of Wyoming		1004506-CHMC	90DDTC0042	93,632	-	91,224	91,224	
	ACL	University Centers for Excellence in Developmental Disabilities Edu, Res & Sc	University of Cincinnati University Centers	University of Cincinnati		90DDUC0013-01-00	90DDUC0013	93,632	-	588,509	588,509	
	ACL	Developmental Disabilities Projects of National Significance	Center for Dignity in Healthcare				90DNHC0001	93,631	26,620	166,865	468,287	
						AADMD			25,000	-	-	
						Autistic Self Advocacy Network Inc			25,000	-	-	
						Family Voices Inc			80,981	-	-	
						Kennedy Krieger Institute, Inc.			18,877	-	-	
						Rutgers, The State University			93,958	-	-	
						University of Kentucky Research Fnd			30,786	-	-	
						Vanderbilt University Medical Center			-	-	-	
	ACL	Strengthening Public Health Systems & Services through National Partnerships	Enhancing Parenting Skills: Application		University of Oregon		239530A	90DPHF0003-01-00	93,433	-	52,667	52,667
	ACL	Strengthening Public Health Systems & Services through National Partnerships	Gaining Real-life skills Over the Web (GROW)					90IFDV0003-02-00	93,433	-	1,472	1,472
	AHQR	Research on Healthcare Costs, Quality and Outcomes	Predicting Pediatric Readmission: Develop					K08H5024735	93,226	-	113,696	113,696
	AHQR	Research on Healthcare Costs, Quality and Outcomes	Hospital Management of Acute Respiratory					K08H5025138	93,226	-	105,722	105,722
	AHQR	Research on Healthcare Costs, Quality and Outcomes	The Patient and Parent Perspec					K08H5026763	93,226	-	146,332	146,332
	AHQR	Research on Healthcare Costs, Quality and Outcomes	AHQR Mentored Clinical Scienti					K08H5026975	93,226	-	120,604	120,604
	AHQR	National Research Service Awards_Health Services Research Training	Describing ventilator weaning	Children's Hospital of Philadelphia		3201350921 PO 20269K12HS026393		93,225	-	243,921	243,921	
	AHQR	Research on Healthcare Costs, Quality and Outcomes	Missed Opportunities for Improving Diag	University of Michigan		3004658567	R01HS024953	93,226	-	1,759	1,759	
	AHQR	Research on Healthcare Costs, Quality and Outcomes	Diagnosis and management of pe	Children's Hospital Los Angeles		000013257-E	R01HS027619	93,226	-	22,265	22,265	
	AHQR	Research on Healthcare Costs, Quality and Outcomes	CHASM: Children Hospitalization				R03HS028102	93,226	-	71,045	71,045	
	AHQR	Research on Healthcare Costs, Quality and Outcomes	Ambulatory Pediatric Safety Le	Children's Hospital Boston		RHS026644B	R1HS026644	93,226	-	231,919	231,919	
	AHQR	Research on Healthcare Costs, Quality and Outcomes	Spread of Safety Interventions	Children's Hospital Boston		RHS027401A	R1HS027401	93,226	-	120,974	120,974	
	CDC	Disabilities Prevention	Improving the Health of People	Ohio State University		SPC - 1000005432	NUZ7DD00032	93,184	-	37,308	37,308	
	CDC	Health Program for Toxic Substances and Disease Registry	Pediatric Environmental Health	Univ of Illinois @ Chicago		17852-00	NU61TS000296	93,161	-	57,397	57,397	
CDC	Occupational Safety and Health Program	Enhanced injury surveillance u				R01OH011996	93,262	-	255,386	255,386		
CDC	Occupational Safety and Health Program	Newman UC sub T42 ERC Renewal	University of Cincinnati		013704-0008	T42OH008432-16-00	93,262	-	15,872	15,872		
CDC	Rare Disorders: Research, Surveillance, Health Promotion, and Education	Woodward CDC NSBPR Registry 20				U01DD001279	93,315	-	78,792	78,792		
CDC	Training and Clinical Skills Improvement Projcts	Enhanced Surv for New Vaccine Prevent				U01HP001059	93,185	-	218,361	218,361		

CDC	Training and Clinical Skills Improvement Projds	COVID-19 Enhanced Surv for New Vaccine Prevent	University of Cincinnati	COVID-19 U01IP001059	93.185	79,204	584,973	664,177
CDC	Training and Clinical Skills Improvement Projds	US Enhanced Surveillance Netwo		U01F001155	93.185	-	841,746	841,746
CDC	Training and Clinical Skills Improvement Projds	COVID-19 US Enhanced Surveillance Netwo		COVID-19 U01IP001155	93.185	-	335,024	335,024
CDC	Assistance Programs for Chronic Disease Prevention and Control	SEARCH for Diabetes in Youth Registry		U18DP006134	93.945	-	5,454	5,454
CDC	Birth Defects and Developmental Disabilities - Prevention and Surveillance	Beyond EHDI Benchmarks in Earf	University of South Carolina	U19DD001218	93.073	-	75,944	75,944
CDC	Blood Disorder Program: Prevention, Surveillance and Research	Community Counts: Public Health Surv	Hemophilia Foundation of Michigan	U27DD001155	93.080	-	36,426	36,426
DHHS/OS	Community Programs to Improve Minorly Health Grant Program	Sickle Cell Clinical Data Plat	American Society of Hemablogy	ASH_Lamou.C	1 SP19P201190-01-00	93.137	412,297	412,297
DHHS/OS	National Biodefense Hospital Preparedness Program	Eastern Great Lakes Pediatric	University Hospital of Cleveland	U3REPI90615-01-00	93.889	-	190,231	190,231
FDA	Food and Drug Administration_Research	Safety and Efficacy of Inhaled Tissue Plasm	University of Michigan	SUBK0006758	93.103	-	5,277	5,277
FDA	Food and Drug Administration_Research	Quercetin Chemoprevention for		R01FD006353	93.103	-	531,067	531,067
FDA	Food and Drug Administration_Research	Abatacept for the treatment of		R01FD007267	93.103	-	229,231	229,231
FDA	Food and Drug Administration_Research	Sirolimus TSC Epilepsy Prevent		R01FD007275	93.103	6,165	259,054	273,366
			The University of Alabama at Birmingham					
			The University of Texas Science Center				8,147	
FDA	Food and Drug Administration_Research	Development of the Pediatric P	Children's Hospital of Philadelphia	GRT-00000431	93.103	-	2,189	2,189
FDA	Food and Drug Administration_Research	I-ACT for Children, Global Pediatric Clinical	Inst For Adv Clin Trials For Children	CCHMC-01	93.103	-	47,851	47,851
HRSA	Grants for Training in Primary Care Medicine and Dentistry	Dental Faculty Loan Repayment Program		D87HP31252	93.884	-	158,520	158,520
HRSA	Maternal and Child Health Federal Consolidated Programs	Region V East Comprehensive Care New	Hemophilia Foundation of Michigan	H30MC24047	93.110	-	20,724	20,724
HRSA	Healthy Start Initiative	HRSA Cradle Cincinnati		H46MC27823	93.926	-	1,139,667	1,139,667
HRSA	Poison Center Support and Enhancement Grant Program	Cincinnati Drug and Poison Inf		H46HS15468	93.253	-	147,318	147,318
HRSA	Affordable Care Act (ACA) Family to Family Health Information Centers	Ohio Family to Family Health I		H84MC28443	93.504	-	80,820	80,820
HRSA	Maternal and Child Health Federal Consolidated Programs	Severe Combined Immunodeficien	University of California, San Francisco	13048sc	93.110	-	5,569	5,569
HRSA	National Research Service Award in Primary Care Medicine	General Pediatrics Research Fe		T32HP10027	93.186	-	426,923	426,923
HRSA	Maternal and Child Health Federal Consolidated Programs	Leadership Education in Neurop	University of Cincinnati	013719-0003	93.110	-	592,662	592,662
HRSA	Emergency Medical Services for Children	Pediatric Emergency Care Appli		U03MC22684	93.127	55,627	465,599	611,020
			Medical College of Wisconsin				89,834	
			Washington University					
HRSA	Maternal and Child Health Federal Consolidated Programs	HRSA Central Region Thalassemi	Ann & Robert H Lurie Children's Hospital	901639-CCHMC	93.110	-	14,447	14,447
HRSA	Sickle Cell Treatment Demonstration Program	Sickle Treatment and Outcomes Resear		U1EMC27863	93.365	19,068	450,648	687,021
			Children's Hosp & Clinics of Minnesota					
			Five Rivers Health Centers				15,766	
			Indiana Hemophilia & Thrombosis Ctr, Inc				51,361	
			Medical College of Wisconsin				30,295	
			Sanford Research				90	
			Sickle Cell Disease Assoc of America				38,852	
			University of Illinois at Chicago				80,941	
HRSA	Maternal and Child Health Federal Consolidated Programs	Center for Pediatric Everyday	University Hospital of Cleveland	U11MC43532-01-00	93.110	-	31,155	31,155
HRSA	Maternal and Child Health Federal Consolidated Programs	Regional Ped Pand Network (ODH)	Ohio State University	GR125125	93.110	129,057	47,848	176,905
HRSA	Maternal and Child Health Federal Consolidated Programs	DBPNet ADHD Node	Children's Hospital of Philadelphia	3208960819-S1	93.110	-	3,304	3,304
HRSA	Maternal and Child Health Federal Consolidated Programs	Identifying Patient Level Fact	University of Colorado Denver	FY22.609.011	93.110	-	2,181	2,181
HRSA	Autism Collaboration, Accountability, Research, Education and Support	DBPNet ADHD Node CHOP Subin RE	Children's Hospital of Philadelphia	GRT-00001441	93.877	-	8,912	8,912
NH	International Research and Research Training	Reducing the Impact of Rheumat	Makereke Institute of Social Research	MskCHS06042022	93.989	-	2,917	2,917
NH	Allergy, Immunology and Transplantation Research	Immunological Identity redefined by gene		D43TW012255	93.855	3,844	752,840	756,684
NH	Trans-NIH Research Support	Engineering multi-organs in a		DP2DK128799	93.310	-	545,882	545,882
NH	Allergy, Immunology and Transplantation Research	Silencer Control of T cell Hom		F30A1157421	93.855	-	4,968	4,968
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Identification of the genetic		F30DK123841	93.847	-	31,468	31,468
NH	Blood Diseases and Resources Research	Elucidating the role of dynein		F30HL156519	93.839	-	18,880	18,880
NH	Mental Health Research Grants	Contributions of the striatal		F30MH123056	93.242	-	29,694	29,694
NH	Oral Diseases and Disorders Research	Role of the Ciliary Protein C2		F31DE030684	93.121	-	37,177	37,177
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Development and Disease of the		F31DK118823	93.847	-	137	137
NH	Child Health and Human Development Extramural Research	SMPD4: Role of a microcephaly		F31HD104350	93.865	-	7,322	7,322
NH	Cardiovascular Diseases Research	Nr2f1a suppresses bulbous ate		F31HL147399	93.837	-	27,465	27,465
NH	Cardiovascular Diseases Research	Prox1 and oscillatory shear st		F31HL150935	93.837	-	33,339	33,339
NH	Cardiovascular Diseases Research	Nr2f1a promotes atrial mainten		F31HL152600	93.837	-	39,636	39,636
NH	Extramural Res Programs in the Neurosciences & Neurological Disorders	The Role of Raptor in Temporal		F31NS115525	93.853	-	34,517	34,517
NH	Extramural Res Programs in the Neurosciences & Neurological Disorders	Role of dentate granule cell g		F31NS122484	93.853	-	34,777	34,777
NH	Extramural Res Programs in the Neurosciences & Neurological Disorders	The role of macrophages in neo		F31NS122494	93.853	-	34,683	34,683
NH	Allergy, Immunology and Transplantation Research	Maternal microchimerism transf		F32A1145184	93.855	-	32,089	32,089
NH	Allergy, Immunology and Transplantation Research	Epithelial antigen presentation		F32A1147591	93.855	-	83,014	83,014
NH	Arthritis, Musculoskeletal and Skin Diseases Research	Elucidating the mechanisms of		F32AR077396	93.846	-	6,625	6,625
NH	Blood Diseases and Resources Research	The role of GPR56 in platelet		F32HL149280	93.839	-	82,032	82,032
NH	Cardiovascular Diseases Research	Defining the role of DHH3 in		F32HL154387	93.837	-	56,782	56,782
NH	Cardiovascular Diseases Research	Tgfb-dependent regulation of e		F32HL154505	93.837	-	68,568	68,568
NH	Cardiovascular Diseases Research	Mechanisms of regulating cardi		F32HL159894	93.837	-	63,336	63,336
NH	Drug Abuse and Addiction Research Programs	Using Administrative and Clinical Data		K01DA041620	93.279	-	100,402	100,402
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	The Role of DDX41 in Inherited		K01DK121733	93.847	-	149,920	149,920
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Glucocorticoid and circadian c		K01DK121875	93.847	-	186,096	186,096
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Enteroendocrine Regulation of		K01DK125341	93.847	-	90,942	90,942
NH	Cancer Research Manpower	Patient Preferences and Adherence in Ad		K07CA200668	93.398	-	32,240	32,240
NH	Arthritis, Musculoskeletal and Skin Diseases Research	Monocyte and macrophage polarization		K08AR072075	93.846	-	197,422	197,422
NH	Cancer Research Manpower	Targeting MBNL1-mediated alter		K08CA237753	93.398	-	249,243	249,243
NH	Biomedical Research and Research Training	The Role of Olfactomedin 4 in Septic Shock		K08GM124298	93.859	-	73,433	73,433
NH	Cardiovascular Diseases Research	The Role of PPARa in Cardiac Dysfunction		K08HL133377	93.837	-	150,994	150,994
NH	Lung Diseases Research	Mechanistic evaluation of a no		K08HL140178	93.838	-	160,677	160,677
NH	Cardiovascular Diseases Research	A genetic and molecular approa		K08HL143177	93.837	-	146,642	146,642
NH	Lung Diseases Research	Personalized Model Systems to		K08HL144825	93.838	-	168,340	168,340
NH	National Center on Sleep Disorders Research	Circadian Clock Dysregulation		K08HL148551	93.233	-	233,402	233,402
NH	Lung Diseases Research	TGF-Beta Regulates CFTR-Mediat		K08HL151762	93.838	-	143,532	143,532
NH	Child Health and Human Development Extramural Research	Improving vaccine efficacy by	Cornell University	215518-3	93.865	-	125,773	125,773
NH	Child Health and Human Development Extramural Research	Rational therapeutic targeting	Cornell University	215518-2	93.865	-	114,650	114,650
NH	Child Health and Human Development Extramural Research	Mechanisms of increased matern	Cornell University	215518-8	93.865	-	133,441	133,441
NH	Child Health and Human Development Extramural Research	Child Health Research Career Dev Award		K12HD028827	93.865	-	408,310	408,310
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Predicting Severity and Improv		K23DK118190	93.847	-	185,009	185,009
NH	Child Health and Human Development Extramural Research	Surviving and Thriving in the		K23HD094855	93.865	-	165,106	165,106
NH	Child Health and Human Development Extramural Research	Electrophysiological Biomarker		K23HD101416	93.865	-	141,203	141,203
NH	Lung Diseases Research	Using technology-assisted step		K23HL139992	93.838	-	181,332	181,332
NH	Blood Diseases and Resources Research	Sickle Cell Anemia, Splenic Pa	Bugando Medical Centre	K23HL153763	93.839	3,250	179,440	182,690
NH	Mental Health Research Grants	Anomalous Sensorimotor Physiology in Fia		K23MH112936	93.242	-	119,739	119,739
NH	Mental Health Research Grants	A Family Navigator Interventio		K23MH125138	93.242	-	184,992	184,992
NH	Nursing Research	Influence of Parent-Nurse Comm	National Institute of Nursing Research	K23NR017396	93.361	-	36,859	36,859

NH	Nursing Research	Fertility Status Assessment Am	Emory University	A567559	K23NR020037	93.361	-	2.853	2.853
NH	Extramural Res Programs in the Neurosciences & Neurological Disorders	Towards biomarkers of resilien			K23NS117734	93.853	-	164.960	164.960
NH	Allergy, Immunology and Transplantation Research	Combinatory Effects of Genetic			K99AI158660	93.855	-	130.083	130.083
NH	Arthritis, Musculoskeletal and Skin Diseases Research	Mitochondrial regulation of ca			K99AR078253	93.846	-	79.962	79.962
NH	National Center on Sleep Disorders Research	Improving Outcomes in Pediatr			K99HL144822	93.233	-	65.005	65.005
NH	National Center for Advancing Translational Sciences	Center for Clinical and Transl	University of Cincinnati	KL2TR001426	KL2TR001426	93.350	-	369.763	369.763
NH	Lung Diseases Research	The RECOVER Post-Acute Sequel	Children's Hospital of Philadelphia	OT2HL161847	OT2HL161847	93.838	-	143.644	143.644
NH	Allergy, Immunology and Transplantation Research	Molecular Mechanisms of the Dy	University of Texas Medical Branch-Galveston	21-85496-01	P01AI150595	93.855	-	164.985	164.985
NH	Child Health and Human Development Extramural Research	Developmental Mechanisms of Trachea	Columbia University		P01HD093933	93.865	291.556	1,033.891	1,325.447
NH	Child Health and Human Development Extramural Research	Pediatric HIV/AIDS Cohort Stud	Harvard Medical School	117267-0184-5119274	P01HD103133	93.865	-	28.299	28.299
NH	Allergy, Immunology and Transplantation Research	Conversations that Matter: Inc	University of North Carolina	5123555	P30AI050410	93.855	-	29.516	29.516
NH	Arthritis, Musculoskeletal and Skin Diseases Research	Cincinnati Rheumatic Diseases Res Center			P30AR070549	93.846	2.854	461.255	464.109
NH	Arthritis, Musculoskeletal and Skin Diseases Research	Pediatric musculoSkeletal and	University of Cincinnati		P30AR076316	93.846	3.934	613.042	616.976
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Digestive Health Center: Bench to Bedside			P30DK078392	93.847	-	1,218.543	1,218.543
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Personalized Cystic Fibrosis T			P30DK117467	93.847	-	1,335.669	1,335.669
NH	Environmental Health	Elucidating the mechanism of	University of Cincinnati	011429-00080	P30ES006096	93.113	-	42.841	42.841
NH	Child Health and Human Development Extramural Research	Xenbase: a Xenopus Model Organ	University of Calgary		P41HD064556	93.865	622.517	1,090.705	1,713.222
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Critical Translational Studies in Ped Nep			P50DK096418	93.847	-	770.128	770.128
NH	Child Health and Human Development Extramural Research	HEAL Initiative: Anteratal Opi	RTI International	5-312-0217179-65988	PL1HD101059	93.865	28.467	196.340	224.807
NH	Cancer Biology Research	The Role of CHAF1B in Maintain			R00CA230314	93.396	-	267.414	267.414
NH	Oral Diseases and Disorders Research	Prolonger progenitor maintenance sculpt			R00DE026239	93.121	-	209.938	209.938
NH	Cardiovascular Diseases Research	Uncovering compensatory mechan			R00HL135258	93.837	-	262.464	262.464
NH	Blood Diseases and Resources Research	The racial disparity in platelet			R00HL136784	93.839	-	244.503	244.503
NH	Lung Diseases Research	Early detection of regional BO			R00HL138255	93.838	-	290.670	290.670
NH	Cardiovascular Diseases Research	Dissecting the role of novel c			R00HL141630	93.837	-	217.687	217.687
NH	National Center on Sleep Disorders Research	Improving Outcomes in Pediatr			R00HL144822	93.233	-	79.616	79.616
NH	Aging Research	Metabolic alterations in age-associated	University of Cincinnati		R01AG053498	93.866	13.616	530.446	544.062
NH	Aging Research	Role of skeletal muscle stem c			R01AG059605	93.866	-	336.389	336.389
NH	Aging Research	Novel mechanism of intestinal			R01AG063967	93.866	-	839.970	839.970
NH	Allergy, Immunology and Transplantation Research	Genetic Linkage in Lupus	Cnfr Foundatn Biomedical Resrch		R01AI024717	93.855	148.500	164.486	312.986
NH	Allergy, Immunology and Transplantation Research	Regulation of Gastrointestinal			R01AI045898	93.855	-	482.019	482.019
NH	Allergy, Immunology and Transplantation Research	Epidemiologic Impact of HPV Va	Indiana University Univ. of California		R01AI104709	93.855	82.255	381.218	483.152
								19.679	
NH	Allergy, Immunology and Transplantation Research	GM-CSF-Induced Metal Sequestra	University of Cincinnati	011636-00010	R01AI106299	93.855	-	20.574	20.574
NH	Allergy, Immunology and Transplantation Research	L-citulline and anti-tuberculosis host			R01AI116698	93.855	-	109.816	109.816
NH	Allergy, Immunology and Transplantation Research	Innate mechanisms of regulatio			R01AI123176	93.855	-	351.619	351.619
NH	Allergy, Immunology and Transplantation Research	Genetic and Immunological Dis			R01AI124355	93.855	-	201.416	201.416
NH	Allergy, Immunology and Transplantation Research	Functional immune tolerance to non-inheri			R01AI124657	93.855	-	244.513	244.513
NH	Allergy, Immunology and Transplantation Research	Role and Regulation of TSLP in Childhoo			R01AI127392	93.855	-	874.826	874.826
NH	Allergy, Immunology and Transplantation Research	Role of Aiolos in eosinophilic asthma			R01AI130033	93.855	-	421.513	421.513
NH	Allergy, Immunology and Transplantation Research	Wimpy antibody isotypes protect against	University of Cincinnati	010728-007	R01AI130103	93.855	-	10.658	10.658
NH	Allergy, Immunology and Transplantation Research	FORWARD Study-Food Allergy Out	Northwestern University Medical School	60057296 CCHMC	R01AI130348	93.855	-	144.139	144.139
NH	Allergy, Immunology and Transplantation Research	Forward genetic prediction and	Pennsylvania State University	5844-CCH-DHHS-269	R01AI132692	93.855	-	13.641	13.641
NH	Allergy, Immunology and Transplantation Research	Role of Microbiome in Neonatal	The Regents of the Univ of California	A18-0659-S001	R01AI138563	93.855	-	152.187	152.187
NH	Allergy, Immunology and Transplantation Research	Non-Invasive Diagnosis of Pedi	Duke University	248445-A031576	R01AI139032	93.855	-	25	25
NH	Allergy, Immunology and Transplantation Research	Early life factors, gene-envir	Wake Forest University Health Sciences	200-45116-100005537	R01AI139126	93.855	-	61.724	61.724
NH	Allergy, Immunology and Transplantation Research	Translational Regulation of CD			R01AI139675	93.855	-	576.658	576.658
NH	Allergy, Immunology and Transplantation Research	SLC9A3 regulation of esophagea	University of Michigan		SUBK00011618	93.855	-	57.605	57.605
NH	Allergy, Immunology and Transplantation Research	Role of TET1 in airway epithel	University of California-Davis	A20-0494S001	R01AI141569	93.855	-	54.059	54.059
NH	Allergy, Immunology and Transplantation Research	Progesterone induced immune mo	Univ of Pennsylvania		R01AI145840	93.855	467.455	259.399	726.854
NH	Allergy, Immunology and Transplantation Research	COVID-19 Progesterone induced immune mo	Univ of Pennsylvania		COVID-19 R01AI145840-03S1	93.855	381.720	21.246	402.966
NH	Allergy, Immunology and Transplantation Research	Rapid, safe suppression of Ige	University of Cincinnati	012329-003	R01AI145991	93.855	-	112.149	112.149
NH	Allergy, Immunology and Transplantation Research	Targeting natural killer cells	Duke University		R01AI148080	93.855	97.388	599.665	697.353
NH	Allergy, Immunology and Transplantation Research	Roles of FFAR 3-SCFA axis in T			R01AI148138	93.855	-	268.265	268.265
NH	Allergy, Immunology and Transplantation Research	Genomics of Inflammatory Bowel	Emory University University of Cincinnati		R01AI148276	93.855	2.908	1,067.092	1,091.504
								21.504	
NH	Biomedical Research and Research Training	Role of Vpu, Tetra, and Sg	University of Wisconsin System		R01AI150475	93.859	40.314	372.994	413.308
NH	Allergy, Immunology and Transplantation Research	Viral and Cellular Determinant			R01AI150486	93.855	-	346.921	346.921
NH	Allergy, Immunology and Transplantation Research	An experimentally-refined, dyn			R01AI153442	93.855	-	634.386	634.386
NH	Allergy, Immunology and Transplantation Research	Immunobiology of Influenza Vr	Children's Hospital Boston	GENFDD002204871	R01AI154470	93.855	-	64	64
NH	Allergy, Immunology and Transplantation Research	Proteasome targeting for allor	University of Pennsylvania	580121	R01AI154932	93.855	-	370.306	370.306
NH	Allergy, Immunology and Transplantation Research	Regulation of TLR signaling, I	Univ of Texas Southwestern		R01AI155426	93.855	105.080	389.485	494.565
NH	Allergy, Immunology and Transplantation Research	Regulation of C. difficile col	University of Cincinnati	019399-00002	R01AI158451	93.855	-	7.512	7.512
NH	Allergy, Immunology and Transplantation Research	Pay-it-forward genomea testi	University of North Carolina	51234791R01AI15882	R01AI158826	93.855	-	49.729	49.729
NH	Allergy, Immunology and Transplantation Research	Leveraging Health Informatio	Children's National Medical Center	30007046	R01AI163232	93.855	-	7.416	7.416
NH	Allergy, Immunology and Transplantation Research	Hyperthydration to Improve Kid	University of Calgary		R01AI165327	93.855	-	2.611	2.611
NH	Arthritis, Musculoskeletal and Skin Diseases Research	Deciphering mechanisms of myob			R01AR068286	93.846	-	308.243	308.243
NH	Arthritis, Musculoskeletal and Skin Diseases Research	Multi-site Randomized Clinical Trial of FIT	Children's Hospital Boston Children's Mercy Hospital Connecticut Children's Medical Center Emory University Indiana University Nationwide Children's Hospital The Ohio State University- Spon Programs		R01AR070474	93.846	40.961	750.522	1,407.409
								169.055	
								200.316	
								47.650	
								96.844	
								83.845	
								18.216	
NH	Arthritis, Musculoskeletal and Skin Diseases Research	In vivo role of the fibroblast in muscular dys			R01AR071301	93.846	-	323.856	323.856
NH	Arthritis, Musculoskeletal and Skin Diseases Research	Transcription Factor Genetics	Boston University New York University School of Medicine		R01AR073228	93.846	33.127	375.438	418.091
								9.526	
NH	Arthritis, Musculoskeletal and Skin Diseases Research	Complement in Human Lupus: Def	Nationwide Children's Hospital	700165-0519-00	R01AR073311	93.846	-	9.769	9.769
NH	Arthritis, Musculoskeletal and Skin Diseases Research	GSK3 beta study in patients w			R01AR073379	93.846	-	363.956	363.956
NH	Arthritis, Musculoskeletal and Skin Diseases Research	Refining entry criteria and ou	Children's Hospital of Philadelphia	3201900722	R01AR074098	93.846	-	250	250
NH	Arthritis, Musculoskeletal and Skin Diseases Research	Identifying neural pathophysio	Universitat De Barcelona		R01AR074795	93.846	68.483	302.540	371.023
NH	Arthritis, Musculoskeletal and Skin Diseases Research	Epigenetic Determinants Influe	Children's Hospital of Philadelphia Duke University Johns Hopkins University Stanford University.		R01AR075857	93.846	31.048	543.857	611.785
								6.112	
								9.692	
								21.176	
NH	Arthritis, Musculoskeletal and Skin Diseases Research	Pathogenesis of Systemic Juven			R01AR079524	93.846	-	27.570	27.570
NH	Research and Training in Complementary and Alternative Medicine	Dissecting Neural Mechanisms S			R01AT010171	93.213	-	653.944	653.944

NH	Research and Training in Complementary and Alternative Medicine	Systems biology of microbe-med	University of Virginia	R01AT010253	R01AT010253	93.213	-	978	978
NH	Cancer Biology Research	Coagulation factors modifiers of the colon			R01CA204058	93.396	-	5.619	5.619
NH	Cancer Biology Research	Leukemia stem cell polarity and different			R01CA204895	93.396	-	412.402	412.402
NH	Cancer Treatment Research	Linked regulation of tumor angiogenesis			R01CA207068	93.395	-	187.394	187.394
NH	Cancer Treatment Research	Mechanism of non-oncogene addition			R01CA211594	93.395	-	345.328	345.328
NH	Cancer Treatment Research	Targeting TET1 signaling to treat acute mye	City of Hope	60677.2004688.6690	R01CA211614	93.395	-	35.552	35.552
NH	Cancer Cause and Prevention Research	Instructive role of MLL fusion proteins in the	The University of Chicago	AWD064422_6306708	R01CA215504	93.393	-	295.569	295.569
NH	Cancer Biology Research	Mechanisms coupling DEK to oncogenesis			R01CA218072	93.396	-	302.403	302.403
NH	Cancer Treatment Research	Innovative Pain and Symptom Ma	Univ of California	2018-3581	R01CA222012	93.395	-	11.762	11.762
NH	Cancer Biology Research	FA pathway activities in norma			R01CA223790	93.396	-	316.345	316.345
NH	Cancer Cause and Prevention Research	Research Into Visual Endpoints	Vanderbilt University Medical Center	VUMV67585	R01CA225005	93.393	-	18.404	18.404
NH	Cancer Cause and Prevention Research	Unbiased identification of sig			R01CA226802	93.393	-	630.245	630.245
NH	Cancer Detection and Diagnosis Research	Integrated Informatic and Expe	University of Pennsylvania	577035	R01CA227485	93.394	-	327.306	327.306
NH	Cancer Cause and Prevention Research	Strengthening epidermal defense			R01CA228113	93.393	-	444.136	444.136
NH	Cancer Treatment Research	(PQ10) Role of Gut Microbiota	The University of Texas Southwestern	PO: 000001910A	GMOR01CA231303	93.395	-	93.576	93.576
NH	Cancer Biology Research	The role of transcription abn			R01CA234038	93.396	-	450.922	450.922
NH	Cancer Treatment Research	Targeted inhibition in Leukemi			R01CA237016	93.395	-	450.959	450.959
NH	Cancer Biology Research	New activities of the human OE	University of Kentucky		R01CA239605	93.396	27.280	471.863	499.143
NH	Cancer Treatment Research	Co-targeting S6 and TAM kinas	University of Cincinnati	12653-002	R01CA239657	93.395	-	23.274	23.274
NH	Cancer Biology Research	Defining genetic and metabolic	University of Cincinnati	012828-002	R01CA239697	93.396	-	164.336	164.336
NH	Cancer Biology Research	Patho-Genetic Analysis of Inva			R01CA240317	93.396	111.161	227.931	513.777
							174.685	-	-
NH	Cancer Biology Research	The Role of HIF1A-DNMT3A axis	University of Minnesota	H0085223701	R01CA248019	93.396	-	31.066	31.066
NH	Cancer Treatment Research	Mechanism of Therapy in high-r			R01CA250516	93.395	-	670.287	670.287
NH	Cancer Biology Research	Modeling myobdysplasia	Johns Hopkins University		R01CA253981	93.396	86.980	293.935	461.849
			Yale University				80.934	-	-
NH	Cancer Treatment Research	Therapeutic resistance and agg	University of Cincinnati	013734-0002	R01CA255331	93.395	-	14.626	14.626
NH	Cancer Biology Research	Dissecting innate immune signa			R01CA271455	93.396	-	58.337	58.337
NH	Drug Abuse and Addiction Research Programs	Role of Siglec-1 in HIV Intra	University of Cincinnati		R01DA051895	93.279	15.439	491.921	507.360
NH	Research Related to Deafness and Communication Disorders	Prevention of Ototoxicity with			R01DC017867	93.173	260.962	341.639	617.058
			Oregon Health & Science University				-	-	-
			Washington University				14.457	-	-
NH	Research Related to Deafness and Communication Disorders	Pediatric dysphonia: Multidisc	University of South Florida	1219-1068-00-B	R01DC018008	93.173	-	53.540	53.540
NH	Research Related to Deafness and Communication Disorders	Technology-assisted language i			R01DC018550	93.173	4.001	592.752	717.693
			Children's Hospital Colorado				-	-	-
			University of Colorado				120.940	-	-
NH	Research Related to Deafness and Communication Disorders	Earliest predictors of languag			R01DC018734	93.173	32.792	863.800	896.592
NH	Research Related to Deafness and Communication Disorders	Neuroimaging Reveals Treatmen	University of Cincinnati	013916-0002	R01DC019337	93.173	-	39.271	39.271
NH	Oral Diseases and Disorders Research	Developing Topical Fluoride He	University of Washington	UWSC10797	R01DE026741	93.121	-	64.925	64.925
NH	Oral Diseases and Disorders Research	Mandible Development			R01DE027046	93.121	-	687.908	687.908
NH	Oral Diseases and Disorders Research	Stoltmann R01 Subaward from Na	Nationwide Children's Hospital	700262-0622	R01DE027091	93.121	-	32.373	32.373
NH	Oral Diseases and Disorders Research	Regulation of Craniofacial Dev			R01DE029417	93.121	-	564.874	564.874
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Immunologic Dysfunction in BI			R01DK064008	93.847	-	417.529	417.529
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Adolescent Bariatric Surgery:			R01DK080020	93.847	46.581	533.600	619.134
			Sanford Research North				-	-	-
			The CDM Group, Inc				38.953	-	-
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Inhibition of an Apical cAMPK			R01DK080834	93.847	13.484	49.022	62.506
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Biological Basis of Phenotypes			R01DK083781	93.847	-	673.117	673.117
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Genetic basis of virus induced	University of Cincinnati		R01DK091566	93.847	9.619	442.242	451.861
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Control of hepatic T cell resp			R01DK095001	93.847	-	348.960	348.960
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Immunopathogenesis of non-abo			R01DK099222	93.847	-	674.694	674.694
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	The Mechanism Regulating Renal Progn			R01DK106225	93.847	-	34.235	34.235
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Mechanisms of genetic risk at 2p23 in Eos			R01DK107502	93.847	-	110.628	110.628
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Role of Hepatic RNA Silencing in Insulin Re			R01DK107530	93.847	-	19.272	19.272
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Building a functional biliary system from hep			R01DK107553	93.847	-	283.558	283.558
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Nonlinear Ultrasound: an Imaging Bom	University of Michigan	3004067897	R01DK109032	93.847	-	43.864	43.864
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Advancing Treatment for Pancreatitis	University of Minnesota	N00515002	R01DK109124	93.847	-	6.294	6.294
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Mapping Disease Pathways for B	University of Pittsburgh	CNVA000054687 (1295	R01DK109365	93.847	-	14.473	14.473
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Level and timing of diabetichyperglycemia			R01DK109956	93.847	28.268	546.394	604.620
			MedStar Health Research Institute, Inc				-	-	-
			Tufts Medical Center, Inc				29.958	-	-
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Fibrin(ogen) control of metabo	University of North Carolina	5116413	R01DK112778	93.847	-	17.459	17.459
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Targeting IRAK1/4 in Myelodysplastic Syn			R01DK113639	93.847	-	146.404	146.404
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Epigenomic control of antimicrobial immun	University of Cincinnati		R01DK114123	93.847	30.968	317.415	348.383
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Host integration of commensal			R01DK116868	93.847	-	273.009	273.009
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Type 2 cytokines and innate ly			R01DK117119	93.847	-	54.493	54.493
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Molecular targets in cholestas			R01DK117266	93.847	-	334.445	334.445
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Manipulating DNA Damage-respon			R01DK117632	93.847	-	351.897	351.897
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Biomarkers for Urinary Tract I	University of Pittsburgh	AWD00000120 (13256	R01DK118033	93.847	-	15.062	15.062
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Surgical or Medical Treatment	University of Colorado		R01DK119450	93.847	92.820	298.010	390.830
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	The role of SPRY2 in the colon	Children's Hospital Los Angeles	RGF0111923-A	R01DK119694	93.847	-	606	606
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Molecular regulation of hepat			R01DK120765	93.847	-	320.053	320.053
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Hox Genes and Lineage Hinfel1			R01DK120842	93.847	-	704.752	704.752
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Retinoic acid gene regulatory			R01DK120847	93.847	-	261.831	261.831
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Regulation of functionality de			R01DK121062	93.847	-	536.227	536.227
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Diabetes Journey: From sympto	University of Florida		R01DK121296	93.847	151.577	291.277	402.854
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Molecular mechanisms for bone	Northwestern University Medical School	60052734_C3HMC	R01DK121354	93.847	-	16.835	16.835
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Sox Proteins Modulate Genomic			R01DK123092	93.847	-	391.883	391.883
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Role of extracellular vesicle	Vanderbilt University		R01DK123181	93.847	26.737	665.848	692.585
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Regulation of Niche Cell Diffe			R01DK123299	93.847	-	16.867	16.867
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Mitochondria mediated intercel	Case Western University	RES516540	R01DK124115	93.847	-	391.244	391.244
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Microbiota-mediated fibrotic r	University of North Carolina	5117429	R01DK124617	93.847	-	12.679	12.679
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Host and viral determinants of	Children's Hospital of Philadelphia	25460-GRT-0000414	R01DK125418	93.847	-	336.301	336.301
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Gene regulatory networks in th			R01DK125577	93.847	-	390.214	390.214
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Determinants of inception of th	Massachusetts General Hospital	239459	R01DK127191	93.847	-	66.618	66.618
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Limited Competition for the O	Wake Forest University Health Sciences	241-100710-553791	R01DK127208	93.847	-	19.404	19.404
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Changing Health And Lifestyle	University of Delaware		R01DK128525	93.847	802	140.865	141.667
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Hedgehog gene regulatory netwo			R01DK131052	93.847	-	140.946	140.946
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Structure, function, and modul	The University of Chicago	AWD102456SUB0000	R01DK131542	93.847	-	19.860	19.860
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Precise Infliximab Exposure an			R01DK132408	93.847	-	17.236	17.236
NH	Discovery and Applied Research for Tech Innovations to Improve Human	HealthMRI Compatible Robot for Impri	Children's National Medical Center	30004680-03	R01EB025179	93.286	-	127.900	127.900

NH	Discovery and Applied Research for Tech Innovations to Improve Human Health	MRI and Deep Learning for Ear				R01EB029944	93.286	-	589,652	589,652
NH	Discovery and Applied Research for Tech Innovations to Improve Human Health	Quantification of Liver Fibrosis		New York University School of Medicine		R01EB030582	93.286	28,584	429,661	520,712
				University of Michigan				26,839	-	-
				University of Wisconsin System				35,628	-	-
NH	Discovery and Applied Research for Tech Innovations to Improve Human Health	MRI-Compatible Robot for Real-time	Children's National Medical Center		30006761-01	R01EB031084	93.286	-	87,742	87,742
NH	Environmental Health	Developmental Effects of Manganese	University of Kentucky		5R01ES026446	R01ES026446	93.113	-	66,786	66,786
NH	Environmental Health	Prenatal Exposure to Endocrine Disruptors	Pennsylvania State University		S000447-NH	R01ES026903	93.113	-	7,131	7,131
NH	Environmental Health	Internalizing Behaviors and Neuroimaging		University of Cincinnati		R01ES027224	93.113	8,192	302,330	314,743
				University of Pennsylvania				4,221	-	-
NH	Environmental Health	Contribution of Thirdhand Smoke to Lung Cancer Risk		San Diego State Univ.		R01ES027815	93.113	150,067	133,866	304,063
				University of Cincinnati				20,130	-	-
NH	Environmental Health	Impact of pre- and postnatal endocrine disruptors on neurodevelopment	University of Pennsylvania		580431	R01ES028277	93.113	-	328,258	328,258
NH	Environmental Health	Longitudinal Study of Endocrine Disruptors	University of Cincinnati		011720-002	R01ES029133	93.113	-	37,364	37,364
NH	Environmental Health	Endocrine disrupting chemical mixtures and neurodevelopment	Johns Hopkins University		2005393998	R01ES030078	93.113	-	294,962	294,962
NH	Environmental Health	Effects of DDE exposure on neurodevelopment	University of Southern California		129965417	R01ES030364	93.113	-	13,922	13,922
NH	Environmental Health	ADVOGATE: Prevalence and Clinical Impact of Autism Spectrum Disorders		San Diego State Univ.		R01ES030743	93.113	324,355	429,301	778,610
				University of Cincinnati				24,954	-	-
NH	Environmental Health	Epigenetics, Air Pollution, and Lung Cancer Risk	University of Cincinnati		013074-00003	R01ES031054	93.113	-	174,547	174,547
NH	Environmental Health	Longitudinal Impact of Air Pollution on Lung Cancer Risk		Brown University		R01ES031621	93.113	17,709	941,440	1,009,283
				University of Cincinnati				50,134	-	-
NH	Environmental Health	Gene-pesticide interactions and neurodevelopment				R01ES032270	93.113	-	461,678	461,678
NH	Environmental Health	Gestational PFAS Mixture Exposures and Neurodevelopment	Brown University		1R01ES032836-01	R01ES032836	93.113	-	32,736	32,736
NH	Vision Research	Regulation of vascular development in the eye		Cleveland Clinic Foundation		R01EY027077	93.867	210,808	20,749	231,557
NH	Vision Research	Gene Therapy of Corneal Dystrophy	University of Cincinnati		012501-002	R01EY029427	93.867	-	16,404	16,404
NH	Vision Research	Predicting uveitis onset in children		Children's Hospital Boston		R01EY030521	93.867	1,279	340,341	367,968
				Children's Hospital of Philadelphia				955	-	-
				University of California				109	-	-
				University of Cincinnati				11,330	-	-
				Wake Forest Univ School of Medicine				13,954	-	-
NH	Vision Research	RNA Nanoparticles for Ocular Drug Delivery	University of Cincinnati		013457-003	R01EY031452	93.867	-	12,837	12,837
NH	Vision Research	Light regulated vascular development				R01EY032029	93.867	-	456,879	456,879
NH	Vision Research	Mechanisms of intrinsic light regulation of retinal development		Georgia Tech Research Corporation		R01EY032752	93.867	9,214	312,893	415,652
NH	Vision Research			University of Alabama at Birmingham				60,966	-	-
NH	Vision Research			Washington University				32,579	-	-
NH	Biomedical Research and Research Training	Biochemical and Computational Analysis of Protein-Protein Interactions				R01GM055479	93.859	-	467,819	467,819
NH	Biomedical Research and Research Training	Mechanisms of Homeostatic Regulation of Protein-Protein Interactions		University of Cincinnati		R01GM079428	93.859	107,597	385,352	492,949
NH	Biomedical Research and Research Training	Studies of Methyl-Dependent Interactions in the Brain		University of Colorado		R01GM094363	93.859	49,033	236,619	285,652
NH	Biomedical Research and Research Training	Age-Dependent Mechanism of Neurodegeneration				R01GM115973	93.859	-	526,890	526,890
NH	Biomedical Research and Research Training	Epigenetic Regulation of Gene Expression during Development	University of California-Davis		A21-3093-S001	R01GM122778	93.859	-	12,531	12,531
NH	Biomedical Research and Research Training	Role of STAT3 in sepsis-induced adipose tissue dysfunction				R01GM126551	93.859	-	346,717	346,717
NH	Biomedical Research and Research Training	Role of Vpu, Tat, Rev, and Sp1 in HIV-1 Pathogenesis				R01GM132088	93.859	-	8,376	8,376
NH	Biomedical Research and Research Training	Functional characterization of the HIV-1 Tat protein		The Ohio State University		R01GM134731	93.859	43,162	247,082	290,244
NH	Child Health and Human Development Extramural Research	Prenatal Genetic Diagnosis by Next-Generation Sequencing	Columbia University Medical Center		1(GG014633-01)	R01HD055651	93.865	-	88,011	88,011
NH	Child Health and Human Development Extramural Research	Molecular signaling in uterine receptivity				R01HD068524	93.865	-	355,350	355,350
NH	Child Health and Human Development Extramural Research	Long-Term Outcomes of Interventions for Preterm Birth	Oklahoma State University		1-5719-18-QHMC	R01HD074579	93.865	-	13,721	13,721
NH	Child Health and Human Development Extramural Research	A Cognitive Test Battery for Children with Intellectual Disability	University of California-Davis		A20-1951-S006	R01HD076189	93.865	-	111,880	111,880
NH	Child Health and Human Development Extramural Research	Bone Mineral Accretion in Young Children		Children's Hospital of Philadelphia		R01HD076321	93.865	16,130	50,359	66,489
NH	Child Health and Human Development Extramural Research	Improving ADHD Teen Driving by Targeting Executive Function		Saint Louis University		R01HD084430	93.865	2,240	191,296	193,536
NH	Child Health and Human Development Extramural Research	The role of executive functions in reading		Kennedy Krieger Institute, Inc.		R01HD086011	93.865	17,681	36,291	93,728
				Technion Research & Development				39,756	-	-
NH	Child Health and Human Development Extramural Research	Decision-Making for Patients Born with Down Syndrome	University of Michigan		3004425008	R01HD086583	93.865	-	67,417	67,417
NH	Child Health and Human Development Extramural Research	Decision-Making for Patients Born with Down Syndrome	Northwestern University Medical School		60046347 CCHMC	R01HD087363	93.865	-	25,490	25,490
NH	Child Health and Human Development Extramural Research	Premature Infants Receiving Covert Genetic Testing	Sharp HealthCare Foundation		#R012021 Cincinnati	R01HD088646	93.865	-	10,554	10,554
NH	Child Health and Human Development Extramural Research	Identifying Pharmacogenomic Predictors of Drug Response		Duke University		R01HD089928	93.865	59,346	79,791	139,137
NH	Child Health and Human Development Extramural Research	FA DDR Pathway in Germline Integrity				R01HD089932	93.865	-	175,612	175,612
NH	Child Health and Human Development Extramural Research	VIRTUOUS Children's Study-Validating the Effect of Emergency Department Visits on Child Health	Children's Hospital of Philadelphia		3200880522	R01HD091185	93.865	-	6,319	6,319
NH	Child Health and Human Development Extramural Research	The Effect of Emergency Department Visits on Child Health	Medical College of Wisconsin		R01HD091302	R01HD091302	93.865	-	42,031	42,031
NH	Child Health and Human Development Extramural Research	Development and Testing of a Pediatric Health Assessment Tool	Nationwide Children's Hospital		700171-0719-00	R01HD091347	93.865	-	21,551	21,551
NH	Child Health and Human Development Extramural Research	Harnessing 'omics': A Systems Biology Approach to Understanding Child Health				R01HD091527	93.865	-	1,038	1,038
NH	Child Health and Human Development Extramural Research	Vocational Fit Assessment and Career Development	Colorado State University		R01HD092474	R01HD092474	93.865	-	76,798	76,798
NH	Child Health and Human Development Extramural Research	Disorders/Differences of Sex Development	University of Michigan		SUBK0008039	R01HD093450	93.865	-	42,576	42,576
NH	Child Health and Human Development Extramural Research	CES1 Genetic Variation Influences Child Health	University of Florida		SUBK0001726	R01HD093612	93.865	-	104,301	104,301
NH	Child Health and Human Development Extramural Research	A multicenter collaborative study of early childhood communication	Children's National Medical Center		30004927-01	R01HD093622	93.865	-	50,800	50,800
NH	Child Health and Human Development Extramural Research	Early Childhood Communication and Child Health	University of California-Davis		A19-0450-S002	R01HD093654	93.865	-	110,612	110,612
NH	Child Health and Human Development Extramural Research	High-Intensity Interval Training for Children	University of Cincinnati		011445-02	R01HD093694	93.865	-	11,424	11,424
NH	Child Health and Human Development Extramural Research	Cognitive Outcome Measures in Children with Down Syndrome		Colorado State University		R01HD093754	93.865	604,119	532,417	1,136,536
NH	Child Health and Human Development Extramural Research	Thrombotic microangiopathy (TMA) in Children		The Hospital for Sick Children		R01HD093773	93.865	16,157	467,179	483,336
				University of Cincinnati				12,944	-	-
NH	Child Health and Human Development Extramural Research	Improving the Detection of ST Segment Elevation Myocardial Infarction	Children's National Medical Center		30004942-05	R01HD094213	93.865	-	87,834	87,834
NH	Child Health and Human Development Extramural Research	Exploring vascular-mesenchymal signaling in the brain				R01HD094698	93.865	-	341,734	341,734
NH	Child Health and Human Development Extramural Research	Dosing and Pilot Efficacy of 2-DG		Connecticut Childrens Medical Center		R01HD094862	93.865	97,198	398,701	686,273
				Nationwide Childrens Hospital				57,742	-	-
				The Broad Institute Inc.				54,770	-	-
				University of Cincinnati				71,862	-	-
NH	Child Health and Human Development Extramural Research	Study of Attitudes and Factors Influencing Child Health	Boston University Medical Campus		4500003864	R01HD095060	93.865	-	980	980
NH	Child Health and Human Development Extramural Research	Stress Hydrocortisone in Pediatric Depression	Children's Hospital Boston		GENFD0001702903	R01HD096901	93.865	-	119,822	119,822
NH	Child Health and Human Development Extramural Research	Deciphering the pathophysiology of pediatric depression				R01HD098280	93.865	-	588,519	588,519
NH	Child Health and Human Development Extramural Research	Discovery of Molecular Targets for Pediatric Depression	UCLA School of Public Health		1651 G WA732	R01HD098389	93.865	-	109,392	109,392
NH	Child Health and Human Development Extramural Research	Executive Function Outcome Measures in Children with Depression	University of California		G-45002-02	R01HD099150	93.865	-	127,218	127,218
NH	Child Health and Human Development Extramural Research	Improving the Effectiveness of Pediatric Depression Treatment		University of Cincinnati		R01HD099775	93.865	259,001	215,620	474,621
NH	Child Health and Human Development Extramural Research	Genomics of bone and body composition	Children's Hospital of Philadelphia		GRT-00000601	R01HD100406	93.865	-	26,589	26,589
NH	Child Health and Human Development Extramural Research	Enhancing Nursing Care Reliability	Ohio State University		60077379	R01HD100455	93.865	-	52,758	52,758
NH	Child Health and Human Development Extramural Research	Development and persistence of neurodevelopmental disorders	North Carolina State University		2020-2189-01	R01HD101406	93.865	-	18,081	18,081
NH	Child Health and Human Development Extramural Research	Skeletal Health and Bone Mass in Children	Children's Hospital Boston		GENFD0002013062	R01HD101421	93.865	-	328,644	328,644
NH	Child Health and Human Development Extramural Research	Pragmatic Pediatric Trial of BDNF	Children's Hospital of Philadelphia		GRT-00000762	R01HD101528	93.865	-	61,242	61,242
NH	Child Health and Human Development Extramural Research	Integrating genomic studies of neurodevelopmental disorders		Univ of California		R01HD101669	93.865	18,060	311,513	329,573
NH	Child Health and Human Development Extramural Research	An Injury Plausibility Assessment	Lurie Children's Hospital of Chicago		9001615-CCHMC	R01HD102428	93.865	-	5,901	5,901

NH	Child Health and Human Development Extramural Research	Endocannabinoid Signaling du			R01HD103475	93.865	-	425,082	425,082
NH	Child Health and Human Development Extramural Research	Integration of spatiotemporal			R01HD103623	93.865	-	239,473	239,473
NH	Child Health and Human Development Extramural Research	Automated Risk Assessment for	University of Pittsburgh		R01HD103630	93.865	53,140	365,629	418,769
NH	Child Health and Human Development Extramural Research	Leveraging the electronic heal			R01HD103654	93.865	-	233,314	233,314
NH	Child Health and Human Development Extramural Research	Using Dogs to Promote Therapeu			R01HD106416	93.865	10,961	255,357	266,338
NH	Human Genome Research	Engaging adolescents in decis			R01HG010166	93.172	-	739,883	739,883
NH	Human Genome Research	Virus-driven human gene miseg	Brigham and Women's Hospital		R01HG010730	93.172	137,050	590,909	755,325
NH	Human Genome Research		University of Cincinnati				-	28,366	-
NH	Human Genome Research	Epigenome-wide variations and			R01HG011411	93.172	-	190,913	190,913
NH	Cardiovascular Diseases Research	Molecular pathways controlling			R01HL060562	93.837	-	436,917	436,917
NH	Cardiovascular Diseases Research	Autophagy and mTORC1 signaling	University of Cincinnati	011762-002	R01HL07394	93.837	-	1,200	1,200
NH	Blood Diseases and Resources Research	Role of FA Proteins in Hematopoies			R01HL076712	93.839	-	235,105	235,105
NH	Lung Diseases Research	Pathogenesis-Based Diagnosis			R01HL085453	93.838	-	423,305	423,305
NH	Cardiovascular Diseases Research	Thrombospondin 4 regulates ada			R01HL105924	93.837	-	634,438	634,438
NH	Cardiovascular Diseases Research	Venous Malformations (VM): A M			R01HL117652	93.837	-	463,439	463,439
NH	Lung Diseases Research	Pulmonary Macrophage Transplan	University of Washington	R01HL118342	93.838	86,793	-	285,835	372,628
NH	Lung Diseases Research	Pediatric Respiratory Illness	Kaiser Foundation Research Institue	RNG221577-CCHMC	R01HL121067	93.838	-	11,301	11,301
NH	Blood Diseases and Resources Research	Mechanisms of granulocyte home			R01HL122661	93.839	-	597,719	597,719
NH	Cardiovascular Diseases Research	Using MRI to visualize regions	Duke University	A034671	R01HL126771	93.837	24,295	115,507	139,802
NH	National Center on Sleep Disorders Research	Upper Airway Structure and Fun	Albert Einstein College of Medicine	311427	R01HL130468	93.233	-	724	724
NH	Lung Diseases Research	UTE MRI to monitor CF lung diseas			R01HL131012	93.838	-	104,038	104,038
NH	Cardiovascular Diseases Research	Functional Impact of Col18a1/Endostain	Johns Hopkins School of Medicine	JHU;R01HL132153	R01HL132153	93.837	-	210	210
NH	Cardiovascular Diseases Research	Hippo Signaling in Heart Development and			R01HL132211	93.837	-	331,461	331,461
NH	Cardiovascular Diseases Research	Unraveling ancestry and environmental exp			R01HL132344	93.837	8,396	930,980	939,376
NH	Cardiovascular Diseases Research	Molecular examination of mtbc			R01HL132831	93.837	207,197	548,301	755,498
NH	Blood Diseases and Resources Research	Chronic thrombus ablation wth	The University of Chicago	FP066598	R01HL133334	93.839	-	19,560	19,560
NH	Cardiovascular Diseases Research	Targeting pathologic G-protein signaling in			R01HL133695	93.837	-	222,753	222,753
NH	Lung Diseases Research	WT1 Regulation of Pulmonary Fibrosis	University of Cincinnati		R01HL134801	93.838	9,755	284,342	323,246
NH	Lung Diseases Research		University of Michigan				-	29,149	-
NH	Cardiovascular Diseases Research	Regulatory mechanisms of adult cardomyo			R01HL135848	93.837	-	155,645	155,645
NH	Blood Diseases and Resources Research	Cellular crosstalk in the hematopoietic			R01HL136529	93.839	-	268,800	268,800
NH	Cardiovascular Diseases Research	Molecular mechanisms of atrial develop			R01HL137766	93.837	-	160,719	160,719
NH	Cardiovascular Diseases Research	Circadian Rhythms and Inflamm	The University of Massachusetts, Amher	19-010568 A00	R01HL138551	93.837	-	139,784	139,784
NH	Lung Diseases Research	Transcriptional Regulation of Endothelial			R01HL141174	93.838	-	436,908	436,908
NH	Cardiovascular Diseases Research	Retinoic acid-dependent epigenetic and			R01HL141186	93.837	-	209,878	209,878
NH	Cardiovascular Diseases Research	Celsr1 in Lung Development and Disease			R01HL141229	93.837	-	477,710	477,710
NH	Lung Diseases Research	R01- Mapping environmental con			R01HL141286	93.838	26,393	412,009	438,402
NH	Blood Diseases and Resources Research	Normal and Pathological Hematopoietic			R01HL141418	93.839	-	400,526	400,526
NH	Cardiovascular Diseases Research	Familial hypercholesterolemia	Columbia University Medical Center	7(GG012850-01)	R01HL141823	93.837	-	45,597	45,597
NH	Lung Diseases Research	Mechanisms controlling early h	The Lundquist Institute	TBD-7R01HL141856	R01HL141856	93.838	-	18,939	18,939
NH	Cardiovascular Diseases Research	Predictive Molecular Markers o			R01HL142210	93.837	-	183,712	183,712
NH	Cardiovascular Diseases Research	Cardiac fibroblasts in postnat			R01HL142217	93.837	-	707,861	707,861
NH	Lung Diseases Research	Development of neonatal innate			R01HL142708	93.838	-	379,012	379,012
NH	Lung Diseases Research	Validating Quantitative Magnet	University of Cincinnati		R01HL143011	93.838	7,465	699,874	707,339
NH	Cardiovascular Diseases Research	Mechanisms of Congenital Heart Valve De			R01HL143881	93.837	-	323,094	323,094
NH	Cardiovascular Diseases Research	HDL composition/function and ca	University of Washington	UWSC10977	R01HL144558	93.837	-	58,166	58,166
NH	Cardiovascular Diseases Research	Molecular mechanisms underlyin			R01HL144774	93.837	-	399,108	399,108
NH	Cardiovascular Diseases Research	Characterizing the formation a	The University of Texas Southwestern	GMO 190108 PO 000	R01HL144793	93.837	-	39,695	39,695
NH	Lung Diseases Research	The role of sex in the life cy	University of Cincinnati	012029-002	R01HL146266	93.838	-	64,294	64,294
NH	Cardiovascular Diseases Research	MRI Phenotyping of Early BPD a	University of Wisconsin System		R01HL146689	93.837	5,121	834,124	885,845
NH	Lung Diseases Research	Sleep-Disordered Breathing in	University of Michigan	SUBK00015153	R01HL147261	93.838	-	29,267	29,267
NH	Lung Diseases Research	Investigating the Mechanisms o	University of Cincinnati		R01HL147351	93.838	1,359	-	16,193
NH	Blood Diseases and Resources Research	Small molecules targeting RhoA			R01HL147536	93.839	-	468,159	468,159
NH	Cardiovascular Diseases Research	Impact of Well-Timed vs. Mis-t	Rush University Medical Center		R01HL147915	93.837	30,023	493,543	523,566
NH	Cardiovascular Diseases Research	Novel Methods to Grow the Impa			R01HL147957	93.837	-	544,594	544,594
NH	Blood Diseases and Resources Research	Linking Endotypes and Outcomes	Children's Hospital of Philadelphia	3201710624	R01HL148054	93.839	-	51,005	51,005
NH	Lung Diseases Research	Bedside Exclusion of Pulmonary	Indiana University	8492-CHMC	R01HL148247	93.838	-	36,212	36,212
NH	Lung Diseases Research	Bedside Exclusion of Pulmonary	Wayne State University	WSU12-2071	R01HL148247	93.838	-	27,982	27,982
NH	Cardiovascular Diseases Research	Ultrasound-Mediated Controlle	University of Cincinnati	012288-003	R01HL148451	93.837	-	81,193	81,193
NH	Lung Diseases Research	Perinatal Dysbiosis, Lung Deve			R01HL149396	93.838	35,977	401,789	437,746
NH	Lung Diseases Research	Molecular Mechanisms Regulated	University of Cincinnati		R01HL149631	93.838	39,277	508,808	548,085
NH	Lung Diseases Research	Role of GM-CSF in Alveolar Mac			R01HL149743	93.838	-	204,809	204,809
NH	Child Health and Human Development Extramural Research	Endotypes in Children with Sev	University of Michigan	SUBK00010627	R01HL149910	93.865	-	4,107	4,107
NH	Lung Diseases Research	Role of IGF Axis in Pulmonary	Johns Hopkins School of Medicine	2004833966	R01HL150070	93.838	-	72,102	72,102
NH	Lung Diseases Research	Imaging and Molecular Phenotyp			R01HL151588	93.838	-	456,282	456,282
NH	Cardiovascular Diseases Research	Accelerating research to advan	Brigham and Women's Hospital		R01HL151604	93.837	9,899	145,176	500,788
NH	Blood Diseases and Resources Research	The role of mitochondria in he			R01HL151654	93.839	27,193	422,572	449,765
NH	Lung Diseases Research	A Role For EYA3 in Vascular RE			R01HL152094	93.838	-	594,700	594,700
NH	Blood Diseases and Resources Research	The Role of Erythroblastic Id	The Feinstein Institute Medical Res		R01HL152099	93.839	221,409	405,847	627,256
NH	Cardiovascular Diseases Research	MINDS Imaging Ancillary Study	University of Pittsburgh	AWD00002377 (13459	R01HL152740	93.837	-	26,465	26,465
NH	Lung Diseases Research	Development of novel therapau			R01HL152973	93.838	-	586,117	586,117
NH	Lung Diseases Research	Uterine signaling networks in	University of Cincinnati		R01HL153045	93.838	268,004	356,336	624,340
NH	Blood Diseases and Resources Research	Mechanisms whereby IFN-gamma s	University of Pittsburgh	AWD00003978	R01HL153106	93.839	-	39,220	39,220
NH	Lung Diseases Research	Penetrating the "Black box".	The Ohio State University		R01HL153108	93.838	2,843	316,901	319,744
NH	Cardiovascular Diseases Research	Spatial control of myeloid df			R01HL153229	93.837	-	227,826	227,826
NH	Blood Diseases and Resources Research	MIDAS: Microangiopathy, Endoth	The Ohio State University Research Fnd	60078812	R01HL153723	93.839	-	145,817	145,817
NH	Cardiovascular Diseases Research	Mechanisms underlying myxomato			R01HL154522	93.837	-	348,704	348,704
NH	Cardiovascular Diseases Research	Hypertrophic Cardiomyopathy: U	Brigham & Women's Hospital	2020A015252	R01HL155568	93.837	-	7,323	7,323
NH	Lung Diseases Research	Tissue niches for IL33 develop			R01HL155611	93.838	-	428,749	428,749
NH	Cardiovascular Diseases Research	Endothelial subpopulations in			R01HL156270	93.837	-	359,862	359,862
NH	Cardiovascular Diseases Research	Innate immune response signal			R01HL156852	93.837	-	196,300	196,300
NH	Lung Diseases Research	Epigenetic Regulation of the M			R01HL156860	93.838	-	323,245	323,245
NH	Cardiovascular Diseases Research	Pathogenesis and Treatment of			R01HL156866	93.837	-	208,961	208,961

NH	Lung Diseases Research	Sox9 Regulation of Fibroblast	University of Cincinnati	R01HL157176	93.838	4,401	496,274	500.675
NH	Cardiovascular Diseases Research	Lipoprotein Interactions in th	University of Cincinnati	93.837	114,748	360,991	475,730	
NH	Lung Diseases Research	TRANSPiRE: A Prospective Cohor	Baylor College of Medicine, Children's Hospital Boston Children's Hospital of Philadelphia Fred Hutchinson Cancer Res Center Seattle Children's Hospital University of Minnesota	R01HL157392	93.838	17,143	550,390	685.837
						7,329	-	-
						51,508	-	-
						18,245	-	-
						8,513	-	-
						32,709	-	-
NH	Cardiovascular Diseases Research	Effect of reproductive history		R01HL158100	93.837	28,707	189,296	218.003
NH	Blood Diseases and Resources Research	Role of the local vascular mic		93.839	-	241,766	241,766	-
NH	Lung Diseases Research	Role of lung endothelial cells		R01HL158659	93.838	-	494,977	494,977
NH	Cardiovascular Diseases Research	Microprotein Regulation of Mt		R01HL160569	93.837	-	194,556	194,556
NH	Blood Diseases and Resources Research	Hematopoietic Stem Cell engraft		R01HL162649	93.839	-	5,890	5,890
NH	Medical Library Assistance	Personal Health Rec for Youth Emancipating		R01LM012816	93.879	-	13,244	13,244
NH	Medical Library Assistance	A Framework for Automated and		R01LM013222	93.879	-	229,700	229,700
NH	Medical Library Assistance	Situation Awareness to Improve	Children's Hospital of Philadelphia	R01LM013526	93.879	-	42,191	42,191
NH	Minority Health and Health Disparities Research	Linking pre-and post-natal	University of California	R01MD013006	93.307	31,331	609,682	641.013
NH	Mental Health Research Grants	Molecular Mechanisms Controlli	University of Cincinnati	R01MH090740	93.242	58,113	540,742	598.855
NH	Mental Health Research Grants	1/2 Anomalous Motor System Phy		R01MH095014	93.242	-	374,621	374,621
NH	Mental Health Research Grants	4/7-Collaborative genomic stud		R01MH115902	93.242	-	120,333	120,333
NH	Mental Health Research Grants	Nationwide dissemination of a	American Academy of Pediatrics.	93.242	15,038	-	787,760	802.798
NH	Mental Health Research Grants	Patient and Provider perspecti	University of North Carolina	5113985	93.242	-	76,785	76,785
NH	Mental Health Research Grants	1/3 Effectiveness Trial of the	Florida State University	R000002935	93.242	-	49,880	49,880
NH	Mental Health Research Grants	Longitudinal Examination of SI		R01MH122415	93.242	-	611,901	611,901
NH	Mental Health Research Grants	Molecular Dissection of Synapt	The University of Massachusetts, Amher	TBD-R01MH122519	93.242	-	68,655	68,655
NH	Mental Health Research Grants	Neuron- and microglia-specific	University of Cincinnati	012928-002	93.242	-	19,922	19,922
NH	Mental Health Research Grants	Parsing Neurobiological Bases	Purdue University University of Cincinnati	93.242	14,910	-	281,509	358.408
						61,989	-	-
NH	Nursing Research	Self-Management in Adolescents	Loyola University Chicago	Loyola/R01NR016235	93.361	-	2,880	2,880
NH	Nursing Research	Self-Management of Adolescent	Children's Hospital of Philadelphia	3201511123	93.361	-	92,025	92,025
NH	Nursing Research	Peer Mentoring to Improve Self	Nationwide Children's Hospital	700160-0219-00	93.361	-	199,815	199,815
NH	Nursing Research	Fostering medication adherence	CHOC Children's Hospital Medical University South Carolina Nationwide Childrens Hospital North Carolina State University Research Inst. at Nationwide Hos University of Florida University of Virginia	R01NR017794	93.361	88,053	279,559	646.211
						137,693	-	-
						82,018	-	-
						7,589	-	-
						16,178	-	-
						35,121	-	-
NH	Nursing Research	Randomized Controlled Trial of		R01NR019426	93.361	193,848	361,626	555.474
NH	Nursing Research	Identification of causal fact	University of Cincinnati	013249-002	93.361	-	37,712	37,712
NH	Extramural Res Programs in the Neurosciences & Neurological Disorders	Mitogenic Activities in Neurofibromatosis		R01NS028440	93.853	-	364,129	364,129
NH	Extramural Res Programs in the Neurosciences & Neurological Disorders	Comparison of Hemorrhagic and	University of Cincinnati	2R01NS030678-26	93.853	-	229,177	229,177
NH	Extramural Res Programs in the Neurosciences & Neurological Disorders	Ultrasound-assisted thrombolysis for stroke	University of Cincinnati	009291-010	93.853	-	8,638	8,638
NH	Extramural Res Programs in the Neurosciences & Neurological Disorders	Molecular, cellular and physiological mech	University of Florida	R01NS054794	93.853	150,912	549,271	700.183
NH	Extramural Res Programs in the Neurosciences & Neurological Disorders	Identification and reversal of		R01NS065020	93.853	-	377,709	377,709
NH	Extramural Res Programs in the Neurosciences & Neurological Disorders	Brain Mechanisms Supporting Individual Diff		R01NS085391	93.853	-	43,327	43,327
NH	Extramural Res Programs in the Neurosciences & Neurological Disorders	MicroRNA-mediated silencing of the Kv4.2		R01NS092705	93.853	-	74,719	74,719
NH	Extramural Res Programs in the Neurosciences & Neurological Disorders	Early Prediction of Cerebral Palsy in Premat		R01NS096037	93.853	-	5,399	5,399
NH	Extramural Res Programs in the Neurosciences & Neurological Disorders	Genetic and environmental influences on ec	Phoenix Children's Hospital University of CA University of Exeter	R01NS096053	93.853	631	173,663	196.311
						14,584	-	-
						7,433	-	-
NH	Extramural Res Programs in the Neurosciences & Neurological Disorders	miR-155 and RUNX function in neurofibro		R01NS097233	93.853	-	39,922	39,922
NH	Extramural Res Programs in the Neurosciences & Neurological Disorders	Binding of Epstein Barr Virus EBNA2 unfi	Stanford University.	R01NS099088	93.853	9,400	351,848	361.248
NH	Extramural Res Programs in the Neurosciences & Neurological Disorders	Mechanisms of Biguanide Sensi		R01NS099162	93.853	-	230,094	230,094
NH	Extramural Res Programs in the Neurosciences & Neurological Disorders	ICH Recovery Grant	University of Cincinnati	011078-003	93.853	-	27,220	27,220
NH	Extramural Res Programs in the Neurosciences & Neurological Disorders	Distinct Mechanisms of Cognitive Behav		R01NS101321	93.853	-	493,670	493,670
NH	Extramural Res Programs in the Neurosciences & Neurological Disorders	Assessing Population-based Rad	University of Cincinnati	011815-003	93.853	-	108,046	108,046
NH	Extramural Res Programs in the Neurosciences & Neurological Disorders	Programulin: A Novel Gene in Gaucher Dis	New York University	17-A0-00-008041-01	93.853	-	110,502	110,502
NH	Extramural Res Programs in the Neurosciences & Neurological Disorders	A novel smart patch for the f	University of Cincinnati	012056-002	93.853	-	257,646	257,646
NH	Extramural Res Programs in the Neurosciences & Neurological Disorders	The Vascular effects of Infect	Univ of California, San Francisco	11258sc	93.853	-	9,367	9,367
NH	Extramural Res Programs in the Neurosciences & Neurological Disorders	Sensitization of developing se		R01NS105715	93.853	-	247,365	247,365
NH	Extramural Res Programs in the Neurosciences & Neurological Disorders	Targeting the Hippo signaling	University of Houston	RZ00017	93.853	-	22,493	22,493
NH	Extramural Res Programs in the Neurosciences & Neurological Disorders	Mechanisms linking hemostatic		R01NS107258	93.853	-	465,119	465,119
NH	Extramural Res Programs in the Neurosciences & Neurological Disorders	Functional analysis of the mic		R01NS107453	93.853	-	366,535	366,535
NH	Extramural Res Programs in the Neurosciences & Neurological Disorders	Creatine Transporter Deficien	University of Virginia	GB10578.160162	93.853	-	59,192	59,192
NH	Extramural Res Programs in the Neurosciences & Neurological Disorders	Headache Assessment of Childr	The Trustees of Columbia University	PECARN Headache	93.853	-	94,341	94,341
NH	Extramural Res Programs in the Neurosciences & Neurological Disorders	Neonatal Seizure Registry Deve	UCSF Human Research Program	11997sc	93.853	-	28,143	28,143
NH	Extramural Res Programs in the Neurosciences & Neurological Disorders	Spinal circuitry for ventilat		R01NS112255	93.853	-	310,795	310,795
NH	Extramural Res Programs in the Neurosciences & Neurological Disorders	Mechanisms of muscle afferent		R01NS113965	93.853	-	786,644	786,644
NH	Extramural Res Programs in the Neurosciences & Neurological Disorders	Bystander gene deletions in ca	University of Cincinnati	R01NS114074	93.853	29,434	283,266	312,700
NH	Extramural Res Programs in the Neurosciences & Neurological Disorders	Uncovering treatment targets f	University of Minnesota	1R01NS115438-01A1	93.853	-	554,592	554,592
NH	Extramural Res Programs in the Neurosciences & Neurological Disorders	CNS in congenital DM1: pathoge		R01NS115662	93.853	-	301,356	301,356
NH	Extramural Res Programs in the Neurosciences & Neurological Disorders	Diagnostic validity and safety	Johns Hopkins University	R01NS115929-01	93.853	-	218,830	218,830
NH	Extramural Res Programs in the Neurosciences & Neurological Disorders	Circuit defects underlying in	Univ of California Los Angeles	1580 G YB180	93.853	-	179,948	179,948
NH	Extramural Res Programs in the Neurosciences & Neurological Disorders	ROSE-LAWN	University of Cincinnati	013382-002	93.853	-	23,105	23,105
NH	Extramural Res Programs in the Neurosciences & Neurological Disorders	Identification of novel pathwa		R01NS120892	93.853	-	194,771	194,771
NH	Extramural Res Programs in the Neurosciences & Neurological Disorders	Anti-epileptogenic role of mTO	NI Inst of Neuro Disorders & Stroke	R01NS121042	93.853	-	4,941	4,941
NH	Extramural Res Programs in the Neurosciences & Neurological Disorders	Roles of Gsx factors in basal		R01NS124660	93.853	-	183,049	183,049
NH	Extramural Res Programs in the Neurosciences & Neurological Disorders	Understanding the Impact of Yo		R01NS125316	93.853	-	92,188	92,188
NH	Drug Abuse and Addiction Research Programs	Automated Substance Use Detect		R03DA054256	93.279	-	7,924	7,924
NH	Oral Diseases and Disorders Research	Tracing the origins of canof		R03DE030200	93.121	-	48,420	48,420
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Durability of Epithelial Defec		R03DK124751	93.847	-	133,085	133,085
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Diabetes Timing and Types and		R03DK131156	93.847	-	28,984	28,984
NH	National Center for Advancing Translational Sciences	Urinary Lipidomic profile in F		R03TR003916	93.350	-	39,889	39,889
NH	Aging Research	A Novel Research Infrastructur	Tulane University	TUL-HSC-556566-18/1	R21AG057983	93.866	8,976	8,976
NH	Allergy, Immunology and Transplantation Research	Obesity, Metabolic Syndrome an		R21AI139829	93.855	-	135,266	135,266
NH	Allergy, Immunology and Transplantation Research	Single cell analysis of transp		R21AI142264	93.855	-	23,851	23,851
NH	Allergy, Immunology and Transplantation Research	Copper tolerance and homeostas	University of Cincinnati.	R21AI143467	93.855	97.687	52,643	150.330

NH	Allergy, Immunology and Transplantation Research	Genetics of organ-specific lup	University of Cincinnati		R21AI145304	93.855	11,229	175,757	186,986
NH	Research Related to Deafness and Communication Disorders	Preserving T cell / antigen pr			R21AI148612	93.855	-	186,372	186,372
NH	Allergy, Immunology and Transplantation Research	Immune Responses in the Mother	Mayo Clinic		R21AI151208	93.855	-	3,764	3,764
NH	Allergy, Immunology and Transplantation Research	Preconceptional paternal environ	Univ of Calif.-Davis-Mmrc	CHI-289276	R21AI152100	93.855	16,886	235,780	252,666
NH	Allergy, Immunology and Transplantation Research	Reconstituting the oligogenic	University of Cincinnati		R21AI152575	93.855	1,945	229,954	231,899
NH	Allergy, Immunology and Transplantation Research	Preconceptional paternal allelge			R21AI156185	93.855	-	212,053	212,053
NH	Allergy, Immunology and Transplantation Research	Genetic ancestry differences i			R21AI157363	93.855	-	105,363	105,363
NH	Allergy, Immunology and Transplantation Research	Immunopathogenesis of Histiopla	University of Cincinnati	013543-0003	R21AI160722	93.855	-	15,405	15,405
NH	Allergy, Immunology and Transplantation Research	Biomarkers of Replication and	University of Cincinnati	013716-0002	R21AI165171	93.855	-	8,058	8,058
NH	Cancer Cause and Prevention Research	Increasing HPV Vaccination Rat			R21CA239170	93.393	-	115,122	115,122
NH	Cancer Detection and Diagnosis Research	Redefining hemophagocytic Imp			R21CA256390	93.394	-	94,131	94,131
NH	Cancer Biology Research	Infectious pressures on cell c			R21CA257994	93.396	-	182,868	182,868
NH	Research Related to Deafness and Communication Disorders	Multimodal Neuroimaging Distn	University of Cincinnati	1R21DC017393-01A1	R21DC017393	93.173	-	27,714	27,714
NH	Research Related to Deafness and Communication Disorders	Investigating the contribution			R21DC020242	93.173	-	11,955	11,955
NH	Oral Diseases and Disorders Research	Function and Regulation of Sem			R21DE030193	93.121	-	211,281	211,281
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Early MRI Prediction of Respo			R21DK114657	93.847	-	6,351	6,351
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Epigenetic and functional dete			R21DK123691	93.847	-	14,731	14,731
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Individualized Structured Meal	University of Cincinnati	013507-0002	R21DK125033	93.847	-	49,869	49,869
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Pilot and Feasibility Clinical			R21DK128635	93.847	-	197,885	197,885
NH	Discovery and Applied Research for Tech Innovations to Improve Human Health	Development of Hybrid Teachas	University of Cincinnati	011164-004	R21EB025378	93.286	-	17,341	17,341
NH	Environmental Health	Developing and Evaluating Noe	University of Kentucky		R21ES030092	93.113	60,776	172,519	233,295
NH	Environmental Health	Innovative Personal Monitoring	RTI International	1-340-0217531-66041	R21ES030142	93.113	-	97,000	97,000
NH	Family Smoking Prevention and Tobacco Control Act Regulatory Research	Distinguishing Exposure to Sec	University of Cincinnati	013228-003	R21ES032161	93.077	-	7,715	7,715
NH	Biomedical Research and Research Training	Death-Seq, a Method for Genome			R21GM135634	93.859	-	224,522	224,522
NH	Biomedical Research and Research Training	A Synthetic Approach for Bacte	University of Cincinnati	013094-002	R21GM137321	93.859	-	12,846	12,846
NH	Child Health and Human Development Extramural Research	Human-animal interaction to pr			R21HD095132	93.865	-	12,646	12,646
NH	Child Health and Human Development Extramural Research	Neonatal PBPk-PD Modeling of M			R21HD095418	93.865	-	11,179	11,179
NH	Child Health and Human Development Extramural Research	Driving Skills of Adolescents			R21HD096014	93.865	-	81,332	81,332
NH	Child Health and Human Development Extramural Research	ROR Plus: Randomized Trial of			R21HD102702	93.865	-	135,450	135,450
NH	Child Health and Human Development Extramural Research	Brain organoid modeling of Gau			R21HD102788	93.865	-	234,843	234,843
NH	Blood Diseases and Resources Research	Defining human hematopoietic c			R21HL150678	93.839	-	146,939	146,939
NH	Cardiovascular Diseases Research	Finding the contribution of ft			R21HL162572	93.837	-	162,794	162,794
NH	Nursing Research	Improving Drug Adherence Using	Nationwide Childrens Hospital		R21NR017633	93.361	2,885	-	2,885
NH	Nursing Research	Reducing Health Disparities th	University of Cincinnati	013513-002	R21NR019126	93.361	-	98,931	98,931
NH	Extramural Res Programs in the Neurosciences & Neurological Disorders	Neuromagnetic High Frequency O			R21NS104459	93.853	-	3,062	3,062
NH	Extramural Res Programs in the Neurosciences & Neurological Disorders	Using a ketogenic diet to tea			R21NS111217	93.853	-	65,043	65,043
NH	Extramural Res Programs in the Neurosciences & Neurological Disorders	Assessing the contribution of			R21NS121644	93.853	-	20,054	20,054
NH	Extramural Res Programs in the Neurosciences & Neurological Disorders	A new human iPSC model of ALS:	The University of Arizona		R21NS122169	93.853	107,955	116,437	224,392
NH	Extramural Res Programs in the Neurosciences & Neurological Disorders	Distinguishing TLE and TLE us			R21NS123630	93.853	-	43,170	43,170
NH	Extramural Res Programs in the Neurosciences & Neurological Disorders	Genetic approaches to address			R21NS123974	93.853	-	20,356	20,356
NH	Extramural Res Programs in the Neurosciences & Neurological Disorders	Impact of L2r1 mutations on o			R21NS125347	93.853	-	59,853	59,853
NH	Extramural Res Programs in the Neurosciences & Neurological Disorders	Cell type-specific functions o			R21NS126740	93.853	-	16,864	16,864
NH	Research Infrastructure Programs	Establish a novel mouse model			R21OD031906	93.351	-	243,034	243,034
NH	Research Infrastructure Programs	Development of a mouse model o			R21OD031907	93.351	-	355	355
NH	International Research and Research Training	An implementation toolkit for	Global Health Uganda	GHU-02-2021-01	R21TW011554	93.989	-	19,989	19,989
NH	Child Health and Human Development Extramural Research	Pediatric Injury: Modules to Manage	University of Utah	1046978	R21HD096350	93.865	-	231,979	231,979
NH	Biomedical Research and Research Training	Growing Community Change Resea	University of Cincinnati	011577-004	R25GM129234	93.859	-	1,595	1,595
NH	Biomedical Research and Research Training	WE ENGAGE via Data & Stories to Improve	Miami University..		R25GM129808	93.859	123,085	98,846	254,350
			University of Cincinnati				32,419	-	-
NH	Aging Research	Mechanisms in Lamin A function			R33AG054770	93.866	-	606,410	606,410
NH	Aging Research	Sub to Tulane -Transfer from R	Tulane University	TUL-HSC-556566	R33AG057983	93.866	-	484,518	484,518
NH	Environmental Health	Assessing Personal Exposure to Ultrafine P			R33ES024713	93.113	-	103,328	103,328
NH	National Center on Sleep Disorders Research	Positive airway pressure fort	Children's Hospital of Philadelphia	GRT-00001521	R33HL151253	93.233	-	139,191	139,191
NH	Extramural Res Programs in the Neurosciences & Neurological Disorders	Targeting complement 5a-mediat			R33NS112407	93.853	-	448,529	448,529
NH	Research and Training in Complementary and Alternative Medicine	Feasibility and acceptability	The Research Instit at Nationwide Hosp	700266-0622-00	R33AT011218	93.213	-	54,018	54,018
NH	Drug Abuse and Addiction Research Programs	4/5 HEAL Consortium: Establish	University of Cincinnati		R34DA050268	93.279	20,844	227,859	248,703
NH	Lung Diseases Research	Procalcitonin to Reduce Antib	Ann & Robert H Lurie Children's Hospital	A21-0001-S001-CCHMR34HL153474	93.838	-	80,804	80,804	
NH	Mental Health Research Grants	Improving Medication Continuity among Ad			R34MH112648	93.242	-	4,002	4,002
NH	Mental Health Research Grants	Emotion coaching skills as an	University of California		R34MH115897	93.242	8,823	122,630	159,055
			University of Georgia				27,602	-	-
NH	Mental Health Research Grants	Improving Adherence in Adolesc	Case Western University	RES514545	R34MH117206	93.242	-	28,071	28,071
NH	Oral Diseases and Disorders Research	Hamessing the therapeutic potential of neur	Nationwide Childrens Hospital		R35DE027557	93.121	15,040	997,424	1,014,636
NH	Oral Diseases and Disorders Research		The Jackson Laboratory				2,172	-	-
NH	Environmental Health	Early Warning Systems for Oil	Icahn School of Medicine at Mount Sinai	0255-D62-4609	R35ES030435	93.113	-	36,762	36,762
NH	Biomedical Research and Research Training	Macrophage regulation of the spermatog			R35GM119458	93.859	-	381,001	381,001
NH	Biomedical Research and Research Training	Sepsis from Bedside to Bench to Bedside	Children's Hosp & Clinics Minnesota		R35GM126943	93.859	500	426,191	460,037
			Children's Hosp Med Center of Akron				500	-	-
			Children's Hospital of Philadelphia				7,500	-	-
			McMaster University				2,022	-	-
			Stanford University..				1,000	-	-
			Univ of California				3,500	-	-
			University of Florida				4,500	-	-
			Vanderbilt University Medical Center				14,324	-	-
NH	Biomedical Research and Research Training	Regulatory Mechanisms Govern			R35GM140805	93.859	-	523,715	523,715
NH	Biomedical Research and Research Training	How CHAF1B maintains cell stat			R35GM142452	93.859	-	300,968	300,968
NH	Blood Diseases and Resources Research	Decoding innate immune signaling in normal			R35HL135787	93.839	-	606,539	606,539
NH	Cancer Biology Research	Pathogenic Role of Foxl1 Hspa	Datrium LLC		R37CA225807	93.396	-	398,360	398,360
NH	Human Genome Research	SciDAP: a next generation data			1R41HG011219-01A1	93.172	-	120,781	120,781
NH	Mental Health Research Grants	Validation of a salivary mRNA	Quadrant Biosciences	1293481860000	R42MH111347	93.242	-	20,460	20,460
NH	Arthritis, Musculoskeletal and Skin Diseases Research	Development of a urinary biom	Ethos Research and Development, LLC	R43AR077338	R43AR077338	93.846	-	17,718	17,718
NH	Allergy, Immunology and Transplantation Research	Low-Cost, Rapid Molecular Diag			1R44AI136161-01	93.855	-	86,036	86,036
NH	Biomedical Research and Research Training	Point-of-Care Prognostic Tool	MBio Diagnostics, Inc.	R44GM125418	R44GM125418	93.859	-	80,689	80,689
NH	Cancer Biology Research	Therapeutic insights through patient			R50CA211404	93.396	-	3,395	3,395
NH	Aging Research	Homeostasis and function of ie			R56AG033057	93.866	-	4,038	4,038
NH	Aging Research	Regulation and function of imm			R56AG065327	93.866	-	224,506	224,506
NH	Allergy, Immunology and Transplantation Research	A Nanoparticle-Based Multivale	Virginia Tech		R56AI148426	93.855	193,955	76,813	270,768
NH	Blood Diseases and Resources Research	Mechanisms of staphylococcal s	University of Nebraska Medical Center	34-6301-2207-201	R56AI162964	93.839	-	114,147	114,147

NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Cyst induction and growth in A			R56DK129238	93.847	-	39,352	39,352
NH	Cardiovascular Diseases Research	Mechanisms of Eosinophil-Assoc	University of Cincinnati	013967-0002	R56HL147898	93.837	-	19,302	19,302
NH	Cardiovascular Diseases Research	Chronomechanisms of Cardiacmeta			R56HL158531	93.837	-	214,079	214,079
NH	Extramural Res Programs in the Neurosciences & Neurological Disorders	Manipulation of microRNA for C	Indiana University		R56NS114124	93.853	15,850	274,206	290,056
NH	Arthritis, Musculoskeletal and Skin Diseases Research	Improving delivery of therapeu			R61AR076771	93.846	-	240,901	240,901
NH	Arthritis, Musculoskeletal and Skin Diseases Research	Electrical Coupling of Circu	Salk Institute		R61AR078060	93.846	30,606	292,984	323,590
NH	Child Health and Human Development Extramural Research	Evaluating Assessment and Medi	Univ of Calif-Davis-Mmrc		R61HD100994	93.865	227,909	241,924	469,833
NH	Trans-NIH Research Support	COVID-19 Network of Networks E	Rutgers	1813	COVID-19 R61HD105619	93.310	-	18,804	18,804
NH	National Center on Sleep Disorders Research	Positive airway pressure forI	Children's Hospital of Philadelphia	3201930820	R61HL151253	93.233	-	63,344	63,344
NH	Lung Diseases Research	Commercial Translation of Biom			R61HL154105	93.838	-	345,504	345,504
NH	Lung Diseases Research	Human gene transfer and macro	University of South Florida		R61HL156888	93.838	15,759	412,802	428,561
NH	Extramural Res Programs in the Neurosciences & Neurological Disorders	SPRINT: Signature for Pain Rec	Stanford University Medical Center	R61NS114926	R61NS114926	93.853	-	328,054	328,054
NH	Extramural Res Programs in the Neurosciences & Neurological Disorders	Developing novel biomarkers of	Ann & Robert H Lurie Children's Hospital	901654-CHMC	R61NS122094	93.853	-	97,564	97,564
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	A generalizable framework for	University of Pittsburgh Yale University		RC2DK122376	93.847	149,107 237,768	609,517 847,285	996,992
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Systems Biology of Bone Marrow	Children's Hospital Boston		GENFD001792965	93.847	-	12,994	12,994
NH	Extramural Res Programs in the Neurosciences & Neurological Disorders	APRISE-Dementia (Assessing Pop	University of Cincinnati	1 RF1 NS117643-01	RF1NS117643	93.853	-	25,347	25,347
NH	Arthritis, Musculoskeletal and Skin Diseases Research	CINCINNATI TRAINING PROGRAM IN			T32AR069512	93.846	-	187,022	187,022
NH	Cancer Research Manpower	Training grant	University of Cincinnati	1017546	T32CA117846	93.398	-	102,260	102,260
NH	Cancer Research Manpower	T32 Training grant	University of Cincinnati	1017278	T32CA236784	93.398	-	160,220	160,220
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Research Training in Pediatric			T32DK007695	93.847	-	167,261	167,261
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Pediatric Gastroenterology and			T32DK007727	93.847	-	554,416	554,416
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Research Training in Child Beh			T32DK063929	93.847	-	439,651	439,651
NH	Environmental Health	Training grant	University of Cincinnati	1016232	T32ES007250	93.113	-	62,074	62,074
NH	Environmental Health	Environmental Carcinogenesis a	University of Cincinnati	1017372	T32ES007250	93.113	-	54,702	54,702
NH	Environmental Health	Training grant	University of Cincinnati	1016305	T32ES010957	93.113	-	74,327	74,327
NH	Biomedical Research and Research Training	Host Response to Trauma Resear	University of Cincinnati	1017224	T32GM847828	93.859	-	76,048	76,048
NH	Child Health and Human Development Extramural Research	Enhancing Pediatric Treatment Adherence			T32HD068223	93.865	-	330,706	330,706
NH	Child Health and Human Development Extramural Research	T32 Cincinnati Pediatric Clin			T32HD069054	93.865	-	146,902	146,902
NH	Lung Diseases Research	Pulmonary Development and Dae			T32HL007752	93.838	-	323,896	323,896
NH	Cardiovascular Diseases Research	Understanding Cardiovascular D			T32HL125204	93.837	-	296,527	296,527
NH	Extramural Res Programs in the Neurosciences & Neurological Disorders	Cerebrovascular Fellowship Tra	University of Cincinnati	013104-002	T32NS047996	93.853	-	10,446	10,446
NH	Lung Diseases Research	Cincinnati Children's Summer M			T32HL113229	93.838	-	59,221	59,221
NH	Allergy, Immunology and Transplantation Research	Gene therapy for SCID-X1 with	Children's Hospital Boston	GENFD001865408	U01AI126511	93.855	-	2,807	2,807
NH	Allergy, Immunology and Transplantation Research	Controlling and Preventing Asthma Prog	Children's Hospital Boston	GENFD002045257	U01AI126514	93.855	-	299,841	299,841
NH	Allergy, Immunology and Transplantation Research	Gene Regulation as a Foundation for Auto	Stanford University, The Scripps Research Institute University of Colorado University of Nebraska Med Center		U01AI130830	93.855	215,638 168,309 36,480 91,462	649,520 817,839 854,319 948,781	1,161,400
NH	Allergy, Immunology and Transplantation Research	COVID-19 Exosomes and the Immune Respon	Stanford University	62502353-128779	COVID-19 U01AI135950-0381	93.855	-	91,681	91,681
NH	Allergy, Immunology and Transplantation Research	Impact of the Initial Influenz	University of Cincinnati		U01AI144673	93.855	373,522	2,855,311	3,228,833
NH	Allergy, Immunology and Transplantation Research	COVID-19 Epidemiology and Immu	University of Cincinnati		COVID-19 U01AI144673-0281	93.855	96,984	3,242,787	3,339,771
NH	Allergy, Immunology and Transplantation Research	Dynamic regulatory network mod	Icahn School of Medicine at Mount Sinai	0255-E053-4609	U01AI150748	93.855	-	351,161	351,161
NH	Allergy, Immunology and Transplantation Research	Atopic dermatitis: mechanisms			U01AI152034	93.855	-	220,694	220,694
NH	Allergy, Immunology and Transplantation Research	Genomics of Nephrotic Syndrome	Duke University	265416 / A034566	U01AI152585	93.855	-	130	130
NH	Allergy, Immunology and Transplantation Research	Randomized trial of viral spec			U01AI157620	93.855	-	497,311	497,311
NH	Allergy, Immunology and Transplantation Research	Multi-omics of the Frequent Ex			U01AI159087	93.855	-	368,268	368,268
NH	Allergy, Immunology and Transplantation Research	Advancing Transplantation Outc	Harvard Medical School	GENFD002098919	U01AI163072	93.855	-	13,856	13,856
NH	Allergy, Immunology and Transplantation Research	Itacitinib to reduce lung infl	Duke University	A03-63481/U01AI1630	U01AI163099	93.855	-	33,308	33,308
NH	Research and Training in Complementary and Alternative Medicine	Mind Body Balance for Pediatr	University of Colorado University of Virginia		U01AT010132	93.213	80,330 21,643	528,116 549,759	630,898
NH	Drug Abuse and Addiction Research Programs	First-In-Human Study of a Huma	University of Cincinnati	012264-003	U01DA048525	93.279	-	72,714	72,714
NH	Drug Abuse and Addiction Research Programs	4/6 HBCD Prenatal Experiences			U01DA055342	93.279	-	291,945	291,945
NH	Oral Diseases and Disorders Research	Velopharyngeal insufficiency f	Phoenix Children's Hospital		U01DE029750	93.121	-	24,983	24,983
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	TODAY2 Phase 2 (TZP2): Long-Term Post	George Washington University	17-D05	U01DK061230	93.847	-	5,066	5,066
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Non Alcoholic Steatohepatitis	Cleveland Clin Lerner Col of Med of CW	1324-SLB	U01DK061732	93.847	-	153,037	153,037
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Clinical Center for Cholestas			U01DK062497	93.847	-	869,719	869,719
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	CKID IV (patient care and sala	Children's Mercy Hospital	18-0007	U01DK066143	93.847	-	65,978	65,978
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	CUREGN 2.0 - Midwest Pediatric	Nationwide Children's Hospital	700198-0620-00	U01DK100866	93.847	-	14,912	14,912
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Defining the intestinal stem c			U01DK103117	93.847	-	274,253	274,253
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Consortium for the Study of Ch	University of Iowa	W001038585	U01DK108328	93.847	-	10,386	10,386
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Phosphate binder therapy and c	UCLA School of Public Health	1652 G YAG29	U01DK122013	93.847	-	6,384	6,384
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Pediatric Acute Liver Failure	Lurie Children's Hospital of Chicago	901628-CCH	U01DK127995	93.847	-	3,264	3,264
NH	Environmental Health	Prenatal inflammatory exposures and neo			U01ES029234	93.113	-	139,000	139,000
NH	Human Genome Research	Polygenic Risk Scores for Heal	Children's Hospital Boston University of Cincinnati		U01HG011172	93.172	82,197 312,462	789,517 1,101,714	1,184,196
NH	Cardiovascular Diseases Research	Vascular Core for Dyslipidemia of Obesity	New England Research Institutes		U01HL068270	93.837	-	299	299
NH	Cardiovascular Diseases Research	Impact of Treatment of Mild Sleep-Disorder	Children's Hospital of Philadelphia		U01HL125295	93.837	-	1,026	1,026
NH	Lung Diseases Research	ORBEX: Primary Prevention of Asthma	University of Arizona	P0 438886	U01HL130045	93.838	-	306,067	306,067
NH	Cardiovascular Diseases Research	Administrative Coordinating Co	Brigham and Women's Hospital Children's Hospital Boston Children's Hospital Los Angeles Children's Hospital of Philadelphia Columbia University Holland Bloomview Kds Mount Sinai School of Medicine University of Utah		U01HL131003	93.837	83,157 203,264 600 75,000 20,159 75,000 43,720 77,304	3,000,374 3,203,638 3,204,238 3,279,238 3,300,397 3,375,397 3,419,117 3,496,421	3,578,578
NH	Cardiovascular Diseases Research	Multicenter Interventional Lymphangioblo	University of Cincinnati	010575-00010	U01HL131755	93.837	-	56,819	56,819
NH	Blood Diseases and Resources Research	Realizing Effectiveness Across Continents	Acclaim Baylor College of Medicine, CEFA/Centre Hospitalier Monkole Hospital Pediatric David Bernardino Mbale Regional Referral Hospital The Chancellor, Masters and Scholars The Feinstein Institute Med Research University Health Network		U01HL133883	93.839	8,442 29,074 67,696 110,356 89,369 67,673 15,460 9,437	337,334 366,408 434,104 523,473 612,842 680,515 738,075 795,542	734,841

NH	Lung Diseases Research		Editing Alveolar Progenitor Cells for Corred	Battelle Memorial Institute Boston University Johns Hopkins University National Jewish Health Univ of Pennsylvania Washington University	U01HL134745	93.838	35,864 353,959 10,500 11,110 527,621 43,963	361,685 -	1,344,702
NH	Blood Diseases and Resources Research		Darbetaoetin Trial to Improve R	University of Utah	10053175-02	93.839	-	29,055	29,055
NH	Blood Diseases and Resources Research		Sickle Cell Improvement, Enhanc	Medical College of Wisconsin	U01HL143477	93.839	-	7,352	7,352
NH	Lung Diseases Research			Cedars-Sinai Medical Center Massachusetts General Hospital The Broad Institute Inc.	U01HL148856	93.838	9,875 103,781 1,254	744,427	859,437
NH	Cardiovascular Diseases Research		LungMap Phase II - Building a Lung Map submission with UC Sa	University of California San Diego	125063615	93.837	-	44,226	44,226
NH	Blood Diseases and Resources Research		Sickle Cell Improvement: Enhanc	Medical College of Wisconsin	U01HL159850	93.839	-	44,335	44,335
NH	Lung Diseases Research		Eliminating Monitor Overuse (E	Children's Hospital of Philadelphia	GRT-00001474	93.838	-	34,743	34,743
NH	Extramural Res Programs in the Neurosciences & Neurological Disorders		Neuronext NN107	University of Cincinnati	009175-018	93.853	-	5,204	5,204
NH	Extramural Res Programs in the Neurosciences & Neurological Disorders		Preventing Epilepsy Using Vgabatin	University of Alabama-Birmingham	U01NS092595	93.853	-	13,452	13,452
NH	Extramural Res Programs in the Neurosciences & Neurological Disorders		High-dose Erythropoietin for Asphyxia	University of California	10018sc	93.853	-	32,669	32,669
NH	Extramural Res Programs in the Neurosciences & Neurological Disorders		Perinatal Arterial Stroke: A M	University of Cincinnati	011961-136901	93.853	-	17,395	17,395
NH	Extramural Res Programs in the Neurosciences & Neurological Disorders		Pediatric Dose Optimization B	Baylor College of Medicine	0001625	93.853	-	62,777	62,777
NH	National Center for Advancing Translational Sciences		STeroids to REduce Systemic inflammation	Duke University	203-8371	93.350	-	6,761	6,761
NH	National Center for Advancing Translational Sciences		Disseminating Curative Biological Theep	Children's Hospital Boston	U01TR001814	93.350	-	94,640	94,640
NH	National Center for Advancing Translational Sciences		Precision Medicine in the Dag	Tufts Medical Center	5016131-SERV	93.350	-	127,907	127,907
NH	National Center for Advancing Translational Sciences		Instrumenting the Delivery Sys	Children's Hospital Boston	GENFD0001706578	93.350	-	208,060	208,060
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research		INSPIRE: A Longitudinal Cohor	University of Iowa	S02042-02	93.847	-	100,639	100,639
NH	Cancer Treatment Research		Dasqupta COG from PH	Public Health Institute	AR04476	93.395	-	7,834	7,834
NH	Cancer Treatment Research		COMMITTEE LEADERSHIP: NIH Nafi	Public Health Institute	AR03217	93.395	-	50,058	50,058
NH	Cancer Treatment Research		O'Brien PHI-COG Study Chair AA	Public Health Institute	AR03402	93.395	-	31,303	31,303
NH	Cancer Treatment Research		Norris PHI-COG Associate Medic	Public Health Institute	AR03186	93.395	-	41,731	41,731
NH	Cancer Treatment Research		Study Chair	Public Health Institute	AR03451	93.395	-	10,435	10,435
NH	Cancer Treatment Research		Study Chair AREN 1721 2021	Public Health Institute	AR03450	93.395	-	10,435	10,435
NH	Cancer Treatment Research		COG NCTN Workload Intensity General	Children's Hospital of Philadelphia	2U10CA180886	93.395	-	8,614	8,614
NH	Cancer Treatment Research		PHI-COG PCR Work Order 2021	Public Health Institute	Nomis_R_PHI/NH	93.395	-	4,524	4,524
NH	Cancer Treatment Research		PHI-COG NCTN Work Order 2021	Public Health Institute	U10CA180886	93.395	-	36,999	36,999
NH	Cancer Treatment Research		NCTN Renal Committee Retest	Public Health Institute	AR04978	93.395	-	8,000	8,000
NH	Cancer Treatment Research		AHEP 1531 (PHI managed)	Public Health Institute	AR0454U10CA1808	93.395	-	29,293	29,293
NH	Cancer Treatment Research		BIOSFPACNS IntegralGU10CA1	Public Health Institute	AR03753	93.395	-	137,719	137,719
NH	Cancer Treatment Research		Biomarker, Imaging and Quality	Public Health Institute	AR04810	93.395	-	8,099	8,099
NH	Cancer Treatment Research		COG NCTN Network Group Operati	Children's Hospital of Philadelphia	20115662 - RSLB	93.395	-	11,046	11,046
NH	Cancer Treatment Research		COG NCTN Network Group Operati	Children's Hospital of Philadelphia	AR03425	93.395	-	15,665	15,665
NH	Cancer Treatment Research		COG NCTN Network Group Operati	Children's Hospital of Philadelphia	U10CA180886 renewa	93.395	-	31,982	31,982
NH	Cancer Treatment Research		COG NCTN Network Group Operati	Public Health Institute	AR04579	93.395	-	11,749	11,749
NH	Cancer Treatment Research		COG NCTN Network Group Operati	Public Health Institute	AR04575	93.395	-	12,062	12,062
NH	Cancer Treatment Research		COG NCTN Network Group Operati	Public Health Institute	AR03426	93.395	-	20,869	20,869
NH	Cancer Treatment Research		Study Chair	Public Health Institute	AR03413	93.395	-	31,302	31,302
NH	Cardiovascular Diseases Research		Phase 1 Trial of Bevacizumab Treatment for	Jaeb Center for Health Res Fdn., Inc.	U10EY011751	93.867	-	31,221	31,221
NH	Cardiovascular Diseases Research		Fontan Udenafli Exercise Longitudnal	New England Research Institutes	U10HL068270	93.837	-	2,497	2,497
NH	Allergy, Immunology and Transplantation Research		Epithelial Genes in Allergic I		U19AI070235	93.855	-	1,318,221	1,318,221
NH	Allergy, Immunology and Transplantation Research		COVID-19 Epithelial Genes in Allergic I		COVID-19 U19AI070235-14S1	93.855	-	20,880	20,880
NH	Allergy, Immunology and Transplantation Research		Airway Inflammation and airway monitoring	University of California San Diego	83115022 (PO S90016	93.855	-	146,159	146,159
NH	Cancer Treatment Research		Childhood Cancer Survivor Study	St. Jude's Children's Hospital	111287260-7914878	93.395	-	364,580	364,580
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research		Investigating the role of VPS4	University of Utah	10055841-25	93.847	-	28,158	28,158
NH	Child Health and Human Development Extramural Research		Neonatal Research Network Caplaton	RTI International	NRN- 0216392	93.865	-	476,169	476,169
NH	Child Health and Human Development Extramural Research		dGTEX BPC Participation	The Natl Disease Research Interchange	1411431/U24HD10653	93.865	-	38,236	38,236
NH	Cardiovascular Diseases Research		Translating gene/pulmonary mac	University of Maryland (Baltimore)	1701192	93.837	-	175,648	175,648
NH	Cardiovascular Diseases Research		Fontan Udenafli Exercise Longitudnal	New England Research Institutes	U24HL135691	93.837	-	8,960	8,960
NH	Cardiovascular Diseases Research		Liver stiffness in Patients w	New England Research Institutes	0001315	93.837	-	29,186	29,186
NH	Cardiovascular Diseases Research		Single Institutional Review Bo	New England Research Institutes	NERI, Crota, James	93.837	-	242,867	242,867
NH	Cardiovascular Diseases Research		Dyslipidemia of Obesity Intervention in Teen	New England Research Institutes	U24HL135691	93.837	-	17,147	17,147
NH	Cardiovascular Diseases Research		Use of Oxandrolone to Promote	New England Research Institutes	U24HL135691	93.837	-	1,808	1,808
NH	Cardiovascular Diseases Research		COVID-19 PHN COVID/MUSIC Study Subcontr	New England Research Institutes	U24HL135691	93.837	-	35,875	35,875
NH	Lung Diseases Research		The LungMAP Data Coordination	Research Triangle Institute The Broad Institute Inc. University of California Santa Cruz University of California, San Diego University of Rochester University of Pennsylvania	U24HL148855	93.838	139,734 284,488 319,038 100,000 100,000 50,000	1,169,847	2,163,107
NH	Extramural Res Programs in the Neurosciences & Neurological Disorders		Electrical Stimulation of Indu	University of Cincinnati	011609-0009	93.853	-	182,123	182,123
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research		Obtain healthy reference tissu	University of Cincinnati	012507-002	93.847	-	20,166	20,166
NH	Trans-NIH Research Support		Decentralized and Reproducible	Duke, Brookamp	U2C0D023375	93.310	-	15,044	15,044
NH	National Center for Advancing Translational Sciences		Data Management and Coordinati	University of Cincinnati	U2CTR002818	93.350	1,145	5,317,274	5,318,419
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research		Clinical, Imaging, and Mucosal	Connecticut Children's Medical Center	21-181065-02	93.847	-	6,416	6,416
NH	Allergy, Immunology and Transplantation Research		PRIMARY IMMUNE DEFICIENCY TREA	The Univ of California, San Francisco	8404sc	93.855	-	624	624
NH	Allergy, Immunology and Transplantation Research		Consortium of Eosinophilic Gas	Ann & Robert H Lurie Children's Hosp Arkansas Children's Hospital Baylor College of Medicine Children's Hospital of Philadelphia Indiana University Mount Sinai School of Medicine Northwestern University Tufts Medical Center, Inc Univ of Pennsylvania University of CA University of Colorado University of North Carolina-Chapel Hill University of Utah Vanderbilt University Medical Center University of Colorado	U54AI117804	93.855	64,218 26,705 19,980 65,867 89,304 23,433 80,074 4,145 72,634 28,521 103,726 56,335 64,168 13,987	804,751	1,517,848
NH	Allergy, Immunology and Transplantation Research		COVID-19 Consortium of Eosinophilic Gas		COVID-19 U54AI117804-06S1	93.855	55,934	34,862	90,796

NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Cincinnati Cooperative Center			U54DK126108	93.847	-	610,162	610,162	
NH	Discovery & Applied Research for Tech Innovations to Improve Human Health	Center for Point-of-Care Techn	Johns Hopkins University	2004018575	U54EB007958	93.286	-	170,131	170,131	
NH	Extramural Res Programs in the Neurosciences & Neurological Disorders	Rett Syndrome, MECP2 Duplication,	International Rett Syndrome Foundation	U54HD061222	U54HD061222	93.853	-	16,507	16,507	
NH	Child Health and Human Development Extramural Research	Translational medicine and me	Univ of Oklahoma Health Sciences Univ of Texas Southwestern University of California, Riverside University of Cincinnati		U54HD104461	93.865	11,285 413,771 115,262 121,890	736,052 - - -	1,398,260	
NH	Extramural Res Programs in the Neurosciences & Neurological Disorders	Brain Vascular Malformation Co	UCSF Human Research Program	11552sc	U54NS065705	93.853	-	240	240	
NH	Extramural Res Programs in the Neurosciences & Neurological Disorders	Developmental Synaptopathies A	Children's Hospital Boston	GENFD001761815	U54NS092090	93.853	-	119,667	119,667	
NH	Extramural Res Programs in the Neurosciences & Neurological Disorders	Developmental Synaptopathies A	Children's Hospital Boston	81199_CCHMC01_PTEU	U54NS02090	93.853	-	57,416	57,416	
NH	Cancer Control	Norris PHI-COG NCOORP PCR Work	Public Health Institute	UG1CA189855-08	UG1CA189855	93.399	-	7,807	7,807	
NH	Drug Abuse and Addiction Research Programs	Ohio Valley Node-Network (OVNN)	University of Cincinnati	013764-0024	UG1DA013732	93.279	-	59,036	59,036	
NH	Vision Research	Adalimumab in Juvenile Idiopath	The Univ of California, San Francisco	11309sc_FEX	UG1EY029658	93.867	-	5,556	5,556	
NH	Child Health and Human Development Extramural Research	NICHD Cooperative Multicenter Neonatal			UG1HD027853	93.865	-	264,954	264,954	
NH	Cardiovascular Diseases Research	Pediatric Heart Network Prtrialend Cons	New England Research Institutes	U24HL135691	UG1HL135678	93.837	132,307	244,540	376,847	
NH	Oral Diseases and Disorders Research	Reduction of bloodstream infec			UG3DE030401	93.121	-	243,015	243,015	
NH	Lung Diseases Research	Hydrocortisone for BPD Respi	Children's Hospital of Philadelphia	3200930822	UG3HL137872	93.838	-	50,728	50,728	
NH	Lung Diseases Research	AZin thromycin Therapy in Presc	University of Arizona	AZ-SWED	UG3HL147016	93.838	-	19,132	19,132	
NH	Cardiovascular Diseases Research	Multicenter Clinical Trial of	University of Maryland (Baltimore)	901632-CCHMC	UG3HL148318	93.837	-	15,021	15,021	
NH	Trans-NIH Research Support	NYU Pediatric Obesity, Metabolism	NYU Sponsored Programs Administratio	UG30D023305	UG30D023305	93.310	-	40,357	40,357	
NH	Allergy, Immunology and Transplantation Research	Extension of clinical data s			UH2AI145837	93.855	-	224,586	224,586	
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Modeling diabetes using an it	Cleveland State University University of Illinois at Chicago		UH8DK119982	93.847	291,553 184,652	1,021,462 -	1,497,667	
NH	Trans-NIH Research Support	Airway microbiome and age 6 ya	Massachusetts General Hospital	233284	UH30D023253	93.310	-	255	255	
NH	Trans-NIH Research Support	Children's Respiratory Reseach	University of Wisconsin-Madison	UG30D023282	UH30D023282	93.310	-	1,050,410	1,050,410	
NH	Trans-NIH Research Support	Developmental Impact of NICU E	Albert Einstein College of Medicine	312044	UH30D023320	93.310	-	204,462	204,462	
NH	National Center for Advancing Translational Sciences	Preclinical characterization o			UH3TR002612	93.350	1,366	120,786	122,152	
NH	National Center for Advancing Translational Sciences	Center for Clinical and Tansl	University of Cincinnati	012847-00008	UL1TR001425	93.350	-	2,362,381	2,362,381	
NH	Allergy, Immunology and Transplantation Research	Inner City Asthma Consortium 3	University of Wisconsin-Madison	839K182	UM1AI14271	93.855	-	98,634	98,634	
NH	Allergy, Immunology and Transplantation Research	Inner City Asthma Consortium (Univ of Wisconsin	000000189	UM1AI14271	93.855	-	11,759	11,759	
NH	Allergy, Immunology and Transplantation Research	Vaccine and Treatment Evaluati	Nationwide Childrens Hospital		UM1AI148372	93.855	18,212	676,520	694,732	
NH	Allergy, Immunology and Transplantation Research	COVID-19 A Phase III Randomized, Double			COVID-19 UM1AI148372-0151	93.855	-	2,188,831	2,188,831	
NH	Allergy, Immunology and Transplantation Research	COVID-19 A Phase III Randomized, Double			COVID-19 UM1AI148372-025203S2	93.855	-	681,012	681,012	
NH	Allergy, Immunology and Transplantation Research	COVID-19 A Phase III Randomized, Double			COVID-19 UM1AI148372-025303S3	93.855	-	618,221	618,221	
NH	Allergy, Immunology and Transplantation Research	COVID-19 Phase 1, Open-Label, Randomize			COVID-19 UM1AI148372-0351	93.855	-	345,745	345,745	
NH	Allergy, Immunology and Transplantation Research	COVID-19 Phase 1, Open-Label, Randomize			COVID-19 UM1AI148372-035402S4	93.855	-	277,305	277,305	
NH	Allergy, Immunology and Transplantation Research	Infectious Diseases Clinical R	Emory University	A414395	UM1AI148884	93.855	-	87,016	87,016	
NH	Allergy, Immunology and Transplantation Research	Childhood Asthma in Urban Sett	Univ of Wisconsin	000001464	UM1AI160040	93.855	-	431,468	431,468	
NH	Cancer Treatment Research	The Pediatric Brain Tumor Cons	St Jude's Children's Hospital	110066220-7998047	UM1CA081457	93.395	-	116,777	116,777	
NH	Cancer Treatment Research	PEP-CTN institutional support	Children's Hospital of Philadelphia	sub2401	UM1CA228823	93.395	-	37,795	37,795	
NH	Cancer Treatment Research	Norris PHI-COG PEP-CTN WLI Or	Public Health Institute	AR06748	UM1CA228823	93.395	-	16,120	16,120	
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Teen Longitudinal Assessment of Bariatric	University of Colorado	FY 18.896.002	UM1DK072493	93.847	-	76,088	76,088	
NH	Diabetes, Digestive, and Kidney Diseases Extramural Research	Teen Longitudinal Assessment of Bariatric	University of Cincinnati	010577-009	UM1DK095710	93.847	-	384,790	384,790	
NH	Allergy, Immunology and Transplantation Research	New Horizons in the Prevention	Johns Hopkins University	2004813187	UM2AI130836	93.855	134,403	527,060	661,463	
SAMHSA	Substance Abuse & Mental Health Svcs Projects of Reg & Nat Significance	Implementation of Screening, B	University of Cincinnati		H79T084035	93.243	17,861	474,882	492,743	
NH		Mouse and Guinea Pig Models for Cytome	Pennington Biomedical Res Center		HHSN272201700017I	93.RD	114,178	622,726	736,904	
NH		Vaccine and Treatment Eval (VTEU)			HHSN272201300016I	93.RD	-	58,218	58,218	
NH		Vaccine and Treat Eval Units (VTEU)			HHSN272201300016I	93.RD	-	127,788	127,788	
NH		Vaccine and Treat Eval Units (VTEU)			HHSN272201300016I	93.RD	-	19,089	19,089	
NH		Vaccine and Treat Eval Units (VTEU)			HHSN272201300016I	93.RD	-	908,181	908,181	
NH		CISA Clinical Vaccine Safety Eval -			200-2012-63661	93.RD	-	181,524	181,524	
NH		Apnea in Hospitalized Preterm Infants	Emory University	200-2012-63661	93.RD	26,637	-	87,407	114,044	
NH		A Multicenter Prospective Study of Human	Children's Hospital of Philadelphia	HHSN272201600014C	HHSN272201600014C	93.RD	-	69,548	69,548	
NH		A Phase II Multi-Center, Prospective, Ran	Northwestern University Medical School	HHSN272201600016C	HHSN272201600016C	93.RD	-	247,217	247,217	
NH		Safety of Recombinant Influenz	University of Cincinnati.	200-2012-63661-0010	93.RD	1,833	-	126,141	127,974	
NH		Vaccine and Treatment Evaluati			HHSN272201300016I	93.RD	-	11,239	11,239	
NH		RTOP FY2020.A1B1C1D10123-HHSN2			HHSN272201300016I	93.RD	-	274,971	274,971	
NH		A Prospective Observational St			200-2012-63661	93.RD	-	235,898	235,898	
NH		Safety of Simultaneous versus			200-2012-63661	93.RD	-	164,982	164,982	
Dept of Health and Human Serv Total							19,307,213	177,315,653	196,622,866	
Dept of Housing and Urban Dev	HJD	Healthy Homes Technical Studies Grants	Role of measured and observed	University of Cincinnati	011199	OH#HU0037-17	14,906	-	3,309	3,309
	HJD	Lead Technical Studies Grants	Analysis of Benefits of Abatam	National Center for Healthy Housing, Inc	MDL TS000818	HUD_NMDL TS0008-18	14,902	-	21,022	21,022
Dept of Housing and Urban Dev Total							-	24,331	24,331	

CHILDREN’S HOSPITAL MEDICAL CENTER AND AFFILIATES

NOTES TO SUPPLEMENTARY SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS FOR THE YEAR ENDED JUNE 30, 2022

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation — The accompanying Supplemental Schedule of Expenditures of Federal Awards (the “Schedule”) includes the federal grant activity of Cincinnati Children’s under programs of the federal government for the year ended June 30, 2022 and is presented on the accrual basis of accounting. This is consistent with the basis of accounting used in the preparation of the basic consolidated financial statements. The information in this Schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, *Uniform Guidance*. Because the Schedule presents only a selected portion of the operations of Cincinnati Children’s, it is not intended to and does not present the financial position, changes in net assets or cash flows of Cincinnati Children’s.

Net Asset Balances — Negative amounts represent grants with deficit balances which were closed during fiscal 2022.

2. DE MINIMIS COST RATE

Cincinnati Children’s did not elect to use the 10% de minimis indirect cost rate as allowed under the Uniform Guidance.

3. SCOPE OF AUDIT

All federal grant operations of Cincinnati Children’s are included in the scope of Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance)*. Single audits under the Uniform Guidance are performed in accordance with the provisions of the Office of Management and Budget (OMB)’s Compliance Supplement for Single Audits of Higher Learning Institutions and other Non-Profit Institutions (the “Compliance Supplement”). The Department of Health and Human Services has been designated as Cincinnati Children’s cognizant agency for the Single audit.

4. PROVIDER RELIEF FUND TAX IDENTIFICATION NUMBER

Cincinnati Children’s received COVID-19 Provider Relief funds under the 31-0833936 tax identification number only.

REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING AND ON COMPLIANCE AND OTHER MATTERS BASED ON AN AUDIT OF FINANCIAL STATEMENTS PERFORMED IN ACCORDANCE WITH *GOVERNMENT AUDITING STANDARDS*

INDEPENDENT AUDITOR'S REPORT

To the Board of Trustees of
Children's Hospital Medical Center and Affiliates
Cincinnati, Ohio

We have audited, in accordance with the auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States, the consolidated financial statements of Children's Hospital Medical Center and Affiliates (the "Company"), which comprise the Company's consolidated statement of financial position as of June 30, 2022, and the related consolidated statements of activities, and cash flows for the year then ended, and the related notes to the financial statements, and have issued our report thereon dated September 30, 2022.

Report on Internal Control Over Financial Reporting

In planning and performing our audit of the financial statements, we considered the Company's internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control. Accordingly, we do not express an opinion on the effectiveness of the Company's internal control.

A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A *material weakness* is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected, on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses or significant deficiencies may exist that were not identified.

Report on Compliance and Other Matters

As part of obtaining reasonable assurance about whether the Company's financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

Purpose of This Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the entity's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the entity's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

Deloitte & Touche LLP

September 30, 2022

REPORT ON COMPLIANCE FOR EACH MAJOR FEDERAL PROGRAM; REPORT ON INTERNAL CONTROL OVER COMPLIANCE; AND REPORT ON SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS REQUIRED BY THE UNIFORM GUIDANCE

INDEPENDENT AUDITOR'S REPORT

To the Board of Trustees
Children's Hospital Medical Center and Affiliates
Cincinnati, Ohio

Report on Compliance for Each Major Federal Program

Opinion on Each Major Federal Program

We have audited Children's Hospital Medical Center and Affiliates (the "Company's") compliance with the types of compliance requirements identified as subject to audit in the OMB *Compliance Supplement* that could have a direct and material effect on each of the Company's major federal programs for the year ended June 30, 2022. The Company's major federal programs are identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

In our opinion, the Company complied, in all material respects, with the compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended June 30, 2022.

Basis for Opinion on Each Major Federal Program

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America (GAAS); the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States (*Government Auditing Standards*); and the audit requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Our responsibilities under those standards and the Uniform Guidance are further described in the Auditor's Responsibilities for the Audit of Compliance section of our report.

We are required to be independent of the Company and to meet our other ethical responsibilities, in accordance with relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on compliance for each major federal program. Our audit does not provide a legal determination of the Company's compliance with the compliance requirements referred to above.

Responsibilities of Management for Compliance

Management is responsible for compliance with the requirements referred to above and for the design, implementation, and maintenance of effective internal control over compliance with the requirements of laws, statutes, regulations, rules and provisions of contracts or grant agreements applicable to the Company's federal programs.

Auditor's Responsibilities for the Audit of Compliance

Our objectives are to obtain reasonable assurance about whether material noncompliance with the compliance requirements referred to above occurred, whether due to fraud or error, and express an opinion on the Company's compliance based on our audit. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with GAAS, *Government Auditing Standards*, and the Uniform Guidance will always detect material noncompliance when it exists. The risk of not detecting material noncompliance resulting from fraud is higher than for that resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Noncompliance with the compliance requirements referred to above is considered material, if there is a substantial likelihood that, individually or in the aggregate, it would influence the judgment made by a reasonable user of the report on compliance about the Company's compliance with the requirements of each major federal program as a whole.

In performing an audit in accordance with GAAS, *Government Auditing Standards*, and the Uniform Guidance, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material noncompliance, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the Company's compliance with the compliance requirements referred to above and performing such other procedures as we considered necessary in the circumstances.
- Obtain an understanding of the Company's internal control over compliance relevant to the audit in order to design audit procedures that are appropriate in the circumstances and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over compliance. Accordingly, no such opinion is expressed.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and any significant deficiencies and material weaknesses in internal control over compliance that we identified during the audit.

Report on Internal Control Over Compliance

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. *A material weakness in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. *A significant deficiency in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the Auditor's Responsibilities for the Audit of Compliance section above and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies in internal control over compliance. Given these limitations, during our audit we did not

identify any deficiencies in internal control over compliance that we consider to be material weaknesses, as defined above. However, material weaknesses or significant deficiencies in internal control over compliance may exist that were not identified.

Our audit was not designed for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, no such opinion is expressed.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

Report on Schedule of Expenditures of Federal Awards Required by the Uniform Guidance

We have audited the financial statements of the Company as of and for the year ended June 30, 2022, and have issued our report thereon dated September 30, 2022, which contained an unmodified opinion on those financial statements. Our audit was performed for the purpose of forming an opinion on the financial statements as a whole. The accompanying schedule of expenditures of federal awards is presented for purposes of additional analysis as required by the Uniform Guidance and is not a required part of the financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information has been subjected to the auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the schedule of expenditures of federal awards is fairly stated in all material respects in relation to the financial statements as a whole.

Deloitte & Touche LLP

November 1, 2022

CHILDREN'S HOSPITAL MEDICAL CENTER AND AFFILIATES

SCHEDULE OF FINDINGS AND QUESTIONED COSTS FOR THE YEAR ENDED JUNE 30, 2022

PART I. SUMMARY OF AUDITOR'S RESULTS

Financial Statements:

Type of auditor's report issued:	Unmodified	
Internal control over financial reporting:		
Material weakness(es) identified?	<u> </u> Yes	<u> X </u> No
Significant deficiency(ies) identified?	<u> </u> Yes	<u> X </u> None reported
Noncompliance material to financial statements noted?	<u> </u> Yes	<u> X </u> No

Federal Awards:

Internal control over major programs:		
Material weakness(es) identified?	<u> </u> Yes	<u> X </u> No
Significant deficiency(ies) identified?	<u> </u> Yes	<u> X </u> None reported
Type of auditor's report issued on compliance for major programs:	Unmodified	
Any audit findings disclosed that are required to be reported in accordance with 2 CFR 200.516(a)?	<u> </u> Yes	<u> X </u> No

Identification of Major Programs:

<u>ALN Number</u>	<u>Name of Federal Program or Cluster</u>
Various	Research and Development*
93.498	COVID-19-Provider Relief Fund And American Rescue Plan (ARP) Rural Distribution

* Cincinnati Children's has determined that its entire research and development program inclusive of all research and development grant activity should be considered clustered and as such, constitutes one major program.

Dollar threshold used to distinguish between Type A and Type B programs?	\$ 3,000,000
Research and Development program tested as a single Type A program	

Auditee qualified as low-risk auditee?	<u> X </u> Yes	<u> </u> No
--	------------------	------------------

CHILDREN'S HOSPITAL MEDICAL CENTER AND AFFILIATES

SCHEDULE OF FINDINGS AND QUESTIONED COSTS FOR THE YEAR ENDED JUNE 30, 2022

PART II. FINDINGS RELATED TO THE FINANCIAL STATEMENTS

None

PART III. FEDERAL AWARD FINDINGS AND QUESTIONED COSTS

None